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ABSTRACT 
Proteins are capable of an astounding array of functions using only the 20 
canonical amino acids; however, the ability to add new functional groups to the 
genetic code through the utilization of unnatural amino acids (UAAs) has greatly 
expanded our ability to study and manipulate proteins. By expanding the diversity 
of functional groups within proteins, a wide variety of applications in industry as 
well as in fields such as diagnostics, biochemistry, and materials science are now 
possible. These applications have further been expanded through the 
development and optimization of bioorthogonal reactions which can occur under 
physiological conditions with a high degree of specificity, allowing modulation of 
the structure and function of proteins within their natural state. Several 
applications of UAA technology involving bioorthogonal reactions will be explored 
in this thesis. Optimization of a previously developed bioorthogonal Glaser-Hay 
reaction between a protein and a fluorophore will be discussed. A further 
application of the Glaser-Hay reaction involving natural product synthesis will 
also be explored. The utilization of UAA technology to form trivalent conjugates 
containing multiple functionalities will be described. Furthermore, the 
development and optimization of organic reactions leading to the formation of 
trivalent structures will be explored with the intention of translating these 
reactions to biological systems. The ability to site-specifically immobilize a 
hyperthermophilic carboxylesterase enzyme onto a stabilizing resin will also be 
discussed and the benefits of protein immobilization will be demonstrated. 
Finally, the synthesis and development of novel TMS and aldehyde UAAs will be 
described and their applications will be explored. The applications highlighted in 
each chapter demonstrate some of the numerous possibilities that can be 
explored through modulation of the building blocks of proteins.
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Chapter 1: Introduction 
Proteins are an essential part of living organisms’ ability to carry out 
routine functions required for their survival and proper function. They are found in 
all living organisms from unicellular organisms to plants and animals.1 Proteins 
are capable of performing countless biological functions including converting light 
energy to chemical energy in photosynthesis, serving as a means to store and 
transport molecules such as oxygen throughout the body, and providing a 
mechanism to combat disease.1 In addition, proteins serve a vital role as 
catalysts, allowing chemical reactions to occur at substantially higher rates, 
making them feasible under the mild conditions required for most biological 
reactions.2 This ability makes proteins valuable not only from a metabolic 
standpoint, but also adds to their industrial value. Consequently, much of current 
research in this field is centered around developing new ways to harness the 
power of proteins for use in therapeutic, diagnostic, and industrial purposes.3 An 
increased understanding of the structure and function of these biomolecules has 
allowed for significant development in these areas. This knowledge has also 
provided researchers with the tools to develop methods for manipulating proteins 
to serve novel functions using their own biological machinery.3 As a result, 
proteins are now able to function in ways previously thought impossible, allowing 
for exciting advances in several fields including medicinal chemistry, cell biology, 
and materials science.4 The foundation of this research is the ability to modify the 
basic building blocks of proteins.3 
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I. The Building Blocks of Proteins 
While proteins vary greatly in their structure function, they are unified in 
that they all share the same basic building 
blocks, amino acids. Proteins are comprised of 
linear chains of amino acids known as 
polypeptides, with some proteins containing 
multiple chains of polypeptides.2 It is the 
unique sequence of amino acids that 
determines a protein’s size, shape, and function.1,2 Αmino acids consist of an α-
carbon as the central atom  (Figure 1.1).2 Three important components surround 
Figure 1.1: The general structure of 
an amino acid (in zwitterionic form). 
Figure 1.2: The 20 canonical amino acids.5 
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the central carbon: an amino group, a carboxylic acid group, and an R group 
(side chain).2 As a result, all amino acids, with the exception of glycine, are chiral, 
meaning that they are present as both L and D stereoisomers; however, only the 
L isomers are found in proteins.2 Amino acids are differentiated by their unique 
side chains. There are 20 amino acids which occur naturally in living organisms. 
Each of these 20 amino acids varies in size, shape, reactivity, hydrophobicity, 
and hydrogen bond capability allowing them to be grouped in several different 
manners (Figure 1.2).2 Depending on the pH of the surrounding environment, 
certain amino acids may become charged, based on their acidic or basic 
character, while others contain biologically unique elements, such as sulfur, 
allowing them to form covalent bonds.2 Typically proteins are formed by chains 
containing an average of 50 to 2000 amino acid residues.2  
Amino acids form linear polymers through the creation of peptide bonds 
between the amine group of one amino acid and the carboxyl group of the 
neighboring amino acid, which is accompanied by the loss of water (Figure 1.3).2 
Peptide bonds have several 
properties that contribute to protein 
stability including resistance to 
hydrolysis, a planar shape owing to 
the double bond character of the C-
N bond, the presence of both a 
hydrogen bond donor (NH) and a 
hydrogen bond acceptor (CO), and 
Figure 1.3: The formation of a peptide bond (new 
bond shown in red). 
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finally, their lack of charge, allowing for the formation of tightly packed globular 
protein structures.2  
Protein structure is divided into four levels; however, some proteins only 
contain the first three levels. A protein’s primary structure is defined by the 
specific linear arrangement and sequence of the 20 amino acids.2 The secondary 
structure of a protein is determined by structures that form as a result of 
hydrogen bonding between the backbone atoms. There are two primary 
elements of secondary structure: the alpha helix and beta sheet. The α-helix is 
rod-shaped and is formed when the carboxyl group of each amino acid in the 
chain forms a hydrogen bond with the amino group on the amino acid four 
residues down the chain.2 β-sheets are comprised of multiple segments of 
polypeptide chains that line up next to each other and form hydrogen bonds 
between the NH and CO groups.2 β-sheets can either be parallel or antiparallel. 
Proteins may contain one, both, or neither of these secondary structures. 
Secondary structure is also characterized by loops and turns. The R-groups of 
amino acids play a key role in determining the tertiary level of structure, the 
protein’s three-dimensional asymmetric structure.2 Several types of interactions 
determine the folding patterns and overall shape of a protein. Hydrophobic 
interactions between non-polar amino acids such as alanine, valine, 
phenylalanine, leucine, isoleucine, methionine, and proline cluster into the center 
of a protein away from water leaving the polar, hydrophilic amino acids on the 
exterior surface.2 Polar R-groups can form hydrogen bonds or dipole 
interactions.2 Ionic interactions can occur between R-groups with opposite 
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charges while R-groups with the same charge will repel one another.2 Cysteines, 
which contain sulfur, form a strong covalent bond known as a disulfide bond.2 
Proteins which contain multiple polypeptide chains linked together possess 
quaternary structure. Quaternary structure is characterized by the same 
interactions as in tertiary structure.2 Environmental factors such as temperature 
and pH must be maintained in order to ensure proper protein folding.2 The 
identity of the R-group of an amino acid plays a significant role in determining the 
structure and function of a protein. Further manipulating these R-groups can lead 
to proteins with novel structures and functions.3  
II. The Central Dogma of Molecular Biology 
All the information required to make a functional protein is stored in an 
organism’s genetic material. The “central dogma” of molecular biology, a term 
coined by Francis Crick in 1957, 
describes the flow of information 
from DNA to protein.1 The 
central dogma describes that the 
information found in DNA is 
used to make RNA, which is then used to make proteins (Figure 1.4).1 DNA is a 
double stranded helix composed of repeating units called nucleotides. Each 
nucleotide is composed of the sugar deoxyribose, a phosphate, and one of four 
nitrogenous bases, adenine (A), thymine (T), guanine (G), or cytosine (C).1 DNA 
is composed of segments called genes, which are expressed to make functional 
products for cells. Genes primarily encode the information needed to make 
Figure 1.4: The central dogma of molecular biology.6 
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polypeptides; however, they can also be used to construct certain types of RNA, 
such as transfer RNA (tRNA) or ribosomal RNA (rRNA), both of which are used 
in the process of polypeptide synthesis.1 RNA resembles DNA; however, RNA 
contains the sugar ribose and the nitrogenous base thymine is replaced with 
uracil (U).1 Gene expression occurs in two sequential steps, transcription and 
translation, which occur through slightly different mechanisms in prokaryotes and 
eukaryotes.   
Transcription is the first step of gene expression and involves the 
conversion of the information in DNA into messenger RNA (mRNA). The process 
involves the binding of RNA 
polymerase and the transcription 
factors to a specific location on 
DNA known as a promoter to 
initiate transcription (Figure 1.5).1 
In bacteria, RNA polymerase 
contains 5 subunits and one 
transcription factor, σ.1 Binding of 
the σ factor allows for specific binding of RNA polymerase and formation of a 
closed structure. Eventually some domains of σ dissociate, forming an open 
structure, which allows transcription to begin.1 In eukaryotes, there are multiple 
types of RNA polymerase containing additional subunits as well as multiple 
transcription factors.1 Transcription initiation is controlled by the specific binding 
of each of these transcription factors to RNA polymerase. Once transcription has 
Figure 1.5: An overview of the process of 
prokaryotic transcription.7 
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been initiated, RNA polymerase unwinds the double-stranded DNA by breaking 
hydrogen bonds between DNA nucleotides.1 A transcription bubble forms and 
RNA polymerase adds complementary RNA nucleotides in the 5’ to 3’ direction.1 
The growing mRNA chain shares an identical sequence to one strand of DNA 
known as the coding strand, with the exception that the nitrogenous base 
thymine is replaced with uracil. The other strand of DNA serves as the template 
strand, which provides the sequence for complementary bases to be added.1 In 
bacteria, transcription is terminated by either a rho-dependent or rho-
independent mechanism. Rho-dependent termination involves the use of a 
protein, rho, to form a stem-loop structure that terminates transcription by 
causing the dissociation of RNA polymerase.1 In rho-independent termination, 
the formation of the stem-loop structure is caused by terminator sequences.1 
Eukaryotic termination is less understood. In prokaryotes, mRNA can be used 
directly for polypeptide synthesis as the processes of transcription and translation 
occur simultaneously within the nucleus.1 In eukaryotes, RNA must be processed 
and certain portions called introns are removed to form mature mRNA.1 The 
mRNA is then exported out of the nucleus into the cytoplasm, where protein 
synthesis occurs. 
 Translation involves the conversion of the information encoded in mRNA 
into the amino acid sequence of a protein. Transfer RNA (tRNA) serves as the 
link between mRNA and the amino sequence of a polypeptide (Figure 1.6).1 
tRNA is a clover shaped adapter molecule. The structure of tRNA is specifically 
suited to this role as it has two distinct ends, a 3’ end serving as the site of amino 
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acid attachment and the opposite end 
containing a three-nucleotide sequence known 
as an anticodon. mRNA nucleotides are read in 
the 5’ to 3’ direction in triplets of three 
nucleotides known as codons. The anticodon of 
the tRNA forms complementary base pairs with 
the mRNA codons. Since there are 4 possible 
nucleotides, there are a total of 64 possible 
combinations of codon triplets (Figure 1.7).1 Of 
these, 61 codons are recognized by tRNAs and used to signal for the 
incorporation of an amino 
acid. Each codon is 
specific only to one of the 
20 amino acids.1 One of 
the codons, AUG, which 
codes for the amino acid 
methionine, is recognized 
as the universal start 
codon.1 The remaining 
three codons, UAA, UAG, 
and UGA in mRNA (or 
TAA, TAG, and TGA in DNA), are known as “stop” codons, which signal the 
termination of translation.1 These codons are also called ochre, amber, and opal, 
Figure 1.6: The general secondary 
structure of tRNA.8 
Figure 1.7: The codon table.9 
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respectively.9 The genetic code is degenerate, meaning that tRNAs specific for a 
certain amino acid can respond to several different codon triplets which differ in 
the third letter.1 In other words, the same amino acid may be encoded by several 
different codon triplets.  
Translation is a highly specific process, which can be attributed to the 
ability of tRNAs to become “charged” with the correct amino acid so that it can be 
placed in the appropriate 
position on the growing 
peptide chain.1 Amino acids 
are attached to tRNAs in a 
two-step enzymatic process. 
The key enzymes involved in 
this process are known as 
aminoacyl-tRNA synthetases (aaRSs). The first step involves binding of both an 
amino acid and a molecule of ATP to the active site of the aminoacyl-tRNA 
synthetase enzyme (Figure 1.8).1 At this stage, the amino acid becomes 
adenylated through reaction with ATP leading to the addition of AMP to the 
amino acid and the release of a pyrophosphate.1 This creates a high energy 
ester bond between the phosphoryl group of AMP and the carboxyl group.1 The 
next step involves the release of AMP and the transfer of the amino acid to the 3’ 
end of tRNA using either the 2’-OH or the 3’-OH depending on the class of 
enzyme involved.1 Aminoacyl-tRNA synthetases specifically match an amino acid 
with the tRNA containing the corresponding anticodon with a remarkably low 
Figure 1.8: The two-step enzymatic process involved in 
“charging” a tRNA with an amino acid.10 
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error rate, which is achieved through several means. One mechanism is through 
specific contacts that occur between the enzymes and the amino acid and tRNA 
substrates in their active site to ensure that the proper substrates are present.1 In 
addition, the enzymes possess editing pockets with specific shapes that are able 
to accommodate specific amino acid side chains, giving them the ability to locate 
and hydrolyze mismatched amino acids before and after transfer to tRNA.1   
Translation ultimately involves the formation of a chain of amino acids 
connected by peptide bonds (Figure 1.9). The process takes place on ribosomes, 
which are composed of a large (50S) and 
small (30S) subunit in prokaryotes.1 The 
small subunit of the ribosome contains 
three binding sites for transfer RNAs 
(tRNAs), the acceptor (A), peptidyl (P), and 
exit (E).1 The A site serves as the site of 
binding for amino acids, the P site contains 
the growing polypeptide chain, and the E 
site serves as the exit where “uncharged” 
tRNAs leave the ribosome.1 Translation 
itself can be divided into three major steps: initiation, elongation and termination. 
mRNA contains a region at the 5’ end known as the untranslated region (UTR).1 
This region serves as the ribosome-binding site. It contains a site known as the 
Shine-Dalgarno box in bacteria and the Kozak box in eukaryotes.1 During the 
initiation phase, an uncharged tRNA is charged with the amino acid methionine 
Figure 1.9: The process of translation.11 
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by a methionyl aaRS.1 Several initiation factors bind to the small subunit of the 
ribosome forming a preinitiation complex. This complex and the methionine-
carrying tRNA bind at the ribosome binding site on the mRNA.1 The small subunit 
then scans the mRNA until it reaches a start codon (AUG). Once the methionine-
carrying tRNA has bound to the start codon, the large ribosomal subunit joins the 
complex, causing the release of the initiation factors.1 The methionine-carrying 
tRNA possesses the unique ability to bind to the P site, leaving the adjacent A 
site empty.1 During the elongation stage, the ribosome translocates in the 5’ to 3’ 
direction on the mRNA using elongation factor G (EF-G).1 Using elongation 
factors (EF-Tu and EF-Ts) and energy from GTP, a tRNA charged with the next 
amino acid to be added to the polypeptide chains binds to the A site based off of 
its anticodon sequence which is complementary to the codon sequence in the A 
site.1 Once the tRNA has bound to the A site, GTP is cleaved to GDP and EF-Tu 
is released.1 A peptide bond then forms between the two adjacent amino acids 
by peptidyl transferase.1 Amino acids are added to the C-terminus of the growing 
polypeptide chain. Once the peptide bond has formed, the tRNA in the P site 
releases the amino acid chain into the A site.1 The ribosome then translocates 
and a new tRNA carrying the next amino acid to be added to the growing 
polypeptide chain is brought into the now empty A site.1 Simultaneously, the 
“uncharged” tRNA from the P site moves into the E site, where it exits the 
ribosome into the cytoplasm.1 The polypeptide chain held in the P site continues 
to grow in length as the process continues. Termination occurs when one of the 
three stop codons, which do not carry tRNAs, reaches the A site.1 Release 
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factors enter the P site, initiating the hydrolysis of the polypeptide chain. The 
ribosomal subunits then dissociate from each other as well as from the mRNA. 
They are then recycled and used in subsequent cycles of translation.1 The 
process of gene expression is both highly efficient and specific, making it of great 
use to biochemists exploring UAA technology. Researchers have been able to 
harness the biological tools utilized in the process of gene expression to 
incorporate UAAs in proteins.  
III. Expanding the Genetic Code 
While proteins are able to carry out a remarkable number of functions 
using the 20 canonical amino acids, proteins are often required to serve functions 
beyond those afforded by the standard amino acids. In order to function, many 
proteins require posttranslational modifications including methylation, 
phosphorylation, glycosylation, and sulfation or cofactors such as metal ions or 
flavins.3 Classic attempts have been made to modify proteins using modifications 
of the standard amino acids including the thiol group of cysteine and the primary 
amine group of lysine.12 Novel methods for protein modification involving the N-
terminus as well as metal-mediated transformations involving cysteine, lysine, 
tyrosine, and tryptophan have been developed.12 However, in most cases, 
residue-specific modification is not possible unless the residue is engineered on 
the protein’s surface.12 In addition, several issues may result from unwanted 
dimerization and solubility.12 Researchers have also examined the impact of 
altering the amino acid residue at a specific location by switching one amino acid 
for one of the other 19 natural amino acids.13 This method is limited; however as 
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very few substitutions are sterically or functionally equivalent.13 Despite these 
drawbacks, characterization of the mutant proteins has allowed for a better 
understanding of the processes of catalysis and recognition in biological 
systems.13 As a result, researchers have shifted their attention toward the 
development of non-standard amino acids. Several archaea and eubacteria have 
previously been found to encode amino acids other than the canonical 20 amino 
acids, giving them additional functions.3 This led to the discovery of the 21st and 
22nd amino acids, selenocysteine and pyrrolysine.3 Both of these amino acids are 
not encoded by the typical genetic code, but are instead encoded using stop 
codons during the process of translation.3 The existence of these amino acids 
underscores the appeal of using an organism’s own biological machinery to 
provide additional functions beyond those provided by the 20 natural amino 
acids.3 The development of organisms with expanded genetic codes such as 
these, provides a variety of possibilities for developing proteins with novel 
functions, opening the door for an exciting avenue of research.  
The process of expanding the genetic code involves a combination of both 
biological and chemical knowledge. Unnatural amino acids (UAAs) which 
possess novel functional groups and structures that can participate in reactions 
not permitted by the 20 canonical amino acids have been synthesized organically 
or by the engineering new biosynthetic pathways within the organism of 
interest.13 Chemists must ensure that these new amino acids are stable, non-
toxic, and able to be efficiently transported into the cell.14 In order to utilize these 
new amino acids; however, a standard method for incorporating these novel 
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amino acids into proteins at 
specific sites using the 
organism’s own biological 
machinery was essential (Figure 
1.10).13 Several methods have 
been employed to incorporate 
UAAs into proteins including 
chemical modification to solvent-
exposed reactive side chains, the use of functional analogues of tRNAs, peptide 
synthesis, and semisynthetic methods.13 Each of these methods are limited 
either by non-selective incorporation of the UAA or size restrictions on the 
protein.13 Researchers have found that the answer to developing a method with 
greater efficiency and selectivity lies in the central dogma of molecular biology.  
IV. Current Methodology for the Site-Specific Incorporation of UAAs 
In order to explore the implications of UAA technology, researchers 
needed to develop a method to express mutant proteins using a model organism 
that provides speed, simplicity, and cost-efficiency for protein expression. E. coli 
is commonly used for large-scale protein production as it has several advantages 
over eukaryotic and mammalian protein expression methodologies, which are 
more prone to contamination, require special growth media, and are genetically 
more complex.15 In addition, E. coli is both cheaper and more susceptible to 
genetic modification.15 E. coli grow and divide rapidly making the process of 
expressing proteins and introducing genetic modifications highly efficient as they 
Figure 1.10: Incorporation of standard and unnatural 
amino acids.15 
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undergo a period of exponential growth that is ideal for inducing protein 
expression (Figure 1.11).15 E. coli 
is limited in its therapeutic utility; 
however, as it is unable to facilitate 
post-translational modifications 
required by most therapeutic 
proteins such as antibodies, 
enzymes, and cytokines.15  
Despite this limitation, the benefits of the E. coli protein expression system have 
made it a promising test organism for research involving UAA incorporation.  
As previously described, during translation amino acids are added in a 
specific order to the growing polypeptide chain through the action of tRNAs, 
which are “charged” with the correct amino acid by aaRSs.1 There are 61 codons 
which direct the incorporation of a specific amino acid and three codons, TAA, 
TAG, and TGA, serve as stop codons that signal the termination of translation.1 
In E. coli, the TAG codon is only used 7% of the time and is rarely used to signal 
the termination of vital genes.15 Attempts were first made to develop orthogonal 
aaRS/tRNA pairs in E. coli, meaning that they would react with each other but not 
the endogenous translational machinery in the cell.14 These attempts were 
unsuccessful due to misaminoacylation of native tRNAs by the evolved aaRS.14 
Instead, orthogonal pairs with distinct tRNA elements from other organisms were 
tested.14 The first successful attempt was achieved using a tRNA and aaRS from 
the archaea Methanococcus jannaschii to express a UAA-containing protein in E. 
Figure 1.11: A typical E. coli growth curve.16 
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coli.14,17 Several considerations were needed when implementing this technique. 
As described previously, the introduced translation machinery needed to be 
orthogonal to the endogenous translational machinery to avoid cross-charging of 
natural amino acids.14,15 Thus, the evolved tRNA could not be a substrate for E. 
coli aaRSs nor could the evolved aaRS aminoacylate E. coli tRNA.14 In addition, 
the tRNA and corresponding aaRS must selectively recognize the selected UAA 
as opposed to a natural amino acid.14 High expression levels were achieved 
utilizing this aaRS/tRNA pair and it was found that there is a lack of an editing 
mechanism which would deacylate the UAA and replace it with the proper natural 
amino acid, making this a promising technique for UAA incorporation in E. coli.14 
Using the principles of the central dogma, researchers were able to successfully 
utilize an exogenous aaRS/tRNA pair from M. jannaschii in order to incorporate 
unnatural amino acids at TAG codons in E. coli.  
In order to utilize an orthogonal aaRS/tRNA pair in E. coli, a series of 
steps must be taken to ensure that the orthogonal tRNA is able to bind the 
orthogonal aaRS and that the aaRS is able to aminoacylate the orthogonal tRNA 
with the selected UAA.14,15,17,18 In order to perform these steps, a mutation on the 
gene of interest is made in order to insert a TAG codon, which will serve as the 
location for site-specific incorporation of the selected UAA if an orthogonal 
aaRS/tRNA pair is successfully evolved.15,17 In cases, where the aaRS/tRNA pair 
is successful, the cell is able to “read-though” the inserted TAG codon and 
produce a functional protein by inserting the UAA at the location of the TAG 
codon.15,17 This process has become known as amber suppression.15 If the 
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Figure 1.12: Evolving an 
orthogonal aaRS.15 
orthogonal aaRS/tRNA pair is not successfully evolved, suppression of the TAG 
codon will not occur and translation will stop at the location of the inserted stop 
codon, yielding a non-functional, truncated protein.15,17 Various reporter genes 
are used throughout the evolution of the orthogonal tRNA/aaRS pair to determine 
whether or not orthogonality has been achieved.15,17 
In order to alter the specificity of the M. jannaschii aaRS for the desired 
UAA, a large library of greater than 108 active-site mutants is constructed, which 
then undergoes a double-sieve selection (Figure 1.12).15,17 The first round of 
selection involves 
the use of a mutated 
aaRS along with 
orthogonal tRNA 
from M. jannaschii 
to screen for the 
ability of aaRS to 
aminoacylate tRNA 
with either the UAA or an endogenous amino acid.15,17 In this step, an amber 
mutation is placed at a permissive site on the chloramphenicol acetyltransferase 
gene and cells are grown in the presence of both chloramphenicol and the 
selected unnatural amino acid.15,17 The chloramphenicol acetyltransferase gene 
is responsible for antibiotic resistance in E. coli; therefore, successful 
incorporation of any amino acid (natural or unnatural) at the amber mutation site 
will allow the gene to be expressed, conferring survival in the presence of 
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Figure 1.13: Evolving an orthogonal tRNA.15 
chloramphenicol.15,17 The survivors of this positive selection encode aaRS 
mutants which can aminoacylate orthogonal tRNA with either an endogenous 
amino acid or the desired UAA. The second selection step involves a negative 
selection to eliminate mutants which aminoacylate endogenous amino acids.15,17 
This step involves the insertion of three TAG mutations into the barnase gene. 
The barnase gene encodes a toxic protein that kills E. coli cells; therefore, cells 
grown in the absence of UAA will survive in cases when the aaRS cannot 
recognize the natural amino acids, resulting in truncated cytotoxic protein that 
lacks function.15,17 As a result of the positive and negative selection process, only 
those aaRSs which charge the tRNAs with the selected UAA remain.15,17 These 
synthetases are then subjected to multiple rounds of positive and negative 
selection, providing the most selective synthetases for that specific UAA.15,17 
In order to design an orthogonal tRNA, a suppressor tyrosine-tRNA from 
M. jannaschii was randomly mutated in the anticodon loop.18 Mutant tRNAs were 
subject to negative selection by transforming them into E. coli cells containing the 
toxic barnase 
gene and 
genetically 
inserted amber 
codons (Figure 
1.13).18 Cells 
that grew were 
unable to read 
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through the TAG codons and did not express the toxic barnase gene, meaning 
these tRNAs could not bind endogenous synthetases.18 In cases where no 
growth occurred, the tRNA were then subject to positive selection. These tRNAs 
were transformed into E. coli cells containing the evolved orthogonal aaRS as 
well as a β-lactamase gene containing a genetically inserted amber codon.18 
These cells were grown in the presence of ampicillin; therefore, growth will only 
occur in cases where the β-lactamase gene, which is responsible for ampicillin 
resistance, is expressed.18 Cells that survive this round of positive selection 
contain tRNAs that are aminoacylated by the mutated orthogonal aaRS.18 
With an orthogonal tRNA/aaRS pair in hand, the expression of a protein 
containing the selected unnatural amino 
acid through amber suppression is now 
feasible (Figure 1.14).4,8 In this process, a 
protein plasmid is mutated to site-
specifically introduce a TAG codon, which 
will serve as the site for future 
incorporation of the selected UAA.4 This 
mutated plasmid is transformed with 
plasmids containing the orthogonal 
tRNA/aaRS genes into electrocompetent 
E. coli cells.4 In a typical case, the protein 
plasmid gene is controlled by a β-D-1-
thiogalactopyranoside (IPTG) promoter harboring an ampicillin resistance gene 
Figure 1.14: Incorporation of a selected 
UAA into green fluorescent protein 
(GFP).4 
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while the tRNA/aaRS genes are under the control of an arabinose promoter 
harboring a chloramphenicol resistance gene.4 Growth in the presence of both 
antibiotics, induction using IPTG and arabinose, and the addition of the selected 
unnatural amino acid will allow for the “charging” of the orthogonal tRNA with the 
desired UAA by the corresponding aaRS.4 The UAA will be inserted at a specific 
site corresponding to the location of the genetically inserted TAG codon.4 In this 
manner, a full-length, functional protein harboring a site-specifically inserted UAA 
can be produced. Glycosylated amino acids as well as those with novel chemical 
and photochemical functionalities in addition to fluorescence, metal-binding, and 
redox activity have been successfully incorporated using this methodology.17 This 
technique has allowed for the incorporation of over 100 novel amino acids into 
bacteria, yeast, and mammalian cells.3 
Ongoing research has led to numerous improvements in the techniques 
used for UAA incorporation. New methods have been used to improve upon the 
cumbersome selection process for designing orthogonal aaRS/tRNA pairs 
previously described.15 One method involves the use of a single genetic 
construct carrying the genes for both the aaRS and tRNA from M. 
jannaschii along with a chloramphenicol resistance tag, allowing aaRS variants to 
be selected in one step.15,19 The system utilizes a T7 RNA polymerase with an 
amber codon and green fluorescent protein (GFP) reporter protein.18 Only 
mutants possessing orthogonal aaRS/tRNA pairs yielded protein.19 Another 
method utilizing a dual positive/negative selection system for the evolution of 
aaRSs has been proposed.20 The system involved utilizes a chloramphenicol 
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acetyltransferase-uracil phosphoribosyltransferase (UPRT) fusion gene with an 
amber codon in the chloramphenicol transferase segment.20 UPRT is an enzyme 
that converts 5-fluorouracil to 5-fluorouracil monophosphate, which inhibits 
thymidylate synthase.15 This enzyme synthesizes thymidine monophosphate, 
which is then phosphorylated to thymidine triphosphate for use DNA synthesis.20 
In the positive selection step, E. coli was grown in the presence of both 
chloramphenicol and a UAA to test for amber supression.20 Negative selection 
was then performed using 5-fluorouracil to determine whether or not DNA 
synthesis is permitted.20 Additional research is focused on overcoming the 
limitations imposed by amber codon suppression, such as low protein yields and 
the fact that only one type UAA can be incorporated into proteins.15 Low protein 
yields can be attributed to the presence of amber-recognizing release factor 
protein 1 (RF1), which is involved the termination of translation.15 RF1 competes 
with tRNA during UAA incorporation and cannot be removed through knockout as 
it encodes essential genes.15 Researchers have developed methods to overcome 
this problem through the creation of an RF1 knockout strain that could be 
complimented with the orthogonal tRNA plus seven essential genes on an 
additional plasmid.21 An RF1-independent E. coli strain JX33, which utilized a 
wild type RF2 and did not require additional genes has also been developed.22 
The use of orthogonal aaRS and tRNA pairs which recognize four codons can be 
used to incorporate multiple UAAs. This has been applied in the development of 
an orthogonal ribosome, Ribo-X, which has increased the efficiency of UAA 
incorporation as well as provided the ability to incorporate multiple UAAs.23,24  
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Recent advances have allowed for the development of synthetases with 
improved yields and other import attributes. The pEVOL vector makes use of 
both a constitutive and an arabinose inducible promoter to make two copies of 
the M. jannaschii aaRS gene.15,25 As a result, a basal level of aaRS is always 
present, which is then supplemented by induction of the second promoter.25 The 
use of this vector has provided protein expression levels as high as 100 mg/L.25 
Further advances have been made though the development of the pUltra plasmid 
system which can be used for single and multiple UAA incorporation.15,26 The 
pUltra system utilizes an amber M. jannaschii tyrosyl tRNA/aaRS pair as well as 
an ochre M. barkeri pyrrolysyl tRNA/aaRS pair.26 It can be used in combination 
with pEVOL synthetases as it contains a spectinomycin antibiotic resistance 
marker.26 Expression levels as high as 30% of the level of wild type protein have 
been reported using this system. Other methods have been developed to 
eliminate the need for timely selection protocols when developing orthogonal 
aaRS/tRNA pairs.27 During selection of an aaRS, there is no selective pressure 
against other UAAs; therefore, it is possible that evolved aaRSs may recognize 
multiple UAAs while remaining orthogonal to endogenous amino acids, a 
phenomenon referred to as promiscuity.27 This promiscuity is not problematic as 
growth media is typically only supplemented with one UAA during protein 
expression.27 As a result of this promiscuity, one orthogonal aaRS/tRNA pair may 
be used to incorporate several UAAs without the need for timely selection 
protocols.27 For example, p-cyanophenylalanine specific aminoacyl-tRNA 
synthetase (pCNF-RS) is capable of incorporating at least 18 different UAAs 
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while remaining orthogonal to endogenous amino acids.27 The continued 
development and improvements in the technique for incorporating UAAs into 
proteins with high specificity and efficiency has made UAA technology a 
promising tool for use in a vast number of applications. 
V. Applications of UAA Technology 
The ability to modify proteins through the addition of novel functional 
groups can lead to proteins with exciting physicochemical, biological, and 
pharmacological properties.3 The ability to site-specifically incorporate UAAs has 
allowed for vast improvements in the process of protein immobilization to be 
made. Protein immobilization has several industrial and therapeutic benefits 
including the use of immobilized enzymes in microarrays, imaging probes, and 
biosensors.28 Immobilized proteins are stable in non-aqueous environments, 
adding to their industrial utility and are also capable of being recycled, making 
them economically beneficial.28 Current methodologies are limited by their lack of 
specificity, which can lead to a reduction in protein activity.28,29 The use of UAAs 
has been shown to solve this specificity problem, allowing site-specific 
immobilization of proteins onto solid supports.28 UAAs created by post-
translationally modifying cysteine have been used for the regio- and 
chemoselective covalent immobilization of soluble proteins onto glass surfaces 
through Click reactions and Staudinger ligations.29 Site-specific incorporation of 
UAAs has been used to immobilize green fluorescent protein (GFP) onto a 
sepharose resin in high yields with remarkable stability in the presence of several 
organic solvents (Figure 1.15).28 In addition, oriented immobilization of the 
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pathogenic DrrA protein has been achieved 
through site-specific UAA incorporation and 
has been used to analyze interactions with 
its binding partner, Rab1.30 The ability to 
site-specifically immobilize proteins is also of 
value in developing protein biochips. Protein 
biochips are a collection of miniaturized 
spots which allow high-throughput protein 
screenings of thousands of protein samples 
through enzyme activity analysis.31 The 
development of protein biochips has key implications in diagnostics, allowing 
quick, reliable, and quantitative comparisons of the expression profiles of patients 
and healthy individuals to be made.31 The ability to covalently immobilize proteins 
in a uniform orientation that allows binding sites to be exposed to sample 
solutions while maintaining high protein yield and activity is key to the 
development of these biochips.28,31  
Understanding complex cellular processes and reactions involving 
proteins, such as those involved in the development and combat of certain 
diseases, is crucial to the development of novel biomedical and therapeutic 
applications.32,33 This understanding is highly dependent on the ability to 
selectively label and modify proteins within their native environment through 
highly specific chemical reactions.32 Examining proteins in their purified and 
isolated forms limits the ability to understand their interactions with other 
Figure 1.15: Site-specific 
immobilization of GFP onto a solid 
support resin.28 
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molecules within the body, such as biopolymers, ions, and metabolites.32 GFP is 
a commonly used reporter protein due to its fluorescence ability; however, its 
large size may cause structural perturbation, negatively impacting the expression 
and function of the protein of interest.32 In addition, GFP cannot be used to 
visualize metabolites, glycans, lipids, or nucleic acids.32 Antibodies are commonly 
used for binding specific epitopes of proteins for visualization purposes as well as 
in drug delivery.32,34 Antibodies can be generated for any epitope, making them 
useful for imaging and drug attachment purposes.32 Nevertheless, their large size 
and the lack of selectivity in drug delivery methods has limited their use.32,34 
Small molecule reporters, such as those with fluorescent properties, are a 
promising method for labeling proteins; however, a means to specifically deliver 
them to proteins was necessary.32 As a result, researchers have employed UAAs 
to develop reactions for protein labeling and drug delivery using small molecules 
that possess a high degree of specificity. 
The development of bioorthogonal reactions using UAAs has 
revolutionized the ability to label proteins in their native context as well as to 
selectively deliver drugs to specific targets.32-34 In this method a UAA containing 
the desired non-
native chemical 
reporter is site-
specifically 
incorporated into 
the protein and 
Figure 1.16: Examples of bioorthogonal reactions including protein 
labeling using a bioorthogonal probe (a) and the addition/removal of a 
protecting group (b).33 
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reacted with an exogenously delivered probe, forming a bioconjugate (Figure 
1.16).4,32,33 Bioconjugates are defined as the association of a biomacromolecule, 
such as a protein, DNA, or RNA, with a secondary molecule, such as labeled 
probe, other biomacromolecule, or small molecule.4 To be successful, these 
reactions must occur efficiently in aqueous environments under physiological 
conditions at a temperature near 37 °C and a pH near 7.2.4,32 The reaction must 
be orthogonal, meaning that it does not cross-react with any endogenous 
functionalities, so as not to interfere with natural cell processes. The reporter, 
probe, and resulting bioconjugate should be metabolically stable and no harmful 
byproducts should be produced. This technology has been used recently in the 
development of antibody-drug conjugates for the targeting of cancer cells 
presenting tumor-associated surface-markers by cytotoxic drugs.34 Bioorthogonal 
reactions have been used in the creation of a bioluminescent assay for 
interferon-γ, which is used to detect bacterial and viral infections, through 
bioorthogonal conjugation of Gaussia luciferase with an anti-interferon-γ 
antibody.35 Recently, a bioorthogonal tetrazine cycloaddition reaction has been 
used in the site-specific glycoconjugation of a protein, which has important 
biological and therapeutic applications.36 
Organic chemists have devised several bioorthogonal conjugation 
reactions between UAA-containing proteins and small molecules, which have 
been used for a variety of purposes. Several UAAs containing a variety of 
functional groups such as thioesters, acetylenes, aldehydes, ketones, azides, 
and alkenes have been utilized.33 Aldehydes and ketones can react with 
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hydrazides and alkoxyamides to make hydrazones and oximes.33 Staudinger 
ligations involving the reduction of azide-containing UAAs with 
triphenylphosphine have been utilized to form stable amide bonds.33 Certain 
phosphine reagents containing an acyl group attached to the phosphine group 
with a cleavable linker can undergo “traceless Staudinger ligations” in which the 
final bioconjugate does not contain the phosphine oxide moiety.33 The ability to 
incorporate UAAs containing terminal alkynes has allowed for the implementation 
of biological Glaser-Hay reactions involving the coupling of two terminal alkynes.4 
In addition, azides can undergo [3+2] cycloadditions with alkynes to produce 
triazoles.33 To avoid constraints imposed by temperature and pressure on yields, 
copper (I) may be used as a catalyst in the copper catalyzed azide-alkyne 
cycloaddition (CuAAC) reaction.33 Ring strain can also be introduced in the 
strain-promoted alkyne-azide cycloaddition (SPAAC).33 Alkynes can also 
undergo a [3+2] cycloaddition with nitrones known as the strain-promoted alkyne-
nitrone cycloaddition (SPANC), which are up to 30 times faster than the SPAAC 
reaction.37 Proteins containing 1,2-aminothiol moieties can undergo condensation 
reactions with 2-cyanobenzothiazole (CBT).37 Photoinduced organic reactions 
between tetrazole derivatives and terminal alkynes have also been explored.33 
These 1,3-dipolar cycloaddition reactions can be induced by UV light.33 Efficient 
protein bioconjugations can also occur using Diels-Alder reactions between a 
tetrazine-containing compound and a strained alkene or alkyne group, such as 
norbornenes (Nor), cyclopropenes (Cyp), bicyclononynes (BCN), or trans-
cyclooctenes (TCO).32 Olefin metathesis involving alkenes can be used to 
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construct new carbon-carbon bonds. A final type reaction involves the use of 
palladium catalysts such as the Suzuki-Miyaura cross-coupling reaction with 
Pd(OAc)2(ADHP)2 and the Sonogashira cross-coupling reaction using an 
aminopyrimidine–palladium(II) complex.32  
A final application of UAA technology is the exploration and modification of 
the structure and function in proteins. Proteins containing UAAs incorporated at 
specific sites have been used in mechanistic and biophysical studies.38 For 
example UAAs have been used as NMR probes to locate the binding site of a 
small molecule inhibitor and monitor changes in protein structure as a result of 
inhibitor binding.38,39 IR and X-ray active UAAs have also proven useful in the 
study of protein structure.38,40 Fluorescent UAAs can be incorporated on the 
surface of proteins and viewed via fluorescence microscopy.38,41 These can be 
used to study protein interactions as well as folding and conformational 
changes.41 Phage-based systems are being implemented to determine if there is 
an evolutionary advantage to UAA incorporation.38 Protein activity can be 
controlled using site-specific incorporation of caging groups on residues, such as 
cysteine, tyrosine, and serine, that are key to protein function.14,38,42 Non-invasive 
light irradiation can then be used to restore protein function through removal of 
the caging group.14,38,42 Redox-active UAAs can be used to probe and manipulate 
electron transfer processes in proteins.43,44 The continued development and 
incorporation of novel UAAs will further enhance the realm of possibilities for 
exploring and manipulating protein structure and function, allowing the number of 
applications possible using UAAs to continue to expand. 
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Chapter 2: Optimization of the Glaser-
Hay Bioconjugation Reaction 
I. Introduction 
With widespread applications in the fields of medicine, materials, and 
pharmaceuticals, bioconjugate chemistry is a rapidly growing area of chemical 
research. Bioconjugates are comprised of a biological macromolecule linked to a 
second molecule, often a surface, probe, nanoparticle, or another biomolecule.1,2 
Protein bioconjugates, wherein at least one of the conjugate partners is a protein, 
have been utilized to enhance drug delivery and cellular imaging through the use 
of antibodies conjugated to cytotoxic drug molecules and luminescent quantum 
dots, in addition to numerous other applications.3-9 
The preparation of covalently-linked protein bioconjugates is often 
accomplished through reaction of a protein’s native nucleophilic residues, such 
as lysine, cysteine, and serine.10 However, through this method, bioconjugation 
can occur at multiple residues within the protein, resulting in non-specific 
conjugation at a varying number of positions.10,11 To overcome this lack of 
selectivity, unnatural amino acids (UAAs) can be site-specifically introduced into 
proteins via suppression of the amber stop codon (TAG) by an evolved 
orthogonal amino acyl synthetase (aaRS)/tRNA pair.12-14 The incorporation of a 
UAA bearing a chemical moiety not found within the twenty naturally occurring 
amino acids not only provides a specific site for conjugation of the protein, but 
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also allows access to several useful conjugation methods previously unavailable 
for bioconjugation reactions involving proteins.15-16 
The Glaser-Hay coupling of two terminal alkynes is among these now-
accessible protein bioconjugation reactions due to the preparation of a terminal 
alkyne containing UAA, p-
propargyloxyphenylalanine 
(pPrF, 1).17 This coupling 
reaction affords a well-
defined, linear 1,3-diyne via 
a copper (I) catalyst and 
bidentate nitrogenous 
ligand (Figure 2.1), most 
often N,N,N′,N′-
tetramethylethylenediamine 
(TMEDA, 2).18-21 Moreover, this generates a new carbon-carbon bond that is 
highly stable and unreactive under typical physiological conditions.18 Diynes and 
other conjugated acetylenic structures generated from the Glaser-Hay coupling 
reaction have many useful applications. Such diynes are the starting point for 
many cycloaddition reactions yielding carbo- and heterocycles that display 
interesting biological, optoelectronic, and photochemical properties.22-26 
Additionally, the Glaser-Hay reaction can be utilized to generate diacetylenes 
employed in crystal-forming polymerization reactions,27 or to prepare classes of 
Figure 2.1: Glaser-Hay reactions. (A) Structure of alkynyl 
amino acid pPrF incorporated into proteins. (B) General 
Glaser-Hay reaction linking two terminal alkynes. (C) Glaser-
Hay bioconjugation of a protein. 
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macrocyclic compounds with diverse applications in supramolecular chemistry 
and nanotechnology.28,29 
II. Results and Discussion 
Transferring the Glaser-Hay coupling to a biological setting for use in 
bioconjugations necessitates relatively mild reaction conditions that are 
compatible with physiological systems, namely a moderate temperature, 
aqueous environment, and short reaction time. Several past experiments have 
successfully employed the Glaser-Hay reaction on biologically relevant 
molecules, though not necessarily under mild conditions. In 2015, oxidative 
coupling of terminal alkynes was reported with the formation of peptoid dimers at 
90 °C in DMSO, and again with macrocyclization of tetrapeptides at 60 °C using 
Cu(OAc2) and NiCl2 catalysts.30,31 
Our previous work demonstrated the first successful biological Glaser-Hay 
coupling in a full-length protein and under mild reaction conditions 
(Figure 2.1C).32-34 With incorporation of pPrF into green fluorescent protein 
(GFP), a protein-fluorophore bioconjugate was generated at 4 °C after 4 hours. 
Despite having successfully employed the Glaser-Hay coupling in a biological 
context, noticeable protein degradation after about 6 hours was observed. It has 
been proposed that this degradation was potentially due to hydroxyl radicals 
generated from the copper (II)-hydroxyl intermediate in the catalytic cycle of the 
Glaser-Hay reaction, which is known to be deleterious to living systems.19,35 This 
protein oxidation was characterized by MS analysis, ultimately resulting in loss of 
protein product (Figure 3.2). To avoid protein degradation, we became interested 
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in developing means to 
circumvent the 
production of harmful 
radical species while 
generating the same 
internal 1,3-diyne 
structure. One such 
method that we 
developed implemented 
the Cadiot-Chodkiewicz 
coupling of a terminal 
alkyne and halo-alkyne 
to afford a protein-fluorophore bioconjugate.36 Because the Cadiot-Chodkiewicz 
mechanism is thought to cycle between the copper (I) and copper (III) states 
while avoiding the harmful copper (II) state, reaction times could be extended 
with minimal protein degradation.37 Furthermore, under the Cadiot-Chodkiewicz 
mechanism, we were able to reduce the amount of catalytic copper ten-fold from 
that required by the Glaser-Hay mechanism and achieve satisfactory coupling. 
While the Cadiot-Chodkiewicz coupling occurred with less protein degradation, it 
did require additional synthetic steps to access bromo-alkyne amino acids or 
brominated coupling partners. Because the terminal alkyne amino acid is 
commercially available, and an orthogonal aaRS/tRNA pair has specifically been 
evolved to incorporate it, the Glaser-Hay coupling is more easily accessible. 
Figure 2.2: MS analysis of protein damage. A) pPrF-GFP when 
subjected optimized conditions at pH 6.0 in the presence of 
CuI/TMEDA. B) When reaction time of the pPrF-GFP is extended to 
10 h at 30 oC, significant oxidative damage to the protein is 
observed. C) Expanded MS of C, indicating +16 repeat units 
resulting from protein oxidation. 
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Thus, we aimed to systematically optimize the traditional Glaser-Hay reaction to 
increase coupling efficiency and preserve protein from degradation, allowing it to 
find more widespread utility. 
In order to further optimize the biological Glaser-Hay reaction, a 250 mL 
expression of GFP harboring pPrF in position 151 was performed to ensure that 
all reactions were conducted on the same protein batch (1.0 mg/mL) to remove 
variability between expressions. With the pPrF-GFP in hand, a range of 
experimental variables was examined in a systematic fashion when reacting the 
mutant GFP with an Alexa Fluor-488 alkyne dye. Due to the production of 
biologically deleterious Cu(II) in the catalytic cycle, we examined the addition of 
both reducing agents and radical scavengers to the reaction as a mechanism to 
mitigate the potential damage caused by the radicals initiated by the Cu(II) 
species. Additionally, we examined the effects of a wide variety of copper 
sources and ligands to further activate the copper center. The impact of reaction 
temperature as well as buffers at varying pH was also investigated. Each variable 
was independently varied based on the previously reported conditions, and 
optimized conditions were then screened in combination to elucidate the best 
Glaser-Hay bioconjugation conditions. 
Initial studies examined the addition of reducing agents to the reaction to 
reduce harmful Cu(II) back to the Cu(I) species. Based on their biological 
compatibility, β-mercaptoethanol, tris(2-carboxyethyl)phosphine (TCEP), 
dithiothreitol (DTT), and nicotinamide adenine dinucleotide (NADH) were 
selected for analysis. Glaser-Hay reactions were conducted with the pPrF-GFP 
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and Alexa Fluor-488 alkyne in the presence of a reducing agent (500 mM), 
TMEDA and CuI for 4 hours at 4 °C. Control reactions were also performed in the 
absence of reducing agent, or in the absence of the CuI/TMEDA. After 
purification and buffer exchange, the reactions were analyzed by SDS-PAGE for 
protein degradation and coupling efficiency. Fluorescence intensity indicated the 
effectiveness of the coupling reaction as the GFP is denatured and no longer 
fluorescent, while the coupling to the fluorophore re-establishes a fluorescent 
signal. Coomassie staining was also performed to indicate protein presence and 
relative degradation. Unfortunately, no reducing agent afforded better coupling 
conditions than the original conditions, and DTT dramatically inhibited efficient 
coupling. Similar results were observed when radical scavengers were employed 
including cysteine, oleic acid, and ascorbic acid. Ascorbic acid also hindered the 
Glaser-Hay reaction from occurring and increased the level of protein 
degradation. 
Based on the literature, a variety of copper sources have been utilized in 
the Glaser-Hay reaction; therefore, several of these copper sources were 
investigated to determine if any 
were more advantageous than the 
previously reported copper iodide. 
Reactions were performed using 
copper(I) iodide, copper(I) chloride, 
copper(II)chloride, and copper(II) 
sulfate. Reactions were additionally 
Figure 2.3: Effect of copper source on coupling. 
Ratios indicate that the previously published 
conditions (lane 1) are superior. 
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performed using copper(II) chloride with nicotinamide adenine dinucleotide and 
copper(II) sulfate with nicotinamide adenine dinucleotide to test whether a 
copper(II) catalyst reduced to copper(I) would be advantageous for the reaction. 
None of these copper sources were able to outperform the previously established 
CuI, as determined by SDS-PAGE (Figure 2.3).  
Literature studies involving the synthesis of diyne-containing peptide 
macrocycles have suggested that the addition of a nickel-containing co-catalyst 
may improve coupling efficiencies and increase reaction rates.38 Therefore, 
Ni(NO3)2•6H2O (500 mM, 5 µL) was added to the catalyst system in conjunction 
with CuI. The addition of Ni(NO3)2•6H2O to the catalyst system was tested with 
each of the previously described copper sources and was compared to a control 
reaction which contained no added Ni(NO3)2•6H2O. Unfortunately, the addition of 
Ni(NO3)2•6H2O caused complete degradation of protein for each copper source 
tested. As a result, additional studies involving the addition Ni(NO3)2•6H2O with 
various radical scavengers and reducing agents were not warranted.  
The next factor to be investigated was the effect of the ligand on the 
Glaser-Hay bioconjugation. Early 
attempts with nitrogenous 
monodentate ligands (TEA, pyrrolidine, 
etc.) did not lead to substantial 
coupling, and a more thorough 
investigation of bidentate nitrogenous 
ligands followed (Figure 2.4). 
Figure 2.4: Structures of ligands employed in 
Glaser-Hay bioconjugation optimization. 
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Ligands 3 and 4 were selected to investigate the optimal chelation ring size, 
and 5, 6, and 7 were employed to probe the substitution of the nitrogen atom. 
Finally, 8 and 9 were selected to alter the electronic environment of the nitrogen 
atoms, while simultaneously testing 
the necessity of chelation. Each 
ligand was tested in the presence 
and absence of a reducing agent, 
tris(2-carboxyethyl)phosphine or 
nicotinamide adenine dinucleotide, 
to determine whether or not the 
combination of a different ligand and 
a copper(II) catalyst reduced to copper(I) would provide an improvement off of 
the previously published 
conditions. These experiments 
indicated that both the 2,2-
bipyridyl ligand (8) and the 
diaminopropane ligand (3), to a 
much lesser extent, were as 
good as or better than 2, with 4-
fold and 0.8–1.2-fold increases 
in coupling efficiency, respectively. Because the results using 8 were dramatically 
better than those using 3, only 8 was tested in future experiments. Despite the 
fact that coupling efficiencies were drastically improved using 8, it had limited 
Figure 2.6: Comparison of dipyridyl nitrogenous ligands, 
with and without addition of reducing agent TCEP. 
Results indicate that in the absence of TCEP, ligands 8 
and 10 show increased coupling over the previously 
published conditions (lane 2). Furthermore, by fully 
solubilizing ligand 10, coupling is enhanced and 
degradation is reduced.  
Figure 2.5: Comparison of dipyridyl nitrogenous 
ligands. Ratios indicate that 8 and 10 result in 
increased coupling over the previously published 
conditions (lane 1), though poor solubility of 10 
resulted in protein degradation and non-optimal 
coupling.   
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solubility in aqueous media, so the commercially available 10 was explored to 
overcome these issues (Figure 2.5). After overcoming initial solubility 
issues, 10 afforded a coupling efficiency nearly 7 times greater than that of 2, 
also surpassing the coupling efficiencies achieved using the less soluble 8. It was 
hypothesized that the combination of the electronic effects of the bipyridyl ligand 
coupled with the rigidity of the ligand aided in the chelation and activation of the 
copper center to improve the reaction.  
After elucidating that ligand 10 resulted in superior coupling, we explored 
whether other copper sources, radical scavengers, or reducing agents would 
further increase the coupling efficiency with these ligands. Varying these other 
conditions did not afford enhanced results, as copper(I) iodide with no added 
agents remained the best condition using either 2 or 10 (Figure 2.6). 
The next variable examined was the effect of solution pH on the reaction. 
GFP was buffer exchanged into PBS at pH 6.0, pH 7.4, pH 8.0, and pH 9.0. Both 
the original ligand (2) and 10 were used for Glaser-Hay couplings in each pH 
solution. Interestingly, reactions employing 2 exhibited higher coupling ratios at 
Figure 2.7: Effect of pH with ligand 2 on 
coupling. Results indicate that optimal coupling 
occurs at pH 6 when ligand 2 is used, which 
represents an increase over the previously 
published conditions (lane 2). 
 
Figure 2.8: Effect of pH with ligand 10 on coupling. 
Results indicate that optimal coupling occurs at pH 
8.0 when ligand 10 is used. Ligand 10 at all pH 
points represents an increase in coupling over 
previously published conditions (lane 1). 
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pH 6.0, and reactions using 10 had the highest Glaser-Hay coupling at pH 8.0 
(Figures 2.7 and 2.8). It was hypothesized that 10 functioned best at pH 8.0 due 
to solubility factors. Because the solubility of 10 was increased upon the addition 
of base, a greater amount was available for reaction at higher pH values as the 
ligand was more completely dissolved. At a pH of 9.0; however, the pH was 
increased to the point where protein degradation became significant and coupling 
efficiencies were reduced. Less degradation of protein was observed under both 
of these new conditions, as observed by comparable amounts of protein on the 
gels as the control reactions, and minimized oxidative damage by MS.  
Due to the decreased oxidative damage, these conditions were then 
employed at different temperatures to see if coupling ratios could be increased 
further, as the previously published conditions were performed at 4 °C to 
minimize degradation. Identical 
reactions with both ligands were 
conducted at 4, 22, 30, and 37 °C for 
4 hours. After quantitation by SDS-
PAGE, the most effective coupling 
condition with the least amount of 
protein degradation was found to be 
room temperature (22 °C) for both 
ligands (Figure 2.9). As a final optimization, the two ligands were employed at 
their appropriate pH and at room temperature over a timespan of 24 hours. The 
results indicate that for both conditions, protein degradation begins to become a 
Figure 2.9: Effect of reaction temperature on 
coupling. Results indicate that room 
temperature (22°C, lane 2) affords an 
increase in coupling over the previously 
published conditions (lane 1). The same trend 
was observed when 10 was used.  
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factor after approximately 8 hours, leading to a subsequent decrease in Glaser-
Hay bioconjugations. The timecourse experiments also reveal that the 
conjugations employing 10 result in less overall protein degradation relative to 
conditions using 2 (Figure 2.10). This decreased degradation allows for 
increased reaction times, which facilitates higher levels of coupling. In the case 
of 2, lowering the pH to 6.0 appears to accelerate the reaction rate, improving 
coupling prior to degradation. 
 
Fig. 2.10: Timecourse data for optimized Glaser-Hay bioconjugations demonstrating coupling 
efficiency (lines) in combination with protein degradation (bars). (A) Timecourse of the Glaser-
Hay bioconjugation with ligand 10, pH 8. (B) Timecourse of the Glaser-Hay bioconjugation with 
ligand 2, pH 6. All reactions were conducted in triplicate to establish appropriate standard 
deviations. 
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Ultimately, two optimized conditions were elucidated that improved 
coupling efficiency and/or minimized protein degradation, resulting in yields of 
∼95% or greater as determined by absorbance spectroscopy. For ligand 2, 
reactions performed at 22 °C, pH 6.0, for 4 hours afforded the best results, 
while 10 functioned best at 22 °C, pH 8.0, for 8 hours (Figure 2.11). Each of these 
conditions facilitates substantial improvement over the previously published 
conditions of 2, 4 °C, pH 7.4, for 4 hours. Selection of appropriate ligand is most 
likely application dependent, as 2 affords shorter reaction times to obtain the 
bioconjugate, while 10 provides slower couplings, but with less protein 
degradation. 
 
Figure 2.11: Optimized Glaser-Hay Bioconjugations. (A) SDS-PAGE analysis of the best 
conditions for the bioconjugation compared to a negative control (lane 1) and the previously 
reported conditions (lane 2). The fluorescence (bottom gel) indicates degree of fluorophore 
coupling and the Coomassie stain (top gel) indicates relative protein concentrations. Ultimately 2, 
pH 6, 4 h (lane 3) and ligand 10, pH 8, 8 h (lane 4) afforded the highest bioconjugate yields with 
minimal protein degradation. (B) Graphical representation of the gel densiometry analysis 
performed on three independent SDS-PAGE experiments quantifying the optimized conditions. 
 
In conclusion, two new reaction conditions have been developed towards 
optimizing Glaser-Hay bioconjugations. The ability to increase coupling 
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efficiency, while simultaneously reducing harmful protein degradation, increases 
the overall utility of this reaction. Expanding the chemical toolbox of 
bioorthogonal bioconjugations is essential towards the preparation of various 
conjugates having medical and materials based applications. The Glaser-Hay 
reaction in particular is unique in its installation of a linear, carbon-carbon 
covalent bond, which also facilitates secondary reactions from the diyne moiety. 
Either lowering the pH with the traditional TMEDA ligand, or employing a 
carboxylated biphenyl ligand generates more efficient couplings with less 
degradation than the previously reported conditions. 
III. Materials and Methods 
General: Solvents and reagents were obtained from either Sigma Aldrich or 
Fischer Scientific and used without further purification. Plasmids were provided 
by the laboratory of Dr. Peter Schultz at The Scripps Research Institute. All 
proteins were purified according to manufacturer’s protocols using a Qiagen Ni-
NTA Quik Spin Kit. Reactions were performed in ambient conditions with non-
distilled solvents. SDS-PAGE gels were imaged on a BioRad Molecular Imager 
(Gel Doc XR+). 
Synthesis of p-propargyloxyphenylalanine (pPrF): Boc-Tyrosine-OMe (114 
mg, 2 eq, 0.39 mmol) was placed in a flame-dried vial. Cesium carbonate (254 
mg, 3 eq, 0.58 mmol) was then added, followed by dry DMF (3 mL). This mixture 
was stirred at 100 °C for 20 minutes. 5- Bromo-1-pentyne (20 μL, 1 eq, 0.19 
mmol) was then added to the mixture, as well as a catalytic amount of potassium 
iodide. The reaction was stirred overnight at 100 °C, then cooled to room 
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temperature and washed with brine (10 mL) and diethyl ether (10 mL). The 
organic layer was then washed with brine (10 mL x 3). The aqueous layer was 
then back-extracted with ether (10 mL). The organic layers were combined, dried 
with magnesium sulfate, filtered, and solvent was removed under reduced 
pressure. Column chromatography (silica gel, 5:1 hexanes/ethyl acetate) was 
performed to yield the desired product as a white crystalline solid (22 mg, 0.061 
mmol, 31.6% yield). 1H NMR (400 MHz, CDCl3): δ 7.02 (d, J = 12 Hz, 2 H), 6.82 
(d, J = 12 Hz, 2 H), 4.95 (d, J = 8 Hz, 1 H), 4.53 (d, J = 8 Hz, 1 H), 4.03 (t, J = 4 
Hz, 2 H), 3.71 (s, 3 H), 3.02 (m, J = 8 Hz, 1 H), 2.39 (t, J = 4 Hz, 2 H), 1.97 (m, J 
= 8 Hz, 2 H), 1.55 (s, 1 H), 1.41 (s, 9 H). 13C NMR (400 MHz, CDCl3): δ 172.4, 
157.9, 130.3, 127.9, 114.5, 83.5, 79.9, 68.8, 66.0, 54.5, 52.2, 37.4, 28.3, 28.2, 
21.1, 15.1.  
Expression of GFP containing pPrF: A pET-GFP-TAG plasmid (0.5 μL) was 
co-transformed with a pEVOL-pPrF aaRS plasmid (0.5 μL) into Escherichia 
coli BL21 (DE3) competent cells using an Eppendorf Eporator electroporator. 
The cells were then plated (100 μL) on LB agar supplemented with ampicillin 
(50 μg/mL) and chloramphenicol (34 μg/mL), then incubated for 16 hours at 
37 °C. One colony was used to inoculate LB media (10 mL) containing ampicillin 
and chloramphenicol. The culture was incubated overnight at 37 °C and used to 
initiate an expression culture (250 mL media, ampicillin 50 μg/mL, 
chloramphenicol 34 μg/mL) at an OD600 = 0.1. The cultures were incubated at 
37 °C until an OD600 = 0.7 was reached. Protein expression was induced by the 
addition of 20% arabinose (250 μL), 0.8 mM isopropyl-β-D-1-
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thiogalactopyranoside (IPTG; 250 μL), and pPrF (1) (2.5 mL, 100 mM). Cultures 
were incubated at 30 °C overnight, then pelleted by centrifugation (5000 rpm, 
10 minutes). Pelleted cells were stored at −80 °C until purification. The cell pellet 
was resuspended with 500 μL of Bugbuster (Novagen) containing lysozyme, and 
200 μL of lysis buffer and incubated for 20 minutes at 37 °C. Cellular debris was 
pelleted out by centrifugation at 5000 rpm for 10 minutes and the supernatant 
was added to an equilibrated Ni-NTA resin (200 μL). GFP was purified according 
to manufacturer’s protocol before being analyzed by SDS-PAGE (BioRad 10% 
precast gels, 150 V, 1.5 hours). Gels were stained using Coomassie Brilliant 
Blue, and destained using destain solution (60% deionized water, 30% MeOH, 
10% acetic acid). 
Biological Glaser-Hay reaction under optimized condition 1: To a sterile 
1.5 mL eppendorf tube, the following were added: 5 μL of a vigorously shaken 
solution of CuI (500 mM in H2O) and 5 μL of tetramethylethylenediamine (2 in 
500 mM in H2O). The two solutions were thoroughly mixed by pipetting. Next, 
30 μL of GFP containing a terminal alkyne UAA (GFP/pPrF; pH = 6.0, 
1.04 ± 0.03 mg/mL) and 20 μL of Alexa Fluor-488 Alkyne (1 mM in DMSO) were 
added to the tube. Negative control reactions were performed containing 10 µL 
1x PBS (pH 7.4) in place of the tetramethylethylenediamine ligand and CuI. The 
reaction was incubated at room temperature (22 °C). After 4 hours, excess 
reactants were removed by buffer exchange using Corning Spin-X UF 
concentrator columns. The reaction was washed with PBS (8 × 200 μL) to a final 
volume of 50 μL. The reaction was analyzed by SDS-PAGE and imaged 
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immediately to analyze fluorescence. The gel was then stained for 3 hours using 
Coomassie Brilliant Blue, then destained overnight using a methanol solution 
(60% deionized water, 30% MeOH, 10% acetic acid). The gel was then analyzed 
again after 24 hours. 
Biological Glaser-Hay reaction under optimized condition 2: To a sterile 
1.5 mL eppendorf tube, the following were added: 5 μL of a vigorously shaken 
solution of CuI (500 mM in H2O) and 5 μL of 2,2′-Bipyridine-4,4′-dicarboxylic acid 
(10, 500 mM in 1 M NaOH). The two solutions were thoroughly mixed by pipetting 
until a dark brown color was achieved. Next, 30 μL of GFP containing a terminal 
alkyne UAA (GFP/pPrF; pH = 8.0, 1.04 ± 0.03 mg/mL) and 20 μL of Alexa Fluor-
488 Alkyne (1 mM in DMSO) were added to the tube. The reaction was 
incubated at room temperature (22 °C). Negative control reactions were 
performed containing 10 µL 1x PBS (pH 7.4) in place of the 2,2’-Bipyridine-4,4’-
dicarboxylic acid ligand and CuI. After 8 hours, excess reactants were removed 
by buffer exchange using Spin-X UF concentrator columns. The reaction was 
washed with PBS (8 × 200 μL) to a final volume of 50 μL. The reaction was 
analyzed by SDS-PAGE and imaged immediately to analyze fluorescence. The 
gel was then stained for 3 hours using Coomassie Brilliant Blue, then destained 
overnight using a methanol solution (60% deionized water, 30% MeOH, 10% 
acetic acid). The gel was then analyzed again after 24 hours. 
References 
1. Hermanson, G. T. Bioconjugate Techniques, 3rd ed.; Academic 
Press: London, 1996. 
51 
 
 
2. Lang, K.; Chin, J. Cellular Incorporation of Unnatural Amino Acids and 
Bioorthogonal Labeling of Proteins. Chem. Rev. 2014, 114, 4764-4806. 
3. Sievers, E. L.; Senter, P. D. Antibody-drug Conjugates in Cancer 
Therapy. Annu. Rev. Med. 2013, 64, 15-29. 
4. Jaiswal, J. K.; Mattoussi, H.; Mauro, J. M.; Simon, S. M. Long-term 
Multiple Color Imaging of Live Cells using Quantum Dot Bioconjugates. 
Nat. Biotechnol. 2003, 21, 47-51. 
5. Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W.; Nie, S. In vivo Cancer 
Targeting and Imaging with Semiconductor Quantum Dots. Nat. 
Biotechnol. 2004, 22, 969-976. 
6. Ghosh, S.; Kao, P.; Mccue, A.; Chappelle, H. Use of Maleimide-thiol 
Coupling Chemistry for Efficient Syntheses of Oligonucleotide-enzyme 
Conjugate Hybridization Probes. Bioconjug. Chem. 1990, 1, 71-76. 
7. Kumaresan, P.; Luo, J.; Song, A.; Marik, J.; Lam, K. Evaluation of 
Ketone-oxime Method for Developing Therapeutic on-demand 
Cleavable Immunoconjugates. Bioconjug. Chem. 2008, 19, 1313-1318. 
8. Khare, P.; Jain, A.; Gulbake, A.; Soni, V.; Jain, N.; Jain, S. 
Bioconjugates: Harnessing Potential for Effective Therapeutics. Crit. 
Rev. Therap. Drug Carr. Sys. 2009, 26, 119-155. 
9. Kalia, J.; Raines, R. Advances in Bioconjugation. Curr. Org. Chem. 
2010, 14, 138-147. 
10. Stephanopoulos, N.; Francis, M. Choosing an Effective Protein 
Bioconjugation Strategy. Nat. Chem. Biol. 2011, 7, 876-884. 
52 
 
 
11. Smith, M. T.; Wu, J. C.; Varner, C. T.; Bundy, B. C. Enhanced Protein 
Stability through Minimally Invasive, Direct, Covalent, and Site-specific 
Immobilization. Biotechnol. Prog. 2013, 29, 247-254. 
12. Liu, C.; Schultz, P.; Kornberg, R.; Raetz, C.; Rothman, J.; Thorner, J. 
Adding New Chemistries to the Genetic Code. Ann. Rev. Biochem. 
2010, 79, 413-444. 
13. Wang, L.; Schultz, P. G. Expanding the Genetic Code. Angew. Chem. 
Int. Ed. Engl. 2004, 44, 34-66. 
14. Young, T. S.; Schultz, P. G. Beyond the Canonical 20 Amino Acids: 
Expanding the Genetic Lexicon. J. Biol. Chem. 2010, 285, 11039-
11044. 
15. Kim, C. H.; Axup, J. Y.; Schultz, P. G. Protein Conjugation with 
Genetically Encoded Unnatural Amino Acids. Curr. Opin. Chem. Biol. 
2013, 17, 412-419. 
16. Maza, J.; Jacobs, T.; Uthappa, D.; Young, D. Employing Unnatural 
Amino Acids in the Preparation of Bioconjugates. Synlett 2016, 27, 
885. 
17. Deiters, A.; Schultz, P. G. In vivo Incorporation of an Alkyne into 
Proteins in Escherichia coli. Bioorg. Med. Chem. Lett. 2005, 15, 1521-
1524. 
18. Vilhelmsen, M.; Jensen, J.; Tortzen, C.; Nielsen, M. The Glaser-Hay 
Reaction: Optimization and Scope Based on C-13 NMR Kinetics 
Experiments. Eur. J. Org. Chem. 2013, 4, 701-711. 
53 
 
 
19. Fomina, L.; Vazquez, B.; Tkatchouk, E.; Fomine, S. The Glaser 
Reaction Mechanism A DFT Study. Tetrahedron 2002, 58, 6741-6747. 
20. Hay, A. Oxidative Coupling of Acetylenes. J. Org. Chem. 1962, 27, 
3320. 
21. Glaser, C. Beiträge zur Kenntniss des Acetenylbenzols. Ber. Dtsch. 
Chem. Ges. 1869, 2, 422-424. 
22. Nizami, T.; Hua, R. Cycloaddition of 1,3-butadiynes: Efficient Synthesis 
of Carbo- and Heterocycles. Molecules 2014, 19, 13788-13802. 
23. Yang, L.; Hua, R. Cycloaddition of 1,4-Diaryl-1,3-butadiynes with 
Nitriles: An Atom-economic One-pot Approach to Benzo[f]quinazolines 
Chem. Lett. 2013, 42, 769-771. 
24. Sun, H.; Wu, X.; Hua, R. Copper(I)-catalyzed Reaction of Diaryl Buta-
1,3-diynes with Cyclic Amines: An Atom-economic Approach to Amino-
substituted Naphthalene Derivatives. Tet. Lett. 2011, 52, 4408-4411. 
25. Pigulski, B.; Mecik, P.; Cichos, J.; Szafert, S. Use of Stable Amine-
capped Polyynes in the Regioselective Synthesis of Push-pull 
Thiophenes. J. Org. Chem. 2017, 82, 1487-1498. 
26. Yu, D.; de Azambuja, F.; Gensch, T.; Daniliuc, C.; Glorius, F. The C-H 
Activation/1,3-diyne Strategy: Highly Selective Direct Synthesis of 
Diverse Bisheterocycles by Rh-III Catalysis. Angew. Chem. Int. Ed. 
2014, 53, 9650-9654. 
54 
 
 
27. Matsuda, H.; Nakanishi, H.; Hosomi, T.; Kato, M. Synthesis and Solid-
State Polymerization of a New Diacetylene. Macromolecules 1988, 21, 
1238-1240. 
28. Iyoda, M.; Yamakawa, J.; Rahman, M. Conjugated Macrocycles: 
Concepts and Applications. Angew. Chem. Int. Ed. 2011, 50, 10522-
10553. 
29. Sindhu, K.; Anilkumar, G. Recent Advances and Applications of Glaser 
Coupling Employing Greener Protocols. RSC Adv. 2014, 4, 27867-
27887. 
30. Brauer, M.; Neves, R.; Westermann, B.; Heinke, R.; Wessjohann, L. 
Synthesis of Antibacterial 1,3-diyne-linked Peptoids from an Ugi-
4CR/Glaser Coupling Approach. Beil. J. Org. Chem. 2015, 11, 1-6. 
31. Verlinden, S.; Geudens, N.; Martins, J.; Tourwe, D.; Ballet, S.; 
Verniest, G. Oxidative Alpha, Omega-diyne Coupling as an Approach 
towards Novel Peptidic Macrocycles. Org. Biomol. Chem. 2015, 13, 
9398-9404. 
32. Lampkowski, J. S.; Villa, J. K.; Young, T. S.; Young, D. D. 
Development and Optimization of Glaser-Hay Bioconjugations. Angew. 
Chem. Int. Ed. Engl. 2015, 54, 9343-9346. 
33. Maza, J. C.; McKenna, J. R.; Raliski, B. K.; Freedman, M. T.; Young, 
D. D. Synthesis and Incorporation of Unnatural Amino Acids to Probe 
and Optimize Protein Bioconjugations. Bioconjug. Chem. 2015, 26, 
1884-1889. 
55 
 
 
34. Maza, J.; Howard, C.; Vipani, M.; Travis, C.; Young, D. Utilization of 
Alkyne Bioconjugations to Modulate Protein Function. Bioorg. Med. 
Chem. Lett. 2017, 27, 30-33.  
35. Ueda, J.; Shimazu, Y.; Ozawa, T. Reactions of Copper(II)-oligopeptide 
Complexes with Hydrogen Peroxide: Effects of Biological Reductants. 
Free Radic. Biol. Med. 1995, 18, 929-933. 
36. Maza, J.; Nimmo, Z.; Young, D. Expanding the Scope of Alkyne-
mediated Bioconjugations Utilizing Unnatural Amino Acids Chem. 
Commun. 2016, 52, 88-91.  
37. Philippe, J.; Chodkiewicz, W.; Cadiot, P. Coupling of 1-haloalkynes 
with True Acetylenes-utilization of 1-chloroalkynes. Tet. Lett. 1970, 21, 
1975. 
38. Verlinden, S.; Geudens, N.; Martins, J. C.; Tourwe, D.; Ballet, S.; 
Verniest, G. Oxidative α,ω-diyne Coupling as an Approach towards 
Novel Peptidic Macrocycles. Org. Biomol. Chem. 2015, 13, 9398-9404. 
Acknowledgements 
I would like to thank Lindsay Chatkewitz for her initial work on this project as well 
as Zachary Nimmo for his assistance in the completion of the optimization of this 
protocol.  
 
 
56 
 
 
Chapter 3: Toward the Development of 
Trivalent Conjugates 
I. Introduction 
 Bioconjugation is a broad term that involves the coupling of a 
biomacromolecule, such a protein or DNA, to another biomacromolecule or a 
smaller molecule such as a fluorophore, small molecule probe, or solid-support.1 
The development and preparation of multivalent bioconjugates is a developing 
field that relies on contributions from both biology and chemistry.1 Numerous 
applications in enzyme immobilization, therapeutics, diagnostics, and materials 
science have benefited from the ability to prepare multivalent systems.1-3 Several 
criteria must be met in order to employ bioconjugation reactions due to the 
biological components involved. The reactions must be able to occur under the 
mild physiological conditions required by biological systems, a pH near 7.2 and 
temperatures near 37 °C, in order to prevent degradation of reaction 
components.1 In addition, reactions must be orthogonal, meaning that they do 
not cross-react with components within the endogenous biological system.1-3 In 
order to prepare multivalent conjugates with proteins under favorable conditions, 
reactions often must first be optimized under organic conditions and translated to 
a physiological setting. Research into the development of novel bioorthogonal 
reactions is a rapidly growing field as they have substantial applicability within 
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biological chemistry, and are specifically required when constructing multivalent 
bioconjugates due to the requirement for multiple reactions.  
 Despite the fact that bioconjugates have drawn substantial attention owing 
to their numerous applications, certain limitations must be addressed in order to 
expand the utility of multivalent conjugates. Most current research has focused 
on the preparation of bivalent conjugates involving only the conjugation between 
two reaction partners, and requiring only a single reaction. While conjugation 
systems containing two functionalities have a variety of applications, there are 
instances where conjugation systems may require more than two functionalities, 
necessitating the need to develop additional reactions based on the functionality 
introduced by the initial conjugation reaction.1 In addition, many current 
methodologies for preparing bioconjugates suffer from a lack of specificity.3 
Methods to produce conjugates using reactive residues such as the amine group 
of lysine or the thiol group of cysteine have been successfully implemented.4 
Nevertheless, these methods rely on the relatively limited amount of reactions 
possible using the naturally occurring amino acids. In addition, these reactions 
can lead to the formation of heterogenous mixtures resulting from random 
coupling.4 This is problematic in protein immobilization as random binding may 
lead to the active site of the enzyme being blocked by the solid support.5,6 In 
addition, attempts to form antibody drug conjugates will be hindered by the fact 
that some antibodies may be conjugated multiple times while others may not be 
conjugated at all, leading to a conjugate mixture with varying properties such as 
stability, pharmacokinetics, affinity, and efficacy.4,7 Furthermore, the non-
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orthogonal nature of these reactions prevents them from being applied to 
biological settings, as side reactions can occur involving other proteins within the 
system aside from the protein of interest resulting from the prevalence of 
cysteine and lysine residues in most proteins.3 UAA technology has been shown 
to be an effective solution to address these limitations. By site-specifically 
incorporating UAAs into proteins, bioorthogonal reactions between a protein and 
a reactive group can be carried out in a controlled manner at the selected site.  
  The ability to site-specifically incorporate UAAs which can then participate 
in bioorthogonal conjugation reactions has led to several exciting applications. 
UAAs have been 
site-specifically 
incorporated into 
antibodies, 
which can then 
be conjugated 
with various small molecules allowing the formation of antibody drug conjugates 
(ADCs) (Figure 3.1).4,7 Unlike previous attempts using reactive amino acid 
residues, the use of site-specifically incorporated UAAs allows for the formation 
of homogenous ADCs.4,7 Upon binding of the ADC to its associated antigen, 
these ADCs can then be endocytosed into the cell where the antibody will be 
degraded in the lysosome, allowing release of the cytotoxic drug.4 UAA-
technology has also been implemented in enzyme immobilization, allowing for 
orientated immobilization to occur using bioorthogonal coupling reactions 
Figure 3.1: Formation of an Antibody Drug Conjugate using a site-
specifically incorporated UAA.4 
59 
 
 
between a UAA-containing enzyme and a solid-support.5,8 This serves an 
important role in lowering the costs of industrial processes by allowing better 
control over reactions, recyclability of enzymes, and improved enzyme stability.5,8 
Further applications of protein immobilization have arisen through the 
development of protein biochips.9,10 Protein biochips have allowed for exciting 
developments to be made in diagnostics. These biochips require the 
immobilization of multiple proteins onto a surface.10 High-throughput screenings 
can then be performed by screening thousands of samples in parallel using 
microarrays.10 These biochips can ultimately be used as a more efficient and 
cost-effective diagnostic tool for the identification of disease biomarkers allowing 
expression profiles to be rapidly and accurately compared in patients and healthy 
individuals.10 The ability to site-specifically immobilize proteins in an oriented 
manner has greatly contributed to the success of this technique. Finally, 
bioconjugation reactions can be utilized in the fluorescent labeling of proteins in 
order to determine the localization of proteins within cells, which can be useful for 
diagnostics (Figure 3.2).11-13 In addition, fluorescence labeling allows for real-time 
studies of conformational 
changes, protein activity, 
and protein interactions.13 
The ability to perform 
bioorthogonal reactions 
between UAA-containing 
proteins and reactive 
Figure 3.2: Protein labeling using a site-specifically 
incorporated UAA followed by a bioorthogonal coupling 
reaction.14 
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functionalities within biological systems is essential in order to maximize the 
potential utility of multivalent conjugates.  Multivalent conjugations are especially 
intriguing as they have the ability to combine several of the previously mentioned 
bioconjugations into a single conjugate. 
Several types of bioconjugation reactions have been implemented toward 
the preparation of bioconjugates. The copper(I)-catalyzed 1,3-dipolar 
cycloaddition 
reaction or “Click” 
reaction is one of 
the most commonly 
utilized bioorthogonal reactions (Scheme 3.1). The reaction was first described 
by Huisgen and involves coupling between a terminal alkyne and an azide to 
form a highly stable 1,4-disubstituted 1,2,3-triazole.15 In separate studies, 
Sharpless and Meldal 
found that the addition of 
copper (I) significantly 
enhanced the reaction rate 
while allowing the reaction 
to be carried out at lower 
temperatures, making it 
suitable for bioorthogonal 
reactions in physiological systems.16,17 This has allowed for its use in a wide 
variety of applications including materials science, drug discovery, and organic 
Scheme 3.1: The 1,3-dipolar cycloaddition yielding a 1,4-disubstituted 
1,2,3-triazole. 
Figure 3.3: A proposed mechanism for the 1,3-dipolar 
cycloaddition reaction.18 
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synthesis.1 The reaction involves the formation of a copper acetylide to activate 
terminal alkynes (Figure 3.3).1,17 The use of tetradentate ligands such as 
tris(benzyltriazolylmethyl) amine (TBTA) has been shown to further enhance the 
reaction rate, allowing reaction times between 2-12 hours.1 In addition, TBTA 
stabilizes the oxidation state of the copper (I) catalyst, preventing it from being 
oxidized into CuII or disproportionating into CuII and Cu0, which modulates and 
increases the reactivity of the copper catalyst throughout the reaction.15,19 The 
addition of a reducing agent such as TCEP can also stabilize the oxidation state 
of copper (I).20 Despite these benefits, the use of copper in this reaction poses 
some limitations. Copper undergoes redox side-reactions that increase toxicity 
and may lead to protein degradation.1 In addition, the poor solubility of certain 
ligands necessitates the use of DMSO to increase solubility, which may 
negatively impact the reaction.1 Despite these limitations, the development and 
successful incorporation of an azide containing UAA, pAzF, has allowed this 
reaction to be utilized within biological systems within the context of proteins.   
 Another valuable bioconjugation reaction involves the coupling of terminal 
alkynes to form a linear diyne product (Scheme 3.2).21 The reaction was first 
reported in 1869 by Glaser and utilized a copper salt and a base, such as 
ammonia in the presence of oxygen.21,22 It is the oldest reaction involving 
coupling of acetylenes.21 Improvements to the reaction were made by Hay in 
1962 utilizing the bidentate tetramethylethylenediamine (TMEDA) ligand as a 
 Scheme 3.2: The Glaser-Hay coupling reaction between terminal alkynes. 
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copper-stabilizing ligand.23 The modified reaction, termed as the Glaser-Hay 
reaction, could proceed at significantly lower temperatures and higher reaction 
rates, making it highly valuable to synthetic chemists due to its mild nature.23 
DFT studies have suggested that the reaction involves a dicopper(III) 
intermediate (Figure 3.4). These studies propose a catalytic cycle from CuI to 
CuIII to CuII back to CuI with the key step being dioxygen activation.21 The 
synthesis and 
incorporation of a 
terminal alkyne-
containing UAA, 
pPrF, has 
allowed for the 
implementation of 
this reaction in 
biological systems. Due to the lack of knowledge about its feasibility in aqueous 
solvents, its use as a bioconjugation reaction remained relatively unexplored. In 
fact, the Glaser-Hay reaction has only recently been applied to biological 
reactions under physiological conditions. It was demonstrated that the Glaser-
Hay reaction could be used to couple a protein to a fluorophore molecule with 
minimal protein degradation and high coupling efficiency.25 This was done at 
relatively low temperatures with relatively high reaction rates.25 Furthermore, the 
reaction has been applied to the immobilization of proteins to resins.5 The 
reaction yields a stable linear diyne product through the formation of a new 
Figure 3.4: The proposed Glaser-Hay reaction mechanism using DFT 
studies.24 
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carbon-carbon bond. The product is electron rich, making it highly reactive and 
susceptible to further modification.1 The reaction is beneficial over the 1,3-
dipolarcycloaddition reaction as there are no regioselectivity issues.1 In addition, 
the reaction only relies on a Cu(I) source and TMEDA, both of which are 
common biological reagents, making it a convenient choice for use in the 
development of multivalent conjugates.1  
While both the Glaser-Hay and 1,3-dipolar cycloaddition coupling 
reactions have proven effective in the development of bivalent systems involving 
two functionalities, our next goal is to utilize these systems to incorporate a third 
functionality, which requires initial optimization of reactions in an organic solvent 
followed by the eventual transfer to biological systems. The Glaser-Hay reaction 
may be ideal for this approach due to the potential reactivity of the diyne 
functionality, whereas the triazole moiety is substantially more limited in engaging 
in secondary reactions. One such reaction which is relevant toward this goal is 
the formation of pyrroles through the reaction of a diyne and aniline.26 This 
reaction has been successfully employed using high temperatures and metal 
catalysts; however, the reaction conditions must be altered as they are not suited 
for biological systems.26 This reaction serves as a model reaction which will be 
optimized and utilized toward the development of trivalent conjugates under 
biological conditions. 
Herein, the initial stages toward the development of trivalent conjugates 
are described. First, the initial stages toward the development of protein hetero 
and homodimers using Green Fluorescent Protein (GFP) and Ubiquitin (Ub) are 
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described to prepare relevant bivalent conjugates that can readily be employed in 
subsequent conjugation reactions. The systematic optimization of both 1,3-
dipolarcycloaddition and Glaser-Hay couplings toward this end are described. 
Upon successful synthesis of protein dimers, reaction conditions allowing the 
attachment of a third group, such as DNA, proteins, fluorophores, or other small 
molecules will be explored to obtain trivalent conjugates (Figure 3.5). 
Additionally, several organic reactions are examined for their ability to add a third 
functional group onto a diyne. Specifically, the utilization of various ligands 
toward the synthesis of pyrrole rings using dimers of phenylacetylene or 
propargyl alcohol with aniline are examined. In addition, the use of microwave 
irradiation in the synthesis of pyrrole rings using these phenylacetylene and 
propargyl alcohol dimers with azidoheptane and benzyl azide was investigated. 
These reaction conditions will be optimized in an organic environment to assess 
their ability to form the desired product, allowing the eventual application of these 
reactions to biological systems.   
Figure 3.5: Organic optimization and utilization of bioorthogonal reactions for the preparation 
of trivalent conjugates.  
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II. Results and Discussion 
A. Toward the Development of Heterodimers via Bioorthogonal Reactions 
 Out of a desire to obtain trivalent conjugates of either a homo or hetero 
protein dimer, we sought to develop a method to obtain protein dimers through 
previously developed bioorthogonal reactions. Ideally, these protein dimers will 
be joined using a diyne 
linkage so that a third 
group, either DNA, a 
fluorophore, or other small 
molecule could be added 
using reactions similar to 
those described in the 
next section (Figure 3.6). 
This section describes the 
systematic optimization of a Glaser-Hay dimerization reaction to yield homo and 
heterodimers. Reactions were also tested using 1,3-dipolar cycloaddition 
reactions; however, due the stable and unreactive nature of the obtained triazole 
product, these products are less likely to be used for further reactions to yield 
trivalent conjugates.   
Two proteins were selected for dimerization studies, ubiquitin (Ub) and 
green fluorescent protein (GFP). A WT Ub and a Ub plasmid containing a 
mutation at residue 45 (Ub 45) was obtained from the Cropp Lab at Virginia 
Commonwealth University. Ub was selected as a viable protein for dimerization 
Figure 3.6: Schematic representation of the targeted 
homodimer (A) and heterodimer (B) structures.27,28  
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studies due to its small size and lack of steric bulk, which we believed would 
allow it to effectively react with other proteins. Green Fluorescent Protein (GFP) 
was selected as a coupling partner for dimerization expressions due to its high 
expression levels, fluorescent properties, relatively small size, and the availability 
of GFP containing mutations at multiple residues, 3, 133, and 151. Each of these 
mutations have been shown in previous studies to be capable of successfully 
undergoing biorthogonal reactions. Prior to beginning dimerization studies, the 
relative efficiency of Ub to undergo 
bioorthogonal reactions was tested. 
The 1,3-dipolar cycloaddition 
reaction and the Glaser-Hay 
reaction were intended to be used 
in dimerization studies; therefore, 
the ability of Ub 45 to participate in 
both reactions needed to be 
confirmed. Ub 45 was expressed 
using both an azide-containing 
UAA, pAzF, and a terminal alkyne-
containing UAA, pPrF, allowing Ub 
45 to participate in both 1,3-dipolarcycloaddition reactions or Glaser-Hay 
reactions. Reactions were carried out between pAzF or pPrF-Ub 45 and Alexa 
Fluor-488 Alkyne. Control 1,3-dipolarcycloaddition reactions and Glaser-Hay 
reactions using GFP 151 were prepared and compared to those using Ub 45. 
Figure 3.7: SDS-PAGE analysis of Glaser-Hay and 
1,3-dipolar cycloaddition reactions using Ub and GFP. 
Reactions between GFP 151-pPrF (Lane 1) and Ub 
45-pPrF (Lane 2) and Alexa Fluor-488 Alkyne yielded 
low to moderate coupling. Reactions between GFP 
151-pAzF (Lane 3) and Ub 45-pAzF (Lane 4) with 
Alexa Fluor-488 Alkyne yielded excellent coupling.  
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The presence of fluorescent bands at approximately 8.5 kDa indicates successful 
coupling of Ub 45 to the fluorophore using both 1,3-dipolar cycloadditions and 
Glaser-Hay reactions at comparable levels to those seen using GFP 151 (Figure 
3.7). It is evident that the 1,3-dipolar cycloaddition reactions showed greater 
coupling for both proteins.   
 Initial attempts toward the development of heterodimers involved the 
implementation of the optimized Glaser-Hay bioconjugation reaction conditions 
described previously.29 These studies showed that relatively equal coupling was 
achieved using CuI and TMEDA at a pH of 6 for 4 hours at room temperature (22 
°C) (condition 1) or CuI and 2,2′-Bipyridine-4,4′-dicarboxylic acid at a pH of 8 for 
8 hours at room temperature (condition 2).29 These conditions were utilized for 
initial dimerization studies. Reactions were prepared using equal amounts (15 
µL) of both Ub 45-pPrF and GFP 151-pPrF for each condition. Homodimerization 
reactions were also prepared using 30 µL of Ub 45-pPrF or GFP 151-pPrF for 
each condition. Negative control 
reactions were prepared using equal 
amounts (15 µL) of the relative 
proteins in PBS buffer without the 
presence of catalyst. SDS-PAGE 
analysis did not indicate that any 
significant coupling occurred as there 
were no apparent shifts in the 
molecular weight for any of the 
Figure 3.8: SDS-PAGE analysis of dimerization 
reactions using denatured protein. Lane 1: Non-
denatured GFP control reaction, Lane 2: 
Denatured GFP 151, Lane 3: Denatured GFP 
151/Ub 45, Lane 4: Denatured Ub 45, Lane 5: 
Non-denatured Ub control reaction. 
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reactions. It was hypothesized that steric hinderance was preventing protein 
dimerization. Consequently, we attempted to reduce steric hinderance by 
denaturing proteins prior to reaction. To carry out these reactions, purified 
proteins were heated at 98 °C for 10 minutes prior to subjecting them to the 
Glaser-Hay reaction conditions. As no significant difference was seen using the 
two optimized conditions, only the TMEDA condition was utilized for this trial. 
Hetero and homodimer reactions were prepared as previously described using 
denatured protein and control reactions were prepared using non-denatured 
protein. No gel shifts were 
evident via SDS-PAGE 
analysis indicating that 
successful coupling did not 
occur (Figure 3.8). We then 
attempted to carry out these 
reactions using the 
TMEDA conditions at 4 °C 
and 37 °C to determine 
the impact of changing reaction temperature; however, again no coupling was 
evident (Figure 3.9). Additionally, we attempted to increase reaction time to 24 
hours and 48 hours to allow more time for coupling to occur; however, this 
resulted in significant protein degradation.  
We then attempted to utilize the 1,3-dipolar cycloaddition reaction to 
synthesize homo and heterodimers. Heterodimerization reactions were prepared 
Figure 3.9: SDS-PAGE analysis of homo and 
heterodimerization reactions conducted at 4 oC and 37 oC. 
Lane 1: GFP 151 control, Lane 2: GFP 151 at 4 oC, Lane 3: 
GFP 151/Ub 45 at 4 oC, Lane 4: Ub 45 at 4 oC, Lane 5: GFP 
151 at 37 oC, Lane 6: GFP 151/Ub 45 at 37 oC, Lane 7: Ub 45 
at 37 oC. 
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using 15 µL each Ub 45-pPrF and GFP 151-pAzF and Ub 45-pAzF and GFP 
151-pPrF. Homodimerization reactions were prepared using 15 µL each of GFP 
151-pPrF and GFP 151-pAzF or Ub 45-pAzF and Ub 45-pPrF. A negative control 
reaction was prepared by mixing 15 µL each protein in PBS in the absence of 
catalyst. Reactions were conducted using CuSO4, TBTA, and TCEP as the 
catalyst system at 4 °C for 14 hours. No successful coupling was observed using 
SDS-PAGE analysis. Due to the lack of coupling when using both 1,3-dipolar 
cycloaddition reaction and the Glaser-Hay reaction, we hypothesized that steric 
hinderance was most likely preventing dimerization, necessitating the use of a 
linker to enhance coupling and overcome steric hinderance.  
Due to the difficulties encountered in obtaining heterodimers, we shifted 
our focus to the optimization of conditions for the development of homodimers, 
which could then be translated to the development of heterodimers. Therefore, 
we only performed linker experiments in the context of developing homodimers. 
A 5000 Da PEG Alkyne was selected as the first linker to be investigated in 
homodimerization experiments due to its length, maximizing distance between 
the protein dimers and minimizing steric hinderance. This linker contains terminal 
alkynes, allowing either 1,3-dipolar cycloaddition reactions or Glaser-Hay 
reactions to occur between the protein and the linker. Both a 1 mM and a 50 mM 
solution of the PEG Alkyne was prepared in deionized water. 1-3-dipolar 
cycloaddition reactions were carried out as described previously for both Ub-
pAzF and GFP 151-pAzF with the addition of 10 µL of PEG Alkyne to the 
reaction mixture. Negative controls for both Ub 45-pAzF and GFP 151-pAzF 
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were prepared as described previously. No coupling was evident for either Ub or 
GFP when using the 1 mM solution of PEG Alkyne. Fortunately, significant 
coupling was demonstrated for GFP 151 when the 50 mM PEG Alkyne solution 
was used (Figure 3.10). A gel shift 
corresponding to approximately 40 
kDa was obtained, indicating the 
formation of dimerized protein. The 
reaction appeared to be favorable as 
it resulted in a 56.7% conversion to 
dimerized product. No significant 
coupling was observed for Ub; 
however, the small size of the 
monomer makes assessment of experimental success challenging. Our next aim 
was to attempt homodimerization using a Glaser-Hay reaction with the PEG 
linker.  
Glaser-Hay homodimerization reactions were prepared as described 
previously using TMEDA and the addition of 20 µL of 50 mM PEG alkyne with 
either Ub 45-pPrF and GFP 151-pPrF. Negative controls for both Ub/pPrF and 
GFP 151/pPrF were prepared as described previously. A gel shift of 
approximately 40 kDa, identical to that seen using the 1,3-dipolar cycloaddition 
reaction, was observed for GFP 151; however, the results were less clear for Ub. 
Despite the presence of a gel shift, significantly less conversion to dimerized 
product was seen, indicating that the Glaser-Hay reaction conditions were less 
Figure 3.10:  SDS-PAGE analysis of GFP 151 
1,3-dipolarcycloaddition reactions using 50 
mM PEG alkyne.  
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efficient than the 1,3-dipolar cycloaddition conditions; therefore, further 
optimization was necessary. We tested the impact of using various linker sizes 
on reaction efficiencies using GFP 151 as a model system. Three linkers of 
varying length were explored: 1,5-hexadiyne, 1,7-octadiyne, and 1,9-decadiyne 
using 50 mM solutions of each in DMSO. Each of these linkers (10 µL) were 
utilized in reactions with GFP 151-pPrF using both the TMEDA and 2,2-
bipyridyldicarboxylic acid conditions (Figure 3.11). SDS-PAGE analysis revealed 
that only slight coupling occurred using 1,5-hexadiyne with both conditions and 
slight coupling occurred using 1,9-decadiyne with the bipyridyl ligand conditions. 
None of these couplings 
were as productive as 
those using the PEG 
Alkyne. In previous 
studies, the Cadiot-
Chodkiewicz reaction 
was shown to have 
increased coupling 
efficiency, quicker reaction times, and less protein degradation.30 Therefore, 
dibromohexadiyne and dibromodecadiyne linkers were dissolved in DMSO to 
give 50 mM and 100 mM concentrations which were subsequently used in 
Cadiot-Chodkiewicz reactions with 50 mM TEA and 50 mM CuI as the catalyst 
system. No coupling was observed when using the Cadiot-Chodkiewicz reaction 
in this context. It appears that the PEG Alkyne linker offers the best 
Figure 3.11:  SDS-PAGE analysis of GFP 151 Glaser-Hay reactions 
using different linkers. Lane 1: GFP 151 control, Lane 2: GFP 151 
with 1,5-hexadiyne using condition 1, Lane 3: GFP 151 with 1,7-
octadiyne using condition 1, Lane 4: GFP 151 with 1,9-decadiyne 
using condition 1, Lane 5: GFP 151 with 1,5-hexadiyne with condition 
2, Lane 6: GFP 151 with 1,7-octadiyne using condition 2, Lane 7: 
GFP 151 with 1,9-decadiyne using condition 2.  
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homodimerization reaction efficiencies for both the 1,3-dipolar cycloaddition 
reaction and the Glaser-Hay reaction; however, further optimization is still 
required.   
After establishing that the PEG Alkyne was the most effective linker, we 
then sought to investigate the impact of other variables including reaction time 
and catalyst concentration. Due to the success of using GFP 151-pPrF and the 
PEG Alkyne linker, we focused our attention primarily on the optimization of 
homodimerization reactions using GFP 151-pPrF. We were specifically interested 
in improving the coupling efficiencies for the Glaser-Hay homodimerization 
reactions. We first sought to compare the two previously optimized Glaser-Hay 
conditions using the 50 mM PEG Alkyne and determine if improvements could be 
observed upon 
alteration of reaction 
time (Figure 3.12). 
Homodimerization 
reactions were set 
up using both the 
TMEDA and 2,2-
bipyridyldicarboxylic 
acid conditions with 
30 µL GFP 151-pPrF and 20 µl of 50 mM PEG Alkyne. Heterodimerization 
reactions were also attempted using both conditions with 15 µL each of Ub 45-
pPrF and GFP 151-pPrF and 20 µl of 50 mM PEG Alkyne. Reactions were 
Figure 3.12:  SDS-PAGE analysis of timecourse Glaser-Hay 
dimerization reactions using each condition. Lane 1: GFP 151 control, 
Lane 2: GFP 151 with condition 1 for 4 hours, Lane 3: GFP 151 with 
condition 2 for 4 hours, Lane 4: GFP 151/Ub 45 with condition 1 for 4 
hours, Lane 5: GFP 151/Ub 45 with condition 2 for 4 hours, Lane 6: 
GFP 151 with condition 1 for 8 hours, Lane 7: GFP 151 with condition 
2, for 8 hours, Lane 8: GFP 151/Ub 45 with condition 1 for 8 hours. 
Lane 9: GFP 151/Ub 45 with condition 2 for 8 hrs. 
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carried out for 4 and 8 hours for each condition for both homo and 
heterodimerization reactions. A negative control reaction was performed as 
described previously. SDS-PAGE analysis revealed that more coupling occurred 
using the 2,2-bipyridyldicarboxylic acid conditions at both reaction times for the 
GFP 151 homodimerization reactions. Coupling efficiencies were significantly 
improved when the 2,2-bipyridyldicarboxylic acid conditions were utilized at 8 
hours as coupling efficiencies near 40% were obtained; however, coupling 
efficiencies were still lower than those attained using the 1,3-dipolar cycloaddition 
reaction. The most significant coupling occurred at a reaction time of 4 hours for 
the TMEDA condition and at a reaction time of 8 hours for the 2,2-
bipyridyldicarboxylic acid condition, which supports the results of previous 
Glaser-Hay optimization studies.29 Heterodimerization reactions were not 
effective as no new bands at the correct molecular weight as the heterodimer 
were observed, indicating that Ub was not coupled to GFP. Overall it did not 
appear that altering reaction time for either condition improved coupling 
efficiency. It did appear; however, that the 2,2-bipyridyldicarboxylic acid 
conditions were more effective than the TMEDA conditions. We next 
hypothesized that the catalyst was being consumed before the reaction could go 
to completion; therefore, we increased the reaction time to 6 hours using both the 
TMEDA conditions and the 2,2-bipyridyldicarboxylic acid conditions and added a 
second aliquot of catalyst (5 µL 500 mM TMEDA or 5 µL 500 mM 2,2-
bipyridyldicarboxylic acid and 5 µL 500 mM CuI) after three hours. No 
improvement in coupling was evident compared to reactions in which no 
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additional catalyst was added for the 2,2-bipyridyldicarboxylic acid conditions 
while slight improvement was observed for the TMEDA conditions upon the 
addition of more catalyst; however, coupling efficiencies still did not surpass 
those using the 2,2-
bipyridyldicarboxylic acid 
conditions (Figure 3.13). 
We then increased the 
reaction time to 24 hours 
and added additional 
catalyst (5 µL 500 mM 
TMEDA or 5 µL 500 mM 
2,2-bipyridyldicarboxylic 
acid and 5 µL 500 mM CuI) to one reaction and additional catalyst as well as 
additional PEG Alkyne (10 µL, 50 mM) to another reaction after 12 hours. No 
significant increases in coupling were observed by adding additional catalyst or 
additional PEG Alkyne.  
We then sought to improve coupling efficiencies for the Glaser-Hay 
dimerization by increasing the amounts of reactants. Doubling the initial protein 
concentration in order to prevent protein degradation and increase the likelihood 
of two proteins interacting was attempted.  When using 50 mM PEG Alkyne, 
dimerization did not increase for either the TMEDA condition or the 2,2-
bipyridyldicarboxylic acid condition. It was hypothesized that increasing the 
concentration of PEG Alkyne may improve coupling efficiencies. PEG Alkyne 
Figure 3.13:  SDS-PAGE analysis of Glaser-Hay dimerization 
reactions using two additions of catalyst compared to those 
with a single addition for each condition. Lane 1: GFP 151 
control, Lane 2: GFP 151, TMEDA condition, Lane 3: GFP 151 
TMEDA condition, double catalyst, Lane 4: GFP 151, 2,2-
bipyridyldicarboxylic acid condition, Lane 5: GFP 151, 2,2-
bipyridyldicarboxylic acid condition, double catalyst. 
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solutions at concentrations of 75 mM, 100 mM, and 125 mM were prepared by 
dissolving the PEG Alkyne in DMSO. DMSO was used to improve the solubility of 
the PEG Alkyne at concentrations greater than 50 mM. Reactions were prepared 
using the 2,2-bipyridyldicarboxylic acid condition and 10 µL of each concentration 
of PEG Alkyne. SDS-PAGE analysis revealed that the use of larger 
concentrations of 
PEG Alkyne appeared 
to improve coupling 
efficiencies when 
compared to 50 mM 
(Figure 3.14). 
Coupling efficiencies 
were greatest when 
using 75 mM PEG 
Alkyne as opposed 
to 100 mM and 125 mM, potentially resulting from the decreased solubility of the 
PEG Alkyne at higher concentrations.   
Numerous other variables were tested in both 1,3-dipolar cycloaddition 
reactions and Glaser-Hay reactions to see if coupling efficiencies were improved. 
The impact of mutations at different residues on GFP was examined, as it was 
hypothesized that these mutations may be more accessible to reaction due to 
their location. Residues 3 and 133 are located within loop motifs at either end of 
β-barrel while residue 151 is located at the terminus of a β-sheet within the β-
Figure 3.14: SDS-PAGE analysis of Glaser-Hay dimerization reactions 
using the 2,2-bipyridyldicarboxylic acid condition with different 
concentrations of PEG Alkyne. Lane 1: GFP 151 control, Lane 2: GFP 
151, 50 mM PEG Alkyne, Lane 3: GFP 151, 75 mM PEG Alkyne, 
Lane 4: GFP 151, 100 mM PEG Alkyne, Lane 5: GFP 151, 125 mM 
PEG Alkyne. 
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barrel (Figure 3.15).31 GFP 3 and GFP 
133 were subjected to 
homodimerization reactions as well as 
heterodimerization reactions with 
each other as well as GFP 151 using 
both 1,3-dipolar cycloaddition 
reactions and Glaser-Hay reaction 
conditions and the PEG linker. For the 
1,3-dipolar cycloaddition and the 
Glaser-Hay reaction, only GFP 151 showed significant coupling as demonstrated 
previously for homodimerization reactions. Reactions between GFP 3 and GFP 
151 showed a gel shift and a higher coupling efficiency when compared to the 
GFP 151 homodimerization reaction; however, it could not be determined if this 
was caused by 
homodimerization of 
GFP 151 or 
heterodimerization as 
both proteins have 
the same molecular 
weight (Figure 3.16). 
We believe that due 
to the lack of 
homodimerization for 
Figure 3.15: The structure of GFP showing 
the location of each mutation.31 
Figure 3.16: SDS-PAGE analysis of 1,3-dipolarcycloaddition 
homo and heterodimerization reactions using mutations at 
residues 3, 133, and 151. Lane 1: GFP 151 control, Lane 2: GFP 
151, Lane 3: GFP 3, Lane 4: GFP 133, Lane 5: GFP 3/GFP 133, 
Lane 6: GFP 3/151, Lane 5: GFP 133/GFP 151. 
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GFP 3 the weight shift resulted from GFP 151 homodimerization. Significant 
degradation occurred for GFP 133; however, this protein was present in lower 
concentrations initially. We attempted to resubject successful 1,3-dipolar 
cycloaddition reactions and Glaser-Hay reactions to the same conditions to see if 
the reaction could be pushed to completion; however, this led to significant 
degradation of the product. Denaturing GFP 151 by heating at 98 °C for 15 
minutes before reaction and subjecting it to either Glaser-Hay condition in the 
presence of 50 mM PEG Alkyne did not lead to any coupling. We then attempted 
to utilize a Cadiot-Chodkiewicz reaction involving a brominated UAA (pBrPrF) in 
the presence of 10 µL of 50 mM PEG Alkyne using 50 mM TEA and 50 mM CuI 
as the catalyst system; however, no significant coupling was observed.  
In summary, conditions for the development of homodimers using GFP 
151 have been optimized. Initial attempts to develop heterodimers using Ub and 
GFP and homodimers using Ub with both 1,3-dipolar cycloaddition addition 
reactions and Glaser-Hay reactions did not yield any significant coupling. 
Homodimers were successfully prepared using GFP 151-pAzF through the 1,3-
dipolar cycloaddition reaction using 20 µL of 50 mM PEG alkyne with coupling 
efficiencies near 56%. Homodimers using the Glaser-Hay reaction using 10 µL of 
75 mM PEG alkyne using either CuI and TMEDA at a pH of 6 for 4 hours at room 
temperature or CuI and 2,2-bipyridyldicarboxylic acid at a pH of 8 for 8 hours at 
room temperature were successfully obtained; however, coupling efficiencies 
were lower than those obtained using the 1,3-dipolar cycloaddition reaction. It 
appeared that the 2,2-bipyridyldicarboxylic acid condition yielded better coupling; 
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however, the lower reaction time and difficulty solubilizing the 2,2-
bipyridyldicarboxylic acid ligand may make the use of the TMEDA condition more 
practical. Future work will involve the continued optimization of these conditions 
to maximize the coupling efficiencies so that these conditions can be expanded 
to the development of heterodimers. Once homo or heterodimers have been 
obtained in significant yields using Glaser-Hay reactions, the diyne product can 
then be subjected to further coupling reactions with other proteins, DNA, 
fluorophores, or small molecules to form trivalent conjugates.  
B. Organic Development of Multivalent Bioconjugation Reactions 
 In order to develop reactions that lead to trivalent conjugates under 
physiological conditions, reactions must first be tested in organic solvents to 
ensure that the desired product can be obtained in high yields under mild 
conditions with reasonable reaction times. Reactions requiring high 
temperatures, extreme pH, harsh reagents, water incompatible catalysts, or long 
reaction times are not optimal in physiological conditions as protein degradation 
may result. Prior to developing these reactions, a suitable starting material must 
be synthesized. The Glaser-Hay reaction has been previously shown to yield 
alkyne dimers in both the organic and biological context. The electron rich diyne 
linkage formed as a product of this reaction provides an adequate starting 
material for use in further reactions to form trivalent conjugates. Two starting 
materials, 1,4-diphenylbuta-1,3-diyne (1) and Hexa-2,4-diyne-1,6-diol (2) were 
synthesized using the traditional Glaser-Hay coupling (Scheme 3.3). Both 
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products were obtained in moderate yields (31-52%) and used in subsequent 
reactions.  
Scheme 3.3: Glaser-Hay coupling reactions used to obtain 1 and 2. 
 The preparation of trivalent molecules was next attempted by reacting 1 
with aniline in the presence of copper chloride and a ligand. Three different 
ligands, tetramethylethylenediamine (TMEDA), triethylamine (TEA), and 2,2’-
Bipyridine were tested to determine their effectiveness in forming a pyrrole 
product (3) (Scheme 3.4). A control reaction was prepared in the absence of a 
ligand. These reactions were performed on a small scale using only 10 mg of 
diyne. Reactions were carried out at 40 °C overnight using THF as the solvent. A 
relatively low temperature was selected for this reaction as a method to 
determine their effectiveness for translation into a physiological context. 
Reactions were monitored by TLC for the formation of 3. After 24 hours, the 
formation of product was identified when using the 2,2’-bipyridine ligand based 
on the appearance of a spot which had a differing Rf value from the starting 
materials. No products were observed using the TMEDA or TEA ligands, or the 
control reaction. These reactions were allowed to continue for an additional 24 
80 
 
 
hours; however, still no product was obtained. We attempted to scale up the 
reaction using the 2,2’-bipyridine ligand using 50 mg of starting material; 
however, we were unable to obtain 3 in high yields and purity due the inability to 
effectively separate the 2,2’-Bipyridine ligand from the reaction mixture. We then 
attempted to use 50 mg of 2 to obtain pyrrole 4; however, NMR spectra did not 
indicate the formation of product. Due to the difficulties encountered in obtaining 
3 and 4 with a high degree of purity, alternative methods of synthesizing pyrroles 
were obtained, such as the use of microwave irradiation. 
Scheme 3.4: Reaction of 1 and aniline to yield pyrrole 3. 
 We then sought to use Microwave irradiation to produce triazoles 5 and 6 
(Scheme 3.5), as microwaves have previously been demonstrated to accelerate 
these types of reactions.32 These reactions were performed in the presence and 
absence of copper, which can be deleterious to living systems when in the Cu(II) 
state. Microwave irradiation was applied using a CEM Discover in SPS mode 
with 300 W of power for 20 minutes. These reactions were also performed 
thermally in the presence and absence of copper. Reactions were stirred at room 
temperature for 24 hours. Pyrrole 5 was successfully obtained in moderate yields 
in the presence and absence of copper using microwave irradiation. A crude 
NMR spectrum indicated the presence of pyrrole 6; however, the product was 
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lost during purification. Unfortunately, products were not obtained when reactions 
were performed thermally, even after an additional 24 hours of reaction time. 
These results indicate that microwave irradiation can be used to successfully 
obtain trivalent products in the absence of copper. In order to translate these 
reactions to proteins, a Coolmate system will need be utilized, meaning that 
these reactions must be tested under these conditions prior to attempting these 
reactions on a protein context.    
Scheme 3.5: Microwave reactions yielding trivalent pyrroles 5 and 6.  
In summary, multivalent reactions have been tested organically using 
various ligands to obtain pyrrole products. It appeared that reactions utilizing the 
2,2’-Bipyridine ligand may have given small amounts of product; however, pure 
product was not obtained in high yields using either 1 or 2. Further attempts will 
be made to scale up these reactions in order to better isolate product. Attempts 
at subjecting internal diynes to microwave irradiation in the absence of copper 
indicated that pyrrole products could be obtained in moderate yields when SPS 
mode was used. Unfortunately, these reactions were unsuccessful when carried 
out at room temperature over the course of two days. In order to translate these 
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reactions to proteins, a Coolmate system will need be used; therefore, future 
work will be aimed at optimizing these reactions using the Coolmate system. 
Continued research will focus on the further development and optimization of 
reactions to produce trivalent organic products.  
III. Materials and Methods 
General: Solvents and reagents were obtained from Sigma Aldrich, Alfa Aesar, 
or Fischer Scientific and used without further purification. Reactions were 
performed under ambient conditions with non-distilled solvents. Microwave 
reactions were performed using CEM Discovery microwave reactors. NMR data 
was acquired using a Varian Gemini 400 MHz NMR. Alkyne-PEG5000-alkyne 
was purchased from JenKem Technology. All GFP and Ub proteins were purified 
according to manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. 
pET-Ub and pET-Ub-TAG plasmids were obtained from the Cropp lab at Virginia 
Commonwealth University.  
1,4-diphenylbuta-1,3-diyne (1): A catalytic amount of CuI (160 mg, 0.04 eq., 
0.84 mmol) and tetramethylethylenediamine (TMEDA) (240 µL, 0.08 eq., 1.60 
mmol) was added to a flame-dried vial. This mixture was dissolved in THF (4 mL) 
and stirred at room temperature for 15 minutes to generate the catalyst system. 
This mixture was then transferred to a flame-dried round-bottom flask containing 
THF (30 mL). Diphenylacetylene (2.15 mL, 2 eq., 19.60 mmol) was added and 
the reaction was stirred at 60 °C in an oil bath for 48 hours. The reaction was 
monitored by TLC for the formation of product. After 48 hours, the reaction was 
cooled and extracted four times using DCM. The organic layer was then washed 
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3 times using deionized water, dried using anhydrous magnesium sulfate, 
filtered, and solvent was evaporated under reduced pressure to yield a dark 
brown solid. The solid was evaporated on a vacuum line for 3 hours to give 1 
(972 mg, 4.81 mmol, 52.1% yield). 1H NMR (CDCl3, 400 MHz): δ 7.63-7.61 (m, 
4H), 7.42-7.40 (m, 6H).  
 
Figure 3.17: 1H NMR of 1 in CDCl3. 
 
Hexa-2,4-diyne-1,6-diol (2): A catalytic amount of CuI (160 mg, 0.02 eq., 0.84 
mmol) and tetramethylethylenediamine (TMEDA) (240 µL, 0.04 eq., 1.60 mmol) 
was added to a flame-dried vial. This mixture was dissolved in THF (4 mL) and 
stirred at room temperature for 15 minutes to generate the catalyst system. This 
mixture was then transferred to a flame-dried round-bottom flask containing THF 
(30 mL). Propargyl alcohol (2.11 mL, 2 eq., 35.70 mmol) was added and the 
reaction was stirred at 60 °C in an oil bath for 48 hours. The reaction was 
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monitored by TLC for the formation of product. After 48 hours, the reaction was 
cooled and extracted four times using DCM. The organic layer was then washed 
3 times using deionized water, dried using anhydrous magnesium sulfate, 
filtered, and solvent was evaporated under reduced pressure to yield a light 
brown solid (610 mg, 5.54 mmol, 31.0% yield). 1H NMR (D2O, 400 MHz): δ 4.16 
(s, 4H). 
 
Figure 3.18: 1H NMR of 2 in D2O. 
 
1,2,5-triphenyl-1H-pyrrole (3): To a flame-dried round-bottom flask was added 
1 (50 mg, 1 eq., 0.25 mmol). 1 was then dissolved in THF (3 mL). Aniline (225 
µL, 10 eq., 2.47 mmol), CuCl (1 mg, 0.1 eq., 0.025 mmol), and 2,2’-Bipyridine (39 
mg, 1 eq., 0.25 mmol) were added to a flame-dried vial and dissolved in THF (3 
mL). This mixture was stirred at room temperature for 15 minutes to generate the 
catalyst system then added to the round-bottom flask containing 1. The reaction 
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was monitored by TLC for the formation of product. Solvent was evaporated 
under reduced pressure to yield an oil. The reaction was purified using column 
chromatography (silica gel, 7:1 hexanes:EtOAc). Yield and NMR data are not 
reported as the product was not successfully obtained.  
(1-phenyl-1H-pyrolle-2,5-diyl)dimethanol (4): To a flame-dried round-bottom 
flask was added 2 (50 mg, 1eq, 0.45 mmol). 2 was then dissolved in THF (3 mL). 
Aniline (415 µL, 10 eq., 4.54 mmol), CuCl (4.49 mg, 0.1 eq., 0.045 mmol), and 
2,2’-Bipyridine (71 mg, 1 eq., 0.45 mmol) were added to a flame-dried vial and 
dissolved in THF (3 mL). This mixture was stirred at room temperature for 15 
minutes to generate the catalyst system. The mixture was then transferred to the 
first round-bottom flask containing 2. The reaction was stirred at 40 °C overnight. 
The reaction was evaporated under reduced pressure to yield an oil. The 
reaction was purified using column chromatography (silica gel, 1:1 
hexanes:EtOAc). Yield and NMR are not reported as the product was not 
successfully obtained.  
2-(1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazol-5-yl)ethyn-1-ol (5): To a 
microwave vial was added a small stir bar, 2 (19 mg, 1 eq., 0.17 mmol), benzyl 
azide (106 µL, 5 eq., 0.85 mmol), deionized water (970 μL), and tert-Butyl alcohol 
(99 %, 1 mL).  The solution was subjected to microwave irradiation (SPS mode, 
20 minutes, 0-300 W, 168 °C, δT= 15 °C). The resulting mixture was then 
quenched with chilled deionized water (10 mL, 0 °C). A rotary evaporator was 
used to remove water from the reaction, and the crude product was purified using 
column chromatography (silica gel, 3:1 EtOAc:hexanes) to yield 5 (10 mg, 0.041 
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mmol, 24.1% yield). 1H NMR (CDCl3, 400 MHz): δ 7.36-7.33 (m, 4H), 7.24-7.21 
(m, 1H), 5.64 (s, 2H). 
 
Figure 3.19: 1H NMR of 5 in CDCl3. 
 
1-heptyl-4-phenyl-5-(phenylethynyl)-1H-1,2,3-triazole (6): To a microwave vial 
was added a small stir bar, 1 (34 mg, 1 eq., 0.17 mmol), azidoheptane (139 µL, 5 
eq., 0.85 mmol), deionized water (970 μL), and tert-Butyl alcohol (99%, 1 mL).  
The solution was subjected to microwave irradiation (SPS mode, 20 minutes, 0-
300 W, 168 °C, δT= 15 °C). The resulting mixture was then quenched with chilled 
deionized water (10 mL, 0 °C). A rotary evaporator was used to remove water 
from the reaction, and the crude product was analysed by NMR. Yield data could 
not be obtained as product was lost during purification. 1H NMR (CDCl3, 400 
MHz): δ 8.20 (d, J = 7.6 Hz, 2H), 7.57-7.18 (m, 8H), 4.51 (t, J = 7.2 Hz, 2H), 
2.04-2.02 (m, 2H), 1.28-1.15 (m, 8H), 0.86-0.84 (m, 3H).  
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Figure 3.20: 1H NMR of 6 in CDCl3. 
Expression and Purification of Ubiquitin containing pAzF and pPrF: A Ub 
plasmid (0.50 µL) was co-transformed with a pEVOL-pCNF plasmid (0.50 µL) 
into Escherichia Coli BL21 (DE3) competent cells by heat shock using an 
Eppendorf eporator electroporator. The cells were then plated (250 µL) on LB 
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and 
incubated at 37 °C overnight. One colony was then used to inoculate LB media 
(10 mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This 
culture was then incubated and allowed to shake at 37 °C overnight. The 
following day, the culture was then used to inoculate an expression culture 
containing LB media (250 mL), ampicillin (50 µg/mL), and chloramphenicol (34 
µg/mL) at a starting OD600 of 0.1. The cultures were incubated and allowed to 
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shake at 37 °C until an OD600 of 0.7 was reached. Protein expression was then 
induced by the addition of 20% arabinose (250 µL), and isopropyl β-D-1-
thiogalactopyranoside (IPTG, 250 µL, 0.8 mM), and pPrF or pAzF (250 mL, 100 
mM). The cultures were then incubated with and allowed to shake at 30 °C for 16 
hours. The cells were then pelleted by centrifugation (5,000 rpm, 10 minutes) and 
stored at -80 °C until purification.  
 Purified Ub was obtained by resuspending the cell pellet in 500 µL of Bug 
Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture was 
incubated with shaking at 37 °C for 20 minutes. The mixture was then transferred 
to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to pellet out 
cellular debris. The supernatant was decanted into an equilibrated HisPur Ni-
NTA spin (Qiagen) column containing Nickel resin (200 µL) and Ub was purified 
according to the manufacturer’s protocol. Purified Ub was analyzed by SDS-
PAGE (BioRad 15% precast gels, 120V, 2 hours). Gels were stained with 
Coomassie Brilliant Blue solution, and destained using a destain solution 
containing 60% deionized water, 30% MeOH, and 10% glacial acetic acid. Gels 
were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel imager 
(Coomassie protocol) after 24 hours. Protein was then concentrated and buffer 
exchanged into PBS buffer at a pH of 7.4 using Corning Spin-X UF purification 
columns. Protein was used without further purification. 
Expression and Purification of GFP containing pAzF and pPrF: A pET-GFP-
TAG plasmid (0.50 µL) was co-transformed with a pEVOL-pAzF plasmid (0.50 
µL) into Escherichia Coli BL21 (DE3) competent cells by heat shock using an 
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Eppendorf eporator electroporator. The cells were then plated (250 µL) on LB 
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and 
incubated at 37 °C overnight. One colony was then used to inoculate LB media 
(10 mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This 
culture was then incubated and allowed to shake at 37 °C overnight. The 
following day, this culture was used to inoculate an expression culture containing 
LB media (250 mL), ampicillin (50 µg/mL), and chloramphenicol (34 µg/mL) at a 
starting OD600 of 0.1. The cultures were incubated and allowed to shake at 37 °C 
until an OD600 of 0.7 was reached. Protein expression was then induced by the 
addition of 20% arabinose (250 µL), and isopropyl β-D-1-thiogalactopyranoside 
(IPTG, 250 µL, 0.8 mM), and pAzF or pPrF (250 mL, 100 mM). The cultures were 
then incubated with and allowed to shake at 30 °C for 16 hours. The cells were 
then pelleted by centrifugation (5,000 rpm, 10 minutes) and stored at -80 °C until 
purification.  
 Purified GFP was obtained by resuspending the cell pellet in 500 µL of 
Bug Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture 
was incubated with shaking at 37 °C for 20 minutes. The mixture was then 
transferred to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to 
pellet out cellular debris. The supernatant was decanted into an equilibrated 
HisPur Ni-NTA spin (Qiagen) column containing Nickel resin (200 µL) and GFP 
was purified according to the manufacturer’s protocol. Purified GFP was 
analyzed by SDS-PAGE (BioRad 10% precast gels, 120V, 2 hours). Gels were 
stained with Coomassie Brilliant Blue solution, and destained using a destain 
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solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic 
acid. Gels were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel 
imager (Coomassie protocol) after 24 hours. Protein was then concentrated and 
buffer exchanged into PBS buffer at a pH of 6.0, 7.4, or 8.0 using Corning Spin-X 
UF purification columns. Protein was used without further purification. 
Optimized Click Dimerization Reaction protocol: The following reagents were 
added to a sterile 1.5 mL eppendorf tube in the order listed: 2 µL CuSO4 (50 mM 
in H2O), 20 µL tris(benzyltriazolylmethyl)amine (5 mM in DMSO), 20 µL of GFP 
containing an azide UAA (GFP/pAzF), 10 µL of Alkyne-PEG5000-alkyne (50 mM 
in H2O), 2 µL tris(2-carboxyethyl)phosphine (50 mM in H2O), and 6 µL PBS (pH 
7.4). A negative control reaction was prepared using 20 µL GFP/pAzF, 10 µL of 
Alkyne-PEG5000-alkyne, and 30 µL PBS in place of the catalyst system. 
Reactions were incubated for 14 hours at 4 °C. Excess reagents were removed 
by buffer exchange (5 x 200 µL of PBS buffer) using Corning Spin-X UF 
purification columns to obtain a final volume of approximately 50 µL. Reactions 
were analyzed for successful dimerization of protein using SDS-PAGE (BioRad 
10% precast gels, 120V, 2 hours). Gels were then stained with Coomassie 
Brilliant Blue solution, and destained using a solution containing 60% deionized 
H2O, 30% MeOH, and 10% glacial acetic acid. Gels were then imaged using a 
Bio-Rad Molecular Imager (Gel Doc XR+) using the Coomassie protocol after 24 
hours. 
Optimized Glaser-Hay Dimerization Reaction protocol: A vigorously shaken 
solution of CuI (500 mM in H2O, 5 µL) and 2,2′-Bipyridine-4,4′-dicarboxylic acid 
91 
 
 
(500 mM, 5 µL) were added to a sterile 1.5 mL eppendorf tube and allowed to 
equilibrate for 10 minutes. The two solutions were thoroughly mixed by pipetting. 
Next, 30 µL of GFP containing a terminal alkyne UAA (GFP/pPrF) and 20 µL 
Alkyne-PEG5000-alkyne (75 mM in H2O) were added. A control reaction was 
prepared using 30 µL GFP/pPrF, 20 µL Alkyne-PEG5000-alkyne, and 10 µL PBS 
buffer in place of the catalyst system. Reactions were incubated at room 
temperature (22 °C). After 8 hours, excess reagents were removed by buffer 
exchange (5 x 200 µL of PBS buffer) using Corning Spin-X UF purification 
columns to obtain a final volume of approximately 50 µL. Reactions were 
analyzed for successful protein dimerization using SDS-PAGE (BioRad 10% 
precast gels, 120V, 2 hours). Gels were then stained with Coomassie Brilliant 
Blue solution, and destained using a solution containing 60% deionized water, 
30% MeOH, and 10% glacial acetic acid. Gels were then imaged with a with a 
Bio-Rad Molecular Imager (Gel Doc XR+) using the Coomassie protocol after 24 
hours. 
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Chapter 4: The Application of 
Microwave Irradiation for Copper-free 
Alkyne/azide 1,3-dipolar Cycloadditions 
I. Introduction 
The alkyne/azide 1,3-dipolar cycloaddition reaction has become an 
indispensable tool for scientists as a mechanism to conjugate an alkyne moiety 
with an azide (Scheme 4.1).1–4 While the general class of pericyclic reactions has 
proven useful to organic chemists,5,6 the robust nature of this particular 
alkyne/azide “click” reaction has allowed it to become ubiquitous in a plethora of 
fields such as drug 
design, sensors, 
catalysis, materials 
chemistry, and 
bioconjugations.7–14 While this specific cycloaddition was first discovered in 1963, 
the copper catalyzed variant has expanded its utility by decreasing reaction times 
and temperatures, while increasing regioselectivity.3 However, the addition of a 
copper catalyst has some limitations within biological systems and in some 
materials applications.15,16 These issues have necessitated the development of 
rapid copper-free conditions, which is typically accomplished through the use of 
highly strained alkynes, many of which are challenging to synthetically access.17–
Scheme 4.1: Standard copper-free 1,3-dipolar cycloaddition. 
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19 Alternatively, heterogeneous reactions employing an immobilized catalyst, and 
non-transition metal catalyzed reactions have been explored.20,21 While these 
methodologies are extremely useful, we became interested in exploring other 
options for rapid copper-free reaction conditions using unstrained alkynes. 
Another mechanism to accelerate the reaction has been the application of 
microwave irradiation, which has been primarily examined under copper-
catalyzed conditions.22–25 Previously, a microwave-mediated copper-free 
cycloaddition toward the preparation of a complex polymer was reported; 
however, little experimental optimization of the reaction was conducted and 
yields were significantly low.26 We aimed to significantly expand on this approach 
by optimizing reaction conditions and broadening its utility towards biological 
applications. 
II. Results and Discussion 
Due to the extensive number of variables associated with microwave 
irradiation, initial investigations involved the optimization of reaction conditions 
with a model system.27 Based on commercial availability of reagents and 
spectroscopic properties, the reaction of benzyl azide (2) and phenylacetylene 
(1) was selected to 
explore the copper-
free microwave 
mediated 1,3-dipolar 
cycloaddition of 
alkynes and azides. The rapid nature of the microwave was expected to facilitate 
Scheme 4.2: The reaction of benzyl azide (2) with phenylacetylene 
(1). 
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productive reactions in a short amount of time, without necessitating the use of a 
copper catalyst, and ultimately making the reaction more useful for biological 
settings or other applications where the use of copper precludes the utilization of 
the reaction. Using a CEM Discover, various temperatures, microwave powers, 
and microwave settings were explored (Table 1). Standard microwave conditions 
involve the input of power until a specific temperature is obtained, followed by 
Table 4.1: Optimization of the copper-free microwave assisted 1,3-dipolar cycloaddition. 
brief bursts of power to maintain the temperature. Power mode involves the 
constant input of a microwave power until a set temperature is reached, followed 
by termination of reaction conditions. Finally, Pulsed Power (SPS) mode involves 
power cycling to maintain the temperature within a specific range (δT). A delicate 
interplay between power input and reactant decomposition was noted, as higher 
product yields were observed with increased power settings (300 W); however, 
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increased irradiation times began to lead to decreased yields. Thus, the SPS 
setting was found to be optimal as it afforded high power inputs with reduced 
times at elevated temperatures. Ultimately, maximizing power to 300 W in SPS 
mode for 20 minutes afforded a 96% yield and was employed in further reactions. 
As expected, a mixture of the two regioisomers (3a and 3b) was obtained under 
all conditions. 
In order to assess the scope of the reaction, we next examined a variety of 
alkynes and azides under the optimized reaction conditions. In addition to benzyl 
azide (2), azidoheptane (4) and trimethylsilyl azide (5) were examined due to 
their commercial availability and chemical functionality. This set of azides was 
reacted with phenylacetylene (1), 1-hexyne (6), and propargyl alcohol (7) under 
the previously optimized microwave conditions. When reacting equimolar ratios 
of the propargyl alcohol and any azide, very little product was recovered (<5%), 
obviating the further optimization of the reaction. It was hypothesized that the 
propargyl alcohol was susceptible to decomposition under the microwave 
conditions as reactions typically resulted in a very dark crude mixture, which was 
unobserved with other alkynes. Two remedies were examined to address the low 
yields, first methyl propargyl ether (8) and trityl-protected propargyl alcohol (9) 
were employed to protect the hydroxyl group, and second, excess of the alkyne 
was employed to identify if decomposition was an issue. Reactions of benzyl 
azide (2) and trimethylsilyl azide (5) with methyl propargyl ether (8) using 1 
equivalent of alkyne continued to result in low yields of product (<5%). Therefore, 
the same reactions were performed utilizing 2 equivalents of alkyne, giving 
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increased yields of 
approximately 20% 
for both reactions, 
indicating that alkyne 
decomposition may 
indeed be a factor. 
To further support 
this, these reactions 
were then performed 
using 5 equivalents 
of alkyne, resulting in 
dramatic increases in 
yields for both 
reactions. Ultimately, 
it appears that alkyne 
decomposition under microwave conditions was the primary factor contributing to 
low yields in previous reactions as increasing alkyne equivalents from 1 to 5 
greatly improved yields. While not ideal in the organic sense, bioconjugation 
reactions typically employ extreme excess of the non-protein partner to drive 
reactions, making the use of 5 equivalents relatively minimal in the context of 
bioconjugation reactions. Consequently, the array of triazole products (3, 10–
23) was re-synthesized using an excess of alkyne. Conveniently, the volatility of 
Figure 4.1: Triazole array prepared to assess the scope of the 
microwave assisted copper-free 1,3-dipolar cycloaddition. 
Reactions were performed with 5 equivalents of alkyne, using 
SPS mode 300 W, 20 minutes. 
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the alkyne reactants allowed for easy purification under vacuum or via column 
chromatography (Figure 4.1).  
Overall, the reactions proceeded in moderate to excellent yield (96–47%), 
with the benzyl azide being the most reactive azide (96–84%), and the 
azidoheptane exhibiting lower activity (94–46%) (Figure 4.1). This may be a 
result of some solubility issues, or simply the aliphatic nature of the azide. Trityl-
protected propargyl alcohol reactions resulted in the lowest yields, potentially due 
to decomposition. These yields could be significantly increased via alteration of 
the protecting group to a methyl substituent. Additionally, reactions performed 
with the TMS-azide in the microwave resulted in desilylation and yielded the free 
triazole ring after column chromatography. Control reactions that mimicked the 
microwave temperature profile without microwave irradiation did afford product, 
albeit in markedly lower yield <20%. Thus, the dramatically increased yields 
using the optimized microwave conditions demonstrate the utility of this 
methodology. While these yields are sometimes comparable to previously 
reported reactions, the combination of decreased reaction times and the absence 
of copper suggest that the methodology may be useful in specific applications.28 
In order to further apply the microwave assisted copper-free 1,3-dipolar 
cycloadditions, we next investigated their use in a biological context. This is 
especially relevant due to the propensity of copper to generate radicals that 
degrade proteins, and due to the general cytotoxicity of copper.15 To accomplish 
this aim, an alkynyl unnatural amino acid was incorporated using the Schultz 
amber suppression technology into green fluorescent protein (GFP).29–34 GFP 
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was selected due to its 
nascent fluorescent 
properties and well-
documented use as a 
reporter protein. The p-
propargyloxyphenylalanine 
(24) unnatural amino acid 
was expressed at residue 
151 of GFP, which is 
located within the rigid β-barrel of the protein (Figure 4.2).13,35,36 With the alkyne-
containing protein in hand, we next investigated the ability to translate our 
previously optimized reaction to a biological context. The mutant GFP was 
reacted with Alexa Fluor-488 azide to generate a fluorescent bioconjugate that 
could be analyzed via SDS-PAGE. Not surprisingly, when subjected to 
microwave irradiation in the standard CEM Discover under a variety of conditions 
(including the previously optimized SPS conditions), protein degradation was 
observed at high temperatures, providing no observable conjugated product. 
In order to prevent protein degradation, the reaction was translated to a 
CEM Coolmate system, which utilizes a jacketed reaction vessel to allow 
microwave transparent cooling fluid to be flowed through to significantly reduce 
reaction temperatures, while still affording microwave irradiation.37 The SPS 
setting previously employed is not feasible under Coolmate conditions, and thus 
modulation of microwave power was the most logical variable to examine. 
Figure 4.2: Incorporation and cycloaddition using an 
unnatural amino acid. A) Structure of p-
propargyloxyphenylalanine incorporated into GFP. B) 
Proposed 1,3-dipolar cycloaddition reaction between the 
mutant GFP and an azide-containing fluorophore in the 
microwave. 
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Reactions containing the mutant protein and azide fluorophore were conducted 
at microwave powers of 100 W, 200 W, and 300 W. The coolant was pre-chilled 
to −50 °C and used to cool the reaction to −30 °C prior to microwave irradiation, 
and the reaction was then irradiated until the temperature reached 40 °C. 
Following irradiation, the protein was denatured and analyzed by SDS-
PAGE. Due to the covalent modification of the protein with a fluorophore, 
successful reactions were expected to yield a fluorescent product even 
Figure 4.3: Microwave-mediated 1,3-dipolar cycloadditions on GFP. A) SDS-PAGE Coomassie 
stain indicating the presence of GFP both with a control reaction not utilizing the microwave 
(Lane 1) and under microwave conditions in the absence of copper (Lane 2). B) SDS-PAGE 
fluorescence image, demonstrating the effective coupling between the protein and the azide 
fluorophore to generate a triazole linkage. The difference in protein concentration is potentially 
due to some minor degradation under microwave conditions. C) Copper-free control reactions in 
the absence of either microwave irradiation or the fluorescently labelled reaction partner. GFP is 
present and non-degraded in both reactions when stained with Coomassie blue. D) 
Fluorescence imaging indicates that no bioconjugation occurs under the two control conditions 
as no fluorescence is observed. 
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after denaturation of the protein fluorophore. Reaction success was determined 
by first examining the fluorescence of the gel, and then staining the gel 
with Coomassie blue to ascertain the presence of protein. Reactions at 300 W 
displayed significant protein degradation, while reactions at 100 W did not exhibit 
significant fluorophore coupling. However, reactions at 200 W displayed 
significant coupling without protein degradation. While other types 
of bioconjugations have been performed in the microwave, we believe this to be 
one of the first reported microwave-mediated bioconjugations involving full length 
proteins.38 In order to further optimize the coupling, the reaction was subjected to 
2 pulses of microwave irradiation at 200 W prior to purification (Figure 4.3). 
Based on both absorption spectroscopy of the conjugates and densiometry 
measurements of the gels, 
the coupling yields are 
∼85%. Additionally, control 
irradiations in the absence 
of the fluorophore were 
performed, demonstrating 
that GFP was still 
fluorescent after irradiation, 
signifying that it was not denatured as a result of microwave irradiation at low 
temperature (Figure 4.4). This is an important aspect when considering the utility 
of these reactions within the context of the microwave. Reactions under identical 
temperature profiles to the microwave yielded no observable conjugate. It is 
Figure 4.4: GFP fluorescence in the presence and absence 
of microwave irradiation (Coolmate; 2x200W), 
demonstrating minimal protein degradation as comparable 
levels of fluorescence are maintained. 
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important to note that GFP is a relatively hearty protein and the presence of 
copper does not necessarily lead to degradation; however, many other less 
stable proteins may require the copper-free conditions, or the eventual 
application of the protein in a biological setting may necessitate the absence of 
copper to prevent cytotoxicity. Attempts were then made to translate these 
Coolmate conditions to the previously optimized small molecule reactions. This 
was demonstrated through the reactions of benzyl azide (2) with phenylacetylene 
(1), 1-hexyne (6), propargyl alcohol (7). In each reaction, 5 equivalents of alkynes 
were used in order to prevent degradation as previously described. These 
reactions resulted in some coupling; however, the obtained yields were between 
9-20%, a significant decrease from the previously optimized conditions. We 
hypothesize this is due to the significantly higher reagent concentrations 
compared to the protein system, coupled with substantially shorter reaction 
times. Thus, optimal conditions for the microwave-mediated click reaction are 
dependent on the nature of the reactants (proteins vs. small molecules).  
In conclusion, we have demonstrated that it is feasible to conduct 
alkyne/azide 1,3-dipolar cycloadditions in the microwave without the requisite of 
a copper catalyst. This has far-reaching applications within the realms of both 
biology and materials science where copper may be prohibitive to specific 
reactions. The microwave-mediated reaction was optimized to afford high yields 
of triazole products and further applied to a protein context via the utilization of 
unnatural amino acids. Overall, we believe this to be one of the first reported 
protein bioconjugations utilizing microwave irradiation. Moreover, the 
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methodology developed facilitates an extremely rapid method to obtain 
bioconjugates in the absence of potentially cytotoxic copper. 
III. Materials and Methods 
General. Solvents and reagents were obtained from either Sigma Aldrich or 
Fischer Scientific and used without further purification. Reactions were performed 
in ambient conditions with non-distilled solvents. Microwave reactions were 
performed using CEM Discovery and CEM Discovery Coolmate microwave 
reactors. NMR data was acquired on a Varian Gemini 400 MHz NMR. GC/MS 
analysis was conducted on an Agilent Technologies 6890N GC system 
interfaced with a 5973N mass selective detector. An Agilent J&W GC capillary 
column (30 m length, 0.32 mm diameter, 0.25 m film) was employed with a 
splitless injection (250° C inlet, 8.8 psi) with an initial 70 °C hold (2 minutes) and 
ramped for 15 minutes to 230 °C. All GFP proteins were purified according to 
manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. NMR data is in 
accordance to previously published NMR spectra of identical compounds. 
General 1,3-dipolar Cycloaddition Method. To a microwave vial was added a 
small stir bar, an alkyne (5.1x10-4 moles; 3 eq.), an azide (1.7x10-4 moles; 1 eq.), 
deionized water (970 μL), and tert-Butyl alcohol (99 %, 1 mL).  The solution was 
subjected to microwave irradiation (SPS mode, 20 minutes, 0-300 W, 168 °C, 
δT= 15 °C). The resulting mixture was then quenched with chilled deionized 
water (10 mL, 0 °C). A rotary evaporator was used to remove water from the 
reaction, and the crude product was purified using flash chromatography (3:1 
hexanes:EtOAc) to yield the product. 
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General GFP Expression Protocol: A pET-GFP-TAG plasmid (0.5 μL) was co-
transformed with a pEVOL-tRNA synthetase plasmid (0.5 μL) into Escherichia 
coli BL21(DE3) cells using an Eppendorf eporator electroporator. The cells were 
then plated (100 μL) on LB agar in the presence of chloramphenicol (Chlr, 34 
mg/mL) and ampicillin (Amp, 50 mg/mL) at 37° C overnight. One colony was then 
used to inoculate LB media (4 mL) containing both ampicillin and 
chloramphenicol. The culture was incubated at 37 °C overnight and used to 
inoculate an expression culture (10 mL LB media, 50 mg/mL Amp, 34 mg/mL 
Chlr) at an OD600 0.1. The cultures were incubated at 37 °C to an OD600 between 
0.7 and 0.9, and protein expression was induced by addition of the respective 
unnatural amino acid (100 μL, 100 mM), 20 % arabinose (10 μL) and 0.8 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG; 10 μL). The cultures were 
incubated at 30 °C for 16-20 hours then pelleted at 5,000 rpm for 10 minutes and 
stored at -80° C for 3 hours. The cell pellet was re-suspended using 500 µL of 
Bugbuster (Novagen) containing lysozyme, and incubated at 37° C for 20 
minutes. The solution was transferred to an Eppendorf tube and centrifuged at 
15,000 rpm for 10 minutes, then the supernatant was added to an equilibrated 
column of Ni-NTA resin (200 µL) and the GFP was purified according to 
manufacturer’s protocol.  
Coolmate Click Procedure: GFP containing 24 at residue 151 (30 μL, 0.5 
mg/mL), Alexa Fluor-488 dye (20 μL, 1 mM), deionized water (1 mL), in the 
presence and absence of CuSO4 (32 μL, 50mM) were added to a Coolmate vial. 
The Coolmate was chilled to -50 °C, and the contents of the vial were cooled to -
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30 °C and subjected to microwave irradiation (200 W) until the contents of the 
vial reached a temperature of 40° C. A buffer exchange was performed with 
Spin-X UF concentrator columns, and PBS buffer (8 x 200 μL) to a final volume 
of 50 μL. The GFP was analyzed by SDS-PAGE (BioRad 10% precast gels, 
150V, 1.5 h). Gels were imaged on a BioRad Molecular Imager (Gel Doc XR+). 
The gels were then stained with Coomassie Brilliant Blue for analysis. 
1-benzyl-4-phenyl-1H-1,2,3-triazole (3):39 The solvent was removed in vacuo to 
give 3 as a solid (38 mg, 0.16 mmol, 96.2% yield) 1H NMR (400 MHz; CDCl3): ∂ 
7.80 (m, 2H), 7.74 (s, 1H), 7.45-7.37 (m, 3H), 7.33-7.24 (m, 4H), 7.09-7.06 (m, 
1H), 5.58 (s, 2H); 13C NMR (400 MHz; CDCl3): ∂ 135.5, 133.3, 129.5, 129.2, 
128.9, 128.9, 128.8, 128.8, 128.1, 127.1, 125.7, 119.5, 54.2, 51.8; GCMS (Rt = 
12.54) calculated for C15H13N3 235.29, was found to be 235.2. Regioisomer ratio 
of 1,4:1,5 adducts was found to be 1.1:1. 
Figure 4.5: 1H NMR of triazole 3. 
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1-heptyl-4-phenyl-1H-1,2,3-triazole (10):40 The solvent was removed in vacuo 
to give a 10 as a solid (16 mg, 0.11 mmol, 19.3% yield) 1H NMR (400 MHz; 
CDCl3): ∂ 7.83 (d, J=8.5 Hz, 2H), 7.74 (s, 1H), 7.50-7.37 (m, 3H), 4.40 (t, J=7.9 
Hz, 2H), 4.34 (t, J=8.0 Hz, 2H), 1.95-1.91 (m, 2H), 1.82 (m, 2H), 1.37-1.17 (m; 
8H), 0.90-0.82 (m, 3H); 13C NMR (400 MHz, CDCl3): ∂ 129.4, 129.0, 128.7, 
125.7, 48.3, 31.5, 30.1, 28.5, 26.3, 22.4, 13.9; GCMS (Rt = 13.77 min) calculated 
for C15H21N3 243.35, was found at 243.2. Regioisomer ratio of 1,4:1,5 adducts 
was found to be 2:1. 
Figure 4.6: 1H NMR of triazole 10. 
4-phenyl-1H-1,2,3-triazole (11):41 The solvent was removed in vacuo to give 11 
as a solid (16 mg, 0.11 mmol, 64.8% yield) 1H NMR (400 MHz; CDCl3): ∂ 7.98 (s, 
1H), 7.83 (d, J=8.5 Hz, 2H), 7.48-7.37 (m, 3H); 13C NMR (400 MHz; CDCl3): ∂ 
129.0, 128.8, 126.1; GCMS (Rt= 8.71 min) calculated for C8H7N3 145.16, was 
found at 145.1. 
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Figure 4.7: 1H NMR of triazole 11. 
1-benzyl-4-butyl-1H-1,2,3-triazole (12):39 The solvent was removed in vacuo to 
give 12 as a solid (35 mg, 0.16 mmol, 96.8% yield) 1H NMR (400 MHz; CDCl3): ∂ 
7.94 (s, 1H), 7.41-7.39 (m, 2H), 7.38-7.26 (m, 3H), 5.56 (s, 2H), 3.09 (t,  J=7.9 
Hz, 2H), 1.77 (q, J= 7.9 Hz, 2H), 1.00-0.91 (m, 3H); 13C NMR (400 MHz; CDCl3): 
∂ 129.3, 129.2, 128., 125.2, 54.5, 41.40, 17.41, 13.8; GCMS (Rt = 11.67 min) 
calculated for C13H17N3 215.30, was found at 215.2. Regioisomer ratio of 1,4:1,5 
adducts was found to be 1:6. 
Figure 4.8: 1H NMR of triazole 12. 
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4-butyl-1-heptyl-1H-1,2,3-triazole (13):42 The solvent was removed in vacuo to 
give 13 as a solid (33 mg, 0.15 mmol, 87.3% yield) 1H NMR (400 MHz; CDCl3): ∂ 
7.73-7.70 (m, 1H), 4.30 (t, 2H), 4.24 (t, J=7.9 Hz, 2H), 1.76-1.73 (m, 2H), 1.41-
1.26 (m, 14H), 1.00-0.85 (m, 6H); 13C NMR (400 MHz; CDCl3): ∂ 130.9, 128.8, 
65.9, 29.3, 28.9, 28.5, 25.9, 25.6, 23.7, 22.5, 14.0; GCMS (Rt = 10.49 min) 
calculated for C13H25N3 223.36, was found at 223.2. Regioisomer ratio of 1,4:1,5 
adducts was found to be 1:1.7. 
Figure 4.9: 1H NMR of triazole 13. 
4-butyl-1H-1,2,3-triazole (14):43 The solvent was removed in vacuo to give 14 
as a solid (20 mg, 0.16 mmol, 94.8% yield) 1H NMR (400 MHz; CDCl3): ∂ 8.18 (s, 
1H), 3.04 (t, J= 7.9 Hz, 2H), 1.84-1.68 (m, 4H), 1.01 (t, 2H); GCMS (Rt = 8.78 
min) calculated for C6H11N3 125.18, was found at 125.1.  
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Figure 4.10: 1H NMR of triazole 14. 
(1-benzyl-1H-1,2,3-triazol-4-yl) methanol (15):44 The solvent was removed in 
vacuo to give 15 as a solid (1.2 mg, 0.62 mmol, 87.0% yield). 1H NMR (400 MHz; 
CDCl3): ∂ 7.41-7.24 (m, 5H), 5.66 (s, 2H), 5.53 (s, 2H), 5.31 (s, 1H), 4.75 (s, 2H), 
4.61 (s, 2H); 13C NMR (400 MHz; CDCl3): ∂ 147.3, 129.3, 129.2, 129.1, 128.7, 
128.3, 127.6, 122.2, 55.3, 54.8, 53.3, 52.7, 29.7; GCMS (Rt = 10.84 min) 
calculated for C10H11N3O 189.22, was found at 189.2. Regioisomer ratio of 
1,4:1,5 adducts was found to be 1:1.5. 
Figure 4.11: 1H NMR of triazole 15. 
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(1-heptyl-1H-1,2,3-triazol-4-yl) methanol (16):45 The solvent was removed in 
vacuo to give 16 as a solid (1.3 mg, 6.65 mmol, 92.5% yield). 1H NMR (400 MHz; 
CDCl3): ∂ 7.68 (s, 1H), 7.58 (s, 1H), 5.49 (s, 1H), 4.79 (d, J=4 Hz, 2H), 4.42-4.35 
(m, 2H), 1.93 (m, 2H), 1.35-1.25 (m, 8H), 0.90-0.86 (m, 3H); 13C NMR (400 MHz; 
CDCl3): ∂ 122.2, 55.3, 53.2, 51.1, 31.6, 31.5, 30.1, 28.7, 28.6, 26.5, 26.3, 22.5, 
13.9; GCMS (Rt = 11.72) calculated for C10H19N3O 197.28, was found at 196.2. 
Regioisomer ratio of 1,4:1,5 adducts was found to be 1.6:1. 
Figure 4.12: 1H NMR of triazole 16. 
(1H-1,2,3-triazol-4-yl) methanol (17):46 The solvent was removed in vacuo to 
give 17 as an oil (< 5% yield). 1H NMR (400 MHz; CDCl3): ∂ 7.64 (s, 1H), 7.52 
(s, 1H), 4.80 (s, 2H); GCMS (Rt = 10.84 min) calculated for C6H13N3OSi 171.28, 
was found at 171.1.  
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Figure 4.13: 1H NMR of triazole 17. 
1-benzyl-4-(methoxymethyl)-1H-1,2,3-triazole (18): The solvent was removed 
in vacuo to give 18 as a solid (29 mg, 0.14 mmol, 84.0% yield). 1H NMR (400 
MHz; CDCl3): ∂ 7.44 (s, 1H), 7.36-7.27 (m, 5H), 5.50 (s, 2H), 4.54 (s, 2H), 3.37 
(s, 3H). Regioisomer ratio of 1,4:1,5 adducts was found to be 1:1.4. 
Figure 4.14: 1H NMR of triazole 18. 
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1-heptyl-4-(methoxymethyl)-1H-1,2,3-triazole (19): The solvent was removed 
in vacuo to give 19 as a solid (27 mg, 0.13 mmol, 75.2% yield). 1H NMR (400 
MHz; CDCl3): ∂ 7.50 (s, 1H), 4.57, (s, 2H), 4.32 (t, J= 14.6 MHz, 2H), 3.40 (s, 
3H), 1.91-1.86 (m, 2H), 1.33-1.24 (m, 8H), 0.87-0.84 (t, J= 7.9 Hz 3H). 
Regioisomer ratio of 1,4:1,5 adducts was found to be 1:1.7.  
Figure 4.15: 1H NMR of triazole 19. 
4-(methoxymethyl)-1H-1,2,3-triazole (20): The solvent was removed in vacuo 
to give 20 as a solid (9 mg, 0.080 mmol, 46.9% yield). 1H NMR (400 MHz; 
CDCl3): ∂ 7.72 (s, 1H), 4.63 (s, 2H), 3.42 (s, 3H), 1.67 (s, 1H). 
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Figure 4.16: 1H NMR of triazole 20. 
1-benzyl-4-(trityloxy)-1H-1,2,3-triazole (21):47 The solvent was removed in 
vacuo to give 21 as a solid (23 mg, 0.062 mmol, 32.7% yield). 1H NMR (400 
MHz; CDCl3): ∂ 7.56 (s, 1H), 7.48 (d, 4H), 7.47-7.18 (m, 16 H), 6.99-6.97 (m, 4H), 
5.52 (s, 2H), 5.50 (s, 2H), 4.31 (s, 2H), 4.08 (s, 2H). Regioisomer ratio of 1,4:1,5 
adducts was found to be 1:3. 
Figure 4.17: 1H NMR of triazole 21. 
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1-heptyl-4-(trityloxy)-1H-1,2,3-triazole (22):47 The solvent was removed in 
vacuo to give 22 as a solid (8 mg, 0.018 mmol, 10.7% yield). 1H NMR (400 MHz; 
CDCl3): ∂ 7.55 (s, 1H), 7.47-7.44 (m, 5H), 7.35-7.26 (m, 10H), 4.19 (s, 2H), 4.16 
(t, J=7.8 Hz, 2H), 1.77-1.75 (m, 2H), 1.25-1.20 (m, 8H), 0.85 (t, J=8.0 Hz, 3H). 
Regioisomer ratio of 1,4:1,5 adducts was found to be 1:3. 
Figure 4.18: 1H NMR of triazole 22. 
4-(trityloxy)-1H-1,2,3-triazole (23):48 The solvent was removed in vacuo to give 
23 as a solid (7 mg, 0.021 mmol, 12.1% yield). 1H NMR (400 MHz; CDCl3): ∂ 
7.61 (d, 2H), 7.59 (d, J=9.2 Hz, 2H), 7.55 (d, J=9.2 Hz, 4H), 7.34-7.23 (m, 10 H), 
3.76 (s, 2H), 3.73 (s, 2H). 
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Figure 4.19: 1H NMR of triazole 23. 
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Chapter 5: Site-directed Immobilization 
of a Carboxylesterase Enzyme onto a 
Stabilizing Resin 
I. Introduction 
While enzymes have long been known to play an indispensable role in 
biological systems, discoveries involving their utility in chemical processes have 
laid the groundwork for exciting new avenues of research. With the development 
of improved methods of enzyme isolation and purification, their role has been 
expanded to include several areas of research including materials science, 
organic chemistry, pharmaceuticals, food and beverage, detergents, textiles, and 
green chemistry.1-4 Enzymes are now employed in the production of over 500 
products used in as many as 50 different applications.1 The ability to use 
enzymes to catalyze chemical reactions holds significant advantages over 
traditional chemical catalysts. Enzymes are derived from renewable resources 
and are biodegradable, which eliminates many environmental concerns 
associated with chemical catalysts and has allowed for the replacement of 
several chemical catalysts in applications such as bread making and textiles.1 
Enzymes provide high reaction rates under mild reaction conditions, such as 
pressure, temperature, and pH levels, permitting these processes to occur at 
lower costs.2-4 In addition, enzymes may eliminate the need for organic solvents 
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in certain reactions.1 Moreover, enzymes are highly specific for their substrates 
and have high stereoselectivities, allowing for the production of enantiomerically 
pure products, which is highly beneficial in the development of pharmaceuticals.4 
Despite the countless benefits of enzymes, there are several associated 
limitations which preclude their widespread use in the industrial realm.  
 The ability to maintain the structural integrity and activity of enzymes 
during biochemical reactions is crucial for their effective use in the industrial 
realm. The conditions for enzymatic reactions must be highly controlled as minor 
changes in pH and temperature can lead to denaturation and inactivation of the 
enzyme.5 Nevertheless, many industrial reactions involving enzymes require high 
temperatures, nonaqueous solvents, or extremely acidic/basic conditions, 
reducing their utility in such processes. Furthermore, transferring the utility of 
enzymes from biological to chemical settings has proven difficult resulting from 
the instability of enzymes in nonaqueous environments, such as organic 
solvents, which are often essential for industrially relevant reactions and 
substrate solubility.2 Additionally, in order for the commercial use of enzymes to 
be economically viable and gain widespread implementation, a means to recycle 
and reuse enzymes must be developed in order to compensate for the potentially 
high cost of enzyme production.5 Furthermore, the inability to separate enzymes 
from the reaction products can lead to contamination of the reaction product.6 
The ability to immobilize enzymes onto solid supports serves as a viable method 
to address many of these limitations.  
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 Protein immobilization is the attachment of an enzyme to a phase different 
from that of the products or substrates, typically a solid matrix or support.5 
Several solid-supports have been utilized for protein immobilization including 
glass, beads, resins, silica, aluminum, titanium, carbon, and even certain 
metals.6,7 The ability to immobilize proteins greatly expands the scope of 
enzymatic reactions beyond biological processes. Significant improvements in 
both the cost and efficiency of industrial processes involving enzymes have been 
made as a result of this technique.6 Immobilized enzymes have greater stability 
in nonaqueous environments, extreme pH levels, and high temperatures, further 
expanding their utility in industrial processes.2 Additionally, with enzymes 
coupled to a solid-support, they are able to be recycled and reused through 
simple filtration.2,6 This also allows better control over reactions by allowing 
separation of the catalyst from the products.6 In this manner, continuous flow 
processes are possible through the elimination of the enzyme in subsequent 
reaction steps.6  Several important applications have arisen from the ability to 
immobilize proteins onto solid supports including the development of protein 
microarrays, biosensors, continuous flow reactors, as well as developments in 
drug discovery, diagnosis, and quality control.2,8    
Several methods are commonly employed for enzyme immobilization 
including adsorption, cross-linking, entrapment, and membrane confinement 
(Figure 5.1).5 Adsorption is the attachment of enzyme to an inert surface, such as 
glass or beads, through noncovalent hydrophobic interactions, salt linkages, and 
polar interactions. This method is limited by slow reaction times. In addition, this 
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method is limited by specificity as enzymes bind heterogeneously and in random 
orientations, meaning that the active site of the enzyme may be inaccessible as a 
result of binding to the matrix.5 Additionally, since a new chemical bond is not 
formed, enzymes may lose their attachment to the matrix, decreasing activity and 
contaminating the solution phase. Entrapment (physical adsorption) involves the 
implementation of an insoluble polymer network, such as silica gel, to cage the 
enzyme.5,9 Enzymes are protected from the environment; however, this method 
limits the accessibility of the enzyme to the substrate and the amount of product 
that can be released.5 Covalent immobilization involves attachment of proteins to 
solid-supports using accessible functional groups of reactive amino acid 
residues, such as cysteine, lysine, serine, and glutamine.8 Attachment may also 
be random in this case as there is little control over the number and location of 
residues that react. In addition, many covalent reactions are caustic and may 
lead to denaturation of the enzyme.11 This reaction provides the strongest bond 
between the enzyme and solid support, preventing leaching of the enzyme during 
the reaction. Enzyme stability and activity may be impacted during immobilization 
due to the transfer of the enzyme from a soluble to insoluble state, making the 
choice of immobilization methodology crucial.10  
Figure 5.1: A visual representation of the different immobilization techniques.9 
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Figure 5.2: A comparison of random vs. controlled protein 
immobilization orientation using UAAs.12  
The use of unnatural amino acid (UAA) technology has been implemented 
to overcome the limitations of current immobilization methodologies. Through the 
use of the Schultz methodology for UAA incorporation, UAAs containing reactive 
groups can be site-specifically incorporated into proteins. Bioorthogonal coupling 
reactions between functional groups present in the UAA and a coupling partner, 
such as a solid support, have previously been optimized.13 These reactions are 
specific in that coupling only occurs between the functional group of the UAA and 
a complementary functional group on the surface without interfering with native 
cellular processes.14 The use of bioorthogonal reactions allows enzymes to be 
immobilized in a homogenously oriented fashion determined by the site of UAA 
incorporation, eliminating the 
production of heterogenous 
mixtures on the solid support 
(Figure 5.2).2 This improves 
enzyme activity levels as the 
accessibility of the active site 
can be controlled. Previous 
work has demonstrated that 
GFP can be site-specifically immobilized onto a solid-support resin using UAAs.2 
It was found that the immobilization of GFP onto the solid-support resin allowed 
the structural integrity of the protein to be maintained under typically denaturing 
conditions.2 While this research served as a valuable proof of concept, GFP is a 
reporter protein and not an enzyme, necessitating the need for further studies 
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involving enzymes. For the purpose of this study, a caboxylesterase enzyme 
(SSO Est) obtained from the archaeon Sulfolobus sulfataricus will be utilized. A 
carboxylesterase enzyme cleaves an ester into an alcohol and a carboxylate 
through a hydrolysis reaction.15 These enzymes are found in a wide variety of 
organisms including plants, animals, and microorganisms.15 The use of SSO Est 
is further step toward the eventual utilization of UAA-mediated protein 
immobilization in industrially relevant hyperthermophilic enzymes.  
Hyperthermophilic enzymes are a fascinating class of enzymes that 
function at extremely high temperatures between 80 and 110 °C. S. sulfataricus 
P1 is a hyperthermophilic archaeon capable of surviving in sulfur-rich volcanic 
hot springs. These organisms thrive at high temperatures and low pH.15,16 
Enzymes from hyperthermophilic archaea have key applications in biotechnology 
and industry resulting from their ability to maintain stability under extreme 
conditions. This increased stability coupled with a solid support is especially 
useful in multiple applications. These enzymes are highly specific and are 
currently being used for a variety of industrial purposes including food, paper, oil 
production, toxic waste removal, detergents, as well as pharmaceuticals.17 In 
addition, they serve as model systems for use in evolutionary studies of 
enzymes, mechanisms of protein stability, and determining the upper 
temperature limit for enzyme function.16 Enzymes from hyperthermophilic 
organisms allow researchers to examine the relationship between structural 
flexibility and catalytic function over large temperature ranges.17 Experimental 
evidence has shown that at increasing temperatures, hyperthermophilic enzymes 
131 
 
 
become less conformationally flexible in order to overcome thermally denaturing 
forces.16,18 Unfortunately, this limits their catalytic functionality at physiological 
temperatures due their rigidity. Various denaturants, detergents, and solvents 
have been shown to activate  hyperthermophilic enzymes at lower temperatures; 
however, these conditions may also lead to protein denaturation.16,18 Studies 
have demonstrated that the introduction of dimethylformamide, acetonitrile, and 
dioxane solvents at physiological temperatures led to a decrease in enzymatic 
activity due to denaturation while DMSO allowed for an increase in enzymatic 
activity due to conformational changes leading to a reduction in rigidity.18 We 
believe that by immobilizing SSO Est onto a solid support, the range of 
conditions, including solvents, in which the enzyme is catalytically active can be 
expanded.   
Herein, the initial steps toward site-specific immobilization of SSO Est onto 
a stabilizing resin using UAAs are 
discussed. This research expands 
off of previous work involving the 
immobilization of GFP onto a solid 
support resin using UAAs. Unlike 
GFP, SSO Est catalyzes an organic 
reaction whose kinetics can be 
quantified through a previously 
established solution based assay. 
Upon successful incorporation of 
Figure 5.3: Structures obtained from 
immobilization of SSO Est using a Glaser-Hay 
reaction (A) and 1,3-dipolar cycloaddition 
bioconjugation reaction (B). 
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azide and terminal alkyne containing UAAs, bioorthogonal 1,3-dipolar 
cycloaddition or Glaser-Hay coupling between the mutated SSO Est and alcohol 
derivatized sepharose resin were carried out (Figure 5.3). Comparisons were 
made via assay between mutant and wild type SSO Est when subject to these 
reaction conditions to demonstrate the continued activity of the enzyme despite 
the insertion of a mutation. Upon optimization, this methodology can then be 
extended to other hyperthermophilic proteins and eventually mesophilic 
enzymes, which have greater industrial relevance. In addition, immobilized SSO 
Est can be subjected to various solvents in order to demonstrate the ability of the 
enzyme to function under a wider range of conditions. Immobilized SSO Est may 
also have utility within microwave irradiation applications.  
II. Results and Discussion 
 Wild type (WT) SSO Est plasmid was obtained from Robert Kelly at North 
Carolina State University. The WT gene was encoded on a pQE-30 plasmid; 
however, this plasmid was not independently compatible with the BL21 (DE3) 
competent cells utilized by our laboratory for protein expression which utilize a T7 
RNA polymerase. The pQE-30 plasmids contain a T5 promoter, which has an 
extremely high transcription rate and is recognized by the T7 RNA polymerase 
within the competent cells. To express proteins containing UAAs, an inducible 
plasmid system is required which is orthogonal to the E. coli expression system. 
This is often accomplished in our laboratory using pET plasmids which contain a 
T7 promoter and BL21 (DE3) competent cells which contain a plasmid harboring 
an IPTG-inducible gene for T7 RNA polymerase. IPTG binds to the lac repressor 
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and releases it from the operator, allowing the expression of lac controlled genes 
only in the presence of IPTG. Consequently, expression of proteins containing 
UAAs only begins after induction by the addition of IPTG. In order to allow for 
inducible gene expression when using pQE-30 plasmids, the plasmids are co-
transformed with a pREP4 plasmid, which contains a kanamycin resistance gene 
and constitutively expresses the lac repressor protein, preventing constitutive 
gene expression from occurring. In this manner, pQE-30 plasmids can be 
expressed using BL21 (DE3) competent cells in an inducible system controlled 
by IPTG.  
 Using the crystal structure of SSO Est, three sites were chosen for site-
specific insertion of UAAs through amber suppression. Because tyrosine shares 
a similar structure to the UAAs to be incorporated into SSO Est, surface-exposed 
tyrosines were selected as the residues to be mutated. Based off an examination 
of the crystal structure, Y90TAG (SSO 90), Y116TAG (SSO 116), and Y191TAG 
(SSO 191) were selected as the three sites for mutagenesis. QuickChange PCR 
was carried out to 
incorporate a TAG 
mutation at the 
selected sites (Figure 
5.4). QuickChange 
PCR utilizes exactly 
complimentary forward and reverse primers containing the TAG mutation in the 
selected position to synthesize a mutant DNA strand using the parental plasmid 
Figure 5.4: QuickChange PCR methodology.21 
134 
 
 
(SSO Est WT) as a template. PCR was carried out using three different 
concentrations of template plasmid: 24.7 ng/µL, 12.3 ng/µL, and 6.2 ng/µL. 
Template plasmid is first denatured by increasing the temperature. The 
temperature is then lowered, allowing the primers to anneal. The temperature is 
then raised allowing DNA polymerase to extend the mutant strand. Methylated 
parental DNA is then digested using DpnI, leaving only plasmid harboring the 
TAG mutation. Negative control reactions in which polymerase was not added 
were prepared for each site to be able to monitor digestion of template primer. 
Both reactions and controls for each site transformed into E. coli cells and were 
plated in the presence of ampicillin. The best differential growth between reaction 
and control plates was obtained using 24.7 ng/µL, particularly for the SSO 90 and 
SSO 191 mutants. Successful incorporation of the TAG mutation for each site 
was confirmed by sequencing at Genewiz using primers specific for the T5 
promoter in the pQE-30 backbone of the SSO Est plasmid. Sequencing results 
confirmed successful incorporation of the TAG mutation in each of the three 
selected sites.  
 With the three mutated plasmids in hand, initial attempts were made to 
express both WT and mutant SSO Est enzymes and evaluate their activity via 
assay. WT enzyme was expressed by co-transforming the SSO Est plasmid (0.5 
µL) with a pREP4 plasmid (0.5 µL). Cells were grown in the presence of 
ampicillin and kanamycin antibiotics. A 50 mL expression was prepared and 
induced by the addition of a 1:1000 ratio of IPTG. The expression was grown for 
16 hours at 37 °C. Because of the hyperthermophilic nature of SSO Est, purified 
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enzyme was obtained by heating the cell lysate at 80 °C for 1 hour. Successful 
expression of WT enzyme was confirmed through SDS-PAGE analysis as a band 
was observed as 33 kDa; however, there was also a band at approximately 37 
kDa indicating the overexpression of a different hyperthermophilic impurity which 
was not removed by heating. To express mutant SSO Est enzyme, a triple 
transformation was carried out by co-transforming a mutant SSO Est plasmid 
(0.33 µL) with a pREP4 plasmid (0.33 µL) and a pEVOL-pCNF synthetase 
plasmid (0.33 µL), allowing for incorporation of UAAs via an orthogonal 
aaRS/tRNA pair evolved from M. jannaschii. Cells were grown in the presence of 
ampicillin, chloramphenicol, and 
kanamycin antibiotics. Expression 
and purification of mutated SSO Est 
at each of the three sites was 
carried out in a similar manner as 
WT with enzyme expression being 
induced by the addition of a 1:1000 
ratio of IPTG and 20% arabinose and 
a 1:100 ratio of pPrF. Unfortunately, 
successful expression of mutated 
SSO Est was not obtained as could 
be seen by the lack of the characteristic SSO Est band on SDS-PAGE gels. In 
addition, the impurity was still present in large quantities despite the lack of SSO 
Est enzyme expression (Figure 5.5). The lack of significant levels of mutant 
Figure 5.5: SDS-PAGE analysis of WT and 
mutant SSO Est enzymes. Lane 1 contains WT 
enzyme. Lane 2 contains SSO 90 expressed 
with pAzF. Lane 3 contains SSO 191 
expressed with a pEVOL WT synthetase which 
incorporates a tyrosine at the site of the TAG. 
Little to no expression of SSO Est is evident for 
the mutants and the impurity is overexpressed. 
The WT expression contained a mixture of 
SSO Est enzyme and the impurity.  
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Scheme 5.1: Carboxylesterase assay reaction.15 
enzyme expression was further confirmed via a colorimetric esterase assay. This 
assay involves the hydrolysis of 4-nitrophenyl hexanoate into an alcohol (4-
nitrophenol) and a carboxylic acid (hexanoic acid) through the activity of the SSO 
Est enzyme (Scheme 5.1).15 The formation of 4-nitrophenol causes a yellow color 
change which can be measured via absorbance measurements taken 405 nm.15 
The formation of this product is used an indicator of SSO Est activity.15 Assay 
results indicated that the WT enzyme had significant activity when compared to 
the mutants, which showed trace to no activity. We hypothesized that this lack of 
activity resulted from the fact that SSO Est enzyme was present in low 
concentrations, but was poorly expressed relative to the impurity, which could not 
be removed through purification. As a result, we sought to optimize the 
expression methodology of SSO Est to improve mutant concentrations and 
reduce the amount of impurity present. 
 Several variables were tested to improve the expression levels of mutant 
SSO Est enzymes. The first variable tested was temperature. Expressions were 
incubated overnight at three different temperatures following induction: room 
temperature (22 °C), 30 °C, and 37 °C. Unfortunately, expressions grown at room 
temperature and 30 °C did not show any significant improvement over those 
grown at 37 °C. Moreover, impurity levels were slightly higher in most cases for 
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those expressions grown at 37 °C (Figure 5.6). It was then hypothesized that 
scaling up the expression size may increase the amount of enzyme obtained. 
Upon increasing expression sizes to 250 mL, the amount of impurity was 
reduced; however, there was no 33 kDa band indicating the presence of SSO 
Est. The purified samples also failed to display any significant activity when 
subject to the esterase assay. Attempts were also made to alter the purification 
method by increasing or decreasing the denaturation time. Upon decreasing the 
heating time from 1 hour to 30 minutes and increasing heating time to 2 hours, 
no changes in the expression level or the amount of impurity were seen. 
Additional attempts to concentrate and buffer exchange SSO Est mutants into 
PBS buffer did not yield successful results. Utilization of the pUltra synthetase for 
unnatural amino acid incorporation also failed to yield SSO Est enzyme for any of 
Figure 5.6: SDS-PAGE analysis of SSO Est mutants expressed at different temperatures. 
These results indicate that for each of the mutants, the levels of impurity were highest at 37 oC 
and lowest at 30 oC. No significant expression of SSO Est was obtained for any of the mutants 
at any of the selected temperatures, which was confirmed using the esterase assay.  
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the mutants. It was then hypothesized that the previously isolated pREP4 
plasmid may have contained WT plasmids that were interfering with enzyme 
expression. To further isolate the pREP4 plasmid, selection pressure was utilized 
by growing the pREP4 plasmid in the presence of kanamycin so that only the 
pREP4 plasmid was maintained within the cells. Four rounds of selection were 
used to obtain pure pREP4 as confirmed via agarose gel electrophoresis. 
Unfortunately, no significant SSO Est expression for any of the mutants 
expressed with the purified pREP4 resulted. It was apparent that the expression 
issues encountered for the mutants resulted from the introduction of the third 
plasmid used for the UAA expression system. To confirm this theory, each of the 
three mutated SSO Est plasmids were co-transformed with purified pREP4 
plasmid and a pEVOL WT synthetase, which would incorporate a standard 
tyrosine into the location of the TAG mutation using the orthogonal aaRS/tRNA 
pair, making WT enzyme. The lack of SSO Est enzyme obtained from these 
expressions confirmed our theory that the three-plasmid system was ineffective 
for expressing the SSO Est mutants.  
 As a result of the difficulties encountered in the expression of mutant SSO 
Est enzyme using the three-plasmid system, we sought to clone WT and mutant 
SSO Est genes into pET 22(b)+ plasmids, which have been successfully used by 
our lab in the expression of several different UAA-containing proteins. We first 
attempted to clone SSO Est WT into a pET 22(b)+ plasmid (Figure 5.7). To clone 
the SSO Est plasmid into the pET plasmid, forward and reverse primers were 
designed that contained restriction sites found in both the SSO Est plasmid and 
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the pET 22(b)+ plasmid. The XhoI and NdeI restriction sites were selected for 
cloning and were included in the primers. First, the vector in which the SSO Est 
insert was to be cloned was prepared. To do this, a pET 22(b)+ plasmid was 
digested at both the XhoI and NdeI restriction sites. The plasmid was then 
dephosphorylated to prevent the plasmid from recircularizing in the absence of 
the SSO Est insert. The plasmid was the analyzed using agarose gel 
electrophoresis (Figure 5.8). The SSO Est insert was prepared by amplifying the 
SSO Est WT gene using PCR. The amplified SSO Est WT gene was then 
digested in the same manner as the pET plasmid using the XhoI and NdeI 
restriction sites. Using digested SSO Est WT insert and the pET 22(b)+ vector, 
ligation reactions were prepared using both a 2:1 and 1:1 ratio of vector to insert. 
Control reactions were prepared using the SSO Est insert to ensure that no 
undigested parent plasmid was present and using the pET 22(b)+ insert to 
ensure that no recircularization of the parent plasmid occurred. Ligation reactions 
and controls were plated on ampicillin plates. No growth was evident on either of 
Figure 5.7: The general methodology for the cloning of the SSO Est gene into the pET 22(b)+ 
vector.22 
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the controls and colonies were evident on the plate using the 2:1 ratio of insert to 
vector. To determine whether the SSO Est WT plasmid was successfully cloned 
into the pET 22(b)+ plasmid, the ligation reaction was digested using SpeI, which 
cuts inside the SSO Est plasmid. Successful digestion of the SSO Est plasmid 
was confirmed via agarose gel electrophoresis, indicating the presence of the 
SSO Est WT gene within the ligated plasmid. The SSO 191 mutant was then 
cloned into the pET 22(b)+ plasmid using the same process.  
 
Figure 5.8: Agarose gels displaying successful cloning of the SSO Est gene into a pET 22(b)+ plasmid. 
Successful amplification of the SSO Est gene was confirmed by the bright band at approximately 1,000 
bp (A). Successful digestion of the pET 22(b)+ plasmid was confirmed by the presence of a band at 
approximately 6,000 bp after digestion compared to the 5,0000 bp band before digestion (B). 
Successful cloning of the ligated plasmid was confirmed through digestion with SpeI, which cuts within 
the SSO Est gene. The appearance of new band at approximately 8,000 bp indicates successful 
digestion and the presence of the SSO Est gene in the ligated plasmid (C). Growth in the presence of 
ampicillin indicates the presence of the pET 22(b)+ plasmid which has an ampicillin resistance tag.  
 
 Having successfully cloned the SSO WT and SSO 191 plasmids into pET 
plasmids, we were able to prepare expressions for both WT and mutant enzyme. 
A 20 mL expression was prepared for WT as described previously. Since the 
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pREP4 plasmid was no longer necessary, cells were only grown in the presence 
of ampicillin. Enzyme expression was induced with a 1:1000 ratio of IPTG. 
Because the pET 22(b)+ plasmid contains a His-Tag, SSO Est could be purified 
using a Ni column. To further 
enhance the purity of the 
enzyme, the cell lysate was 
heated at 80 °C prior to 
purification using the Ni 
column. The presence of 
purified WT enzyme was 
confirmed through the 
presence of a 33 kDa band 
via SDS-PAGE (Figure 5.9). SSO 191 was expressed and purified in a similar 
manner by growing cells in the presence of ampicillin and chloramphenicol and 
inducing with a 1:1000 ratio of IPTG and 20% arabinose and a 1:100 ratio of an 
azide containing UAA, pAzF. A second expression was carried out to express 
SSO 191 with a terminal alkyne containing UAA, pPrF. Negative control 
expressions were prepared which were not induced with UAA. The presence of 
SSO 191 was confirmed by via SDS-PAGE analysis. Only minimal levels of 
enzyme expression occurred in the absence of UAA due to the incorporation of 
tyrosine at the TAG mutation site. The 37 kDa impurity was no longer present in 
either the WT or mutant samples. Fortunately, when subject to the esterase 
assay, WT and SSO 191 in the presence of both UAAs showed enzymatic 
Figure 5.9: SDS-PAGE analysis of WT and SSO 191 
expressions with and without the addition of pAzF. Pure 
WT and SSO 191 enzyme were obtained. Minimal 
expression was seen in the absence of UAA as 
expected. Slightly lower expression levels were seen in 
mutant vs. WT enzyme. 
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activity, with SSO 191 mutants displaying slightly more activity compared to WT. 
The assay was carried out in triplicate to verify the reproducibility of these results 
(Figure 5.10). These results confirmed that both WT and mutated SSO Est 
enzyme containing UAAs were successfully expressed and were both active. It 
was evident that introduction of UAAs did not lead to any significant reduction in 
enzymatic activity.  
Figure 5.10: A comparison of esterase assay results using WT and SSO 191 containing pAzF. 
Results indicate enzymatic activity levels were maintained in mutant enzymes as can be seen by 
comparable absorbance levels at 405 nm for WT and SSO 191 enzymes. The differences in 
absorbance at 405 nm. is evident through the yellow color of both the WT and mutant samples 
when compared to negative control (pictured). Error bars represent standard deviation. 
 
With the UAA containing enzymes in hand, we next sought to immobilize 
SSO Est onto a stabilizing resin. Previous studies involving the immobilization of 
GFP have shown the Epoxy Sepharose 6B resin allows for the most efficient 
immobilization of proteins. In order to immobilize protein onto the resin, the resin 
must first be coupled with an alcohol containing a terminal alkyne, allowing 
bioorthogonal reactions to occur between the resin and the UAA-containing 
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protein (Figure 5.11). 
A 1,3-dipolar 
cycloaddition reaction 
could then occur 
between the terminal 
alkyne of the resin and 
the azide group of 
SSO 191 containing 
pAzF. In addition, a 
Glaser-Hay reaction 
could occur between 
the terminal alkyne of 
the resin and the terminal alkyne of SSO 191 containing pPrF.  In order to 
optimize the immobilization conditions, Sepharose resin was coupled with alkynyl 
alcohols containing carbon linkers of various lengths. Resins were coupled with 
propargyl alcohol, 5-hexyn-1-ol, and 10-undecyn-1-ol. Coupled resins were then 
reacted with ethanolamine to prevent non-specific coupling of enzyme to the 
resin. The use of bioorthogonal reactions ensures that the immobilization 
reaction is specific, occurring only between the resin and the functional group of 
the UAA incorporated at the specific residue on the enzyme.   
SSO 191 containing pAzF was subjected to 1,3-dipolar cycloaddition 
reactions with each of the three resins. Reactions were prepared using CuSO4, 
TBTA, and TCEP as the catalyst system at 4 °C for 14 hours. A control reaction 
Figure 5.11: Immobilization reactions using Sepharose 6B resin. 
Resin is first coupled with an alcohol containing a linker of varying 
length (A). Bioorthogonal reactions can then occur allowing for 
coupling between the terminal alkyne of the resin and the UAA 
using either a Glaser-Hay coupling (B) or a 1,3-
dipolarcyloaddition (C).  
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was prepared using WT enzyme to ensure that non-specific coupling of SSO Est 
did not occur. A separate control reaction was prepared using only resin and 
PBS buffer in to eliminate any background absorbance caused by the resin when 
performing the assay. Upon completion of the reaction, resins were washed 10 
times using PBS buffer to wash away any unreacted enzyme. Washed resins 
were then subject to the esterase assay. Assay reactions for SSO 191 and each 
of the controls were performed in triplicate. No significant absorbance was 
observed for SSO 191 or any of the controls when 5-hexyn-1-ol was used as the 
linker (results not shown). A significant difference in activity was evident between 
SSO 191 and the WT control when propargyl alcohol was used as the linker 
(Figure 5.12). A similar difference was seen between SSO 191 and WT when 
using 10-undecyn-1-ol as the linker, but with less overall activity. These results 
Figure 5.12: Esterase assay results for 1,3-dipolar cycloaddition immobilization reactions. It is 
evident that site-specific immobilization occurred using both resins; however, more efficient 
coupling was attained using propargyl alcohol. Activity levels were significantly reduced when 
WT enzyme was utilized in the reaction. Error bars represent standard deviation.  
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indicate that shorter linker length allows for better immobilization, which 
corroborated previous studies. For both resins, it was evident that the SSO 191 
enzyme was site-specifically coupled to the resin; however, based off the activity 
levels observed when using WT enzyme, some non-covalent association of the 
WT enzyme also occurred.  
Similar results were obtained when SSO 191 was subject to Glaser-Hay 
reactions with each of the three resins. Reactions were carried out for 6 hours at 
37 °C using a CuI and TMEDA catalyst system followed by 10 washes with PBS. 
Control reactions were prepared as described previously. Assay results indicated 
that SSO 191 showed increased activity when compared to the WT control for 
both the propargyl alcohol and 10-undecyn-1-ol resins, with propargyl alcohol 
resin showing slightly more activity. Interestingly, there was less of a difference 
between propargyl alcohol and 10-undecyn-1-ol resins using the Glaser-Hay 
reaction as opposed to the 1,3-dipolar cycloaddition reaction. Standard 
deviations were significantly larger for each trial for these reactions; however, 
which highlights the need further optimization of the assay protocol. In this 
scenario it appears that the 1,3-dipolar cycloaddition lead to more enzymatic 
immobilization. It was evident that site-specific immobilization occurred; however, 
there was also some non-specific coupling as can be seen by the activity in the 
WT control for both resins. Significant coupling was not obtained for SSO 191 or 
the controls using hexyn-1-ol resin (results not shown). Overall, these results 
indicate that SSO Est was site-specifically immobilized onto the Sepharose resin 
using both 1,3-dipolar cycloaddition reactions and Glaser-Hay reactions with 
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relatively equal efficiencies. In addition, it was evident that shorter linkers allow 
for optimum immobilization.  
 In summary, both WT and SSO 191 enzyme were successfully cloned into 
pET plasmids. Alkyne and azide-containing UAAs were successfully incorporated 
into SSO 191 and activity levels were maintained. Using SSO 191, 
immobilization reactions were carried out using resins containing carbon linkers 
of various lengths through both 1,3-dipolar cycloadditions and Glaser-Hay 
reactions. SSO 191 was successfully coupled to the resin using both reactions 
and resins contained activity levels significantly larger than the WT controls. 
More effective immobilization was achieved using shorter carbon linkers, 
especially using the 1,3-dipolar cycloaddition reaction. Future work will involve 
the cloning and expression of additional mutants, SSO 90 and SSO 116, to 
determine if either of these sites allow for more effective immobilization. In 
addition, studies will be conducted to non-specifically couple SSO Est to a 
stabilizing resin using reactive amino acid residues, such as cysteine. It is 
hypothesized that the activity levels of these resins will be significantly lower than 
those obtained using the technique described herein, which will prove its utility. 
This technique can then be translated to other proteins of therapeutic and 
industrial significance. Studies will also be conducted involving resubjecting 
resins to multiple assays to demonstrate the recyclability of the SSO Est enzyme 
when immobilized on the resin. Using this technique, we will demonstrate that 
UAA technology can be used to site-specifically immobilize enzymes onto 
stabilizing resins, allowing for recyclability and an improvement in activity levels 
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when compared to techniques that utilize non-specific coupling. This work will 
also facilitate studies in nonaqueous solvents and enzymatic activation via 
microwave irradiation. 
III. Materials and Methods 
General: Solvents and reagents were either obtained from Fisher Scientific or 
Sigma-Aldrich and used without further purification unless otherwise noted. 
Epoxy-activated 6B resin was obtained from GE Healthcare. The SSO P1 
Carboxylesterase plasmid was obtained from the Kelley lab at NCSU. PCR was 
performed using a Bio-RAD icycler and the Quick-Change II kit. All SSO proteins 
were purified according to the manufacturer’s protocols using a Qiagen Ni-NTA 
Spin Kit. The esterase assay was performed using a Synergy HT microplate 
reader.  
Quick-Change PCR Protocol: Three sites were selected for insertion of the 
TAG mutation: Y90, Y116, and Y191. A pQE-30 plasmid harboring SSO P1 
carboxylesterase was diluted to 24.7 ng/µL using sterilized deionized water. The 
PCR reaction mixture was prepared by adding the diluted plasmid (5 µL) to 10 
mM DNTPs (0.75 µL), KAPA Hi-Fi Polymerase (0.5 µL), forward primers (10 mM, 
0.75 µL), reverse primer (10 mM, 0.75 µL), KAPA buffer (5 µL), and Milliq water 
(12.25 µL). A negative control PCR mixture was prepared without the addition of 
KAPA Hi-Fi polymerase. The reaction mixture was subjected to the following 
heating protocol: 95 °C (1 min.), eighteen cycles of melting (95 °C, 30 s), 
annealing (55 °C, 30 s), and, extension (68 °C, 6 min), followed by an additional 
extension cycle (68 °C, 6 min) then an infinite hold at 4 °C. For both the reaction 
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and control mixtures, the parent plasmid was digested and the mutant plasmid 
was ligated by the addition of DPN1 (20,000 units/µL, 2 µL), 5x T4 Ligase buffer 
(4 µL), and T4 Ligase (1 µL). The mixtures were then heated at 37 °C for 2 hours 
followed by one cycle of heat deactivation at 80 °C for 15 minutes. The reaction 
and control mixtures were cleaned and concentrated using a Zymo DNA Clean 
and Concentrator kit. The reaction and control mixtures were transformed (5 µL) 
into BL21 DE3 Escherichia coli cells by heat shock using an Eppendorf eporator 
electroporator. The transformed cells were plated and cultured (500 µL) onto LB 
agar containing ampicillin (50 µg/mL) and incubated at 37 °C overnight. 
Differential growth between the reaction and control plates was observed. One 
colony from the reaction plate was used to inoculate 10 mL of LB media 
containing ampicillin (50 µg/mL). This culture was incubated and allowed to 
shake at 37 °C overnight. The resulting cells were mini-prepped using an IBI 
High Speed Plasmid Mini Kit to isolate the DNA. The isolated plasmids were 
analyzed for successful insertion of the TAG mutation by sequencing at Genewiz. 
The primers were obtained from IDT DNA Technologies Inc. and are as follows: 
Y90TAG 5’-TGT AAT AGG CGA TGT GGA ATC TTA GGA CCC ATT ATG TAG 
AG-3’ (forward) and 5’-CTC TAC ATA ATG GGT CCT AAG ATT CCA CAT CGC 
CTA TTA CA-3’ (reverse), Y116TAG: 5’- CTA TAG GTT AGC TCC AGA ATA 
GAA GTT TCC TTC TGC AGT-3’ (forward) and 5’-ACT GCA GAA GGA AAC 
TTC TAT TCT GGA GCT AAC CTA TAG-3’ (reverse), Y191TAG 5’-CAA GAT 
CCA TGA TAG AGT CTG ATG GGT TCT TCC T- 3’ (forward) and 5'-AGG AAG 
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AAC CCA TCA GAC TAC TCT ATC ATG GAT CTT G-3’ (reverse). The 
sequencing primer was 5’-TTC TGC TGA GCG GAT AAC-3’.  
Cloning of SSO into a pET 22(b)+ Vector: SSO Est WT and each of the three 
SSO Est TAG mutant plasmids were cloned into a pET 22(b)+ vector. Plasmids 
were cut using the XhoI (forward) and NdeI (reverse) restriction sites. PCR 
reactions were carried out on SSO Est WT and each of the three SSO Est TAG 
mutant plasmids to amplify the SSO Est gene. Reaction mixtures were prepared 
by adding SSO Est plasmid (2 µL) to 10 mM DNTPs (2 µL), KAPA Hi-Fi 
Polymerase (1 µL), forward primer (10 mM, 2 µL), reverse primer (10 mM, 2 µL), 
KAPA buffer (5 µL), and Milliq water (11 µL). The reaction mixture was subjected 
to the following heating protocol: 95 °C (4 min.), thirty cycles of melting (95 °C, 30 
s), annealing (51 °C, 30 s), and, extension (72 °C, 45 s), followed by an 
additional extension cycle (72 °C, 5 min) then an infinite hold at 4 °C. Successful 
amplification of the SSO Est gene was determined using agarose gels (1%) 
stained with ethidium bromide. Gels were run for 1 hour at 80V in 1x TAE buffer 
(diluted from a 5x stock containing 242 g Tris-base, 57.1 mL glacial acetic acid, 
100 mL 0.5 M EDTA (pH 8.0), 842 mL deionized water). Gels were analyzed 
using a Bio-Rad Molecular Imager (Gel Doc XR+) gel imager (Ethidium bromide 
protocol). Double digestion of the PCR product was carried out by preparing a 
reaction mixture containing 23 µL of the amplified SSO Est plasmid, 20 µL sterile 
deionized water, 0.5 µL BSA, 5 µL 10x CutSmart buffer, 1 µL Xhol restriction 
enzyme, and 1 µL NdeI restriction enzyme. The mixture was heated for 3 hours 
at 37 °C followed by one cycle of heat deactivation at 80 °C for 15 minutes. The 
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reaction mixture was cleaned and concentrated using a Zymo DNA Clean and 
Concentrator kit. Successful digestion of the SSO Est plasmid at both restriction 
sites was confirmed using an agarose gel (1%) as described previously. Double 
digestion of the pET 22(b)+ plasmid was performed in an identical manner as the 
SSO Est plasmid. Dephosphorylation of the digested pET 22(b)+ plasmid was 
carried out by preparing a reaction mixture containing 20 µL of cut pET 22(b)+ 
plasmid, 5 µL Antarctic phosphodiesterase buffer, 2 µL phosphatase enzyme, 
and 23 µL sterile deionized water. The reaction mixture was incubated for 1 hour 
at 37 °C followed by one cycle of heat deactivation at 80 °C for 15 minutes. The 
product was then cleaned and concentrated using a Zymo DNA Clean and 
Concentrator kit. A ligation reaction was prepared using a 1:1 ratio of digested 
SSO Est insert to digested pET 22(b)+ vector by mixing 2 µL digested SSO Est 
plasmid, 2 µL digested pET 22(b)+ plasmid, 1 µL T4 ligase buffer, 1 µL T4 ligase, 
and 4 µL sterile deionized H2O. A second ligation reaction was prepared using a 
2:1 ratio of digested SSO Est insert to digested pET 22(b)+ vector by mixing 4 µL 
digested SSO Est plasmid, 2 µL digested pET 22(b)+ plasmid, 1 µL T4 ligase 
buffer, 1 µL T4 ligase, and 2 µL sterile deionized water. A control reaction was 
prepared for the SSO Est insert by mixing 1 µL digested SSO Est vector, 1 µL T4 
ligase buffer, 1 µL T4 ligase, and 7 µL sterile deionized water. A second control 
reaction was prepared for the pET 22(b)+ insert by mixing 1 µL digested pET 
22(b)+ plasmid, 1 µL T4 ligase buffer, 1 µL T4 ligase, and 7 µL sterile deionized 
water. Ligation reactions were incubated overnight for approximately 16 hours at 
4 °C. The reaction and control mixtures were transformed (4 µL) into BL21 DE3 
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Escherichia coli cells by heat shock using an Eppendorf eporator electroporator. 
The transformed cells were plated and cultured (500 µL) onto LB agar containing 
ampicillin (50 µg/mL) and incubated at 37 °C overnight. Differential growth 
between the reaction and control plates was observed. One colony from the 
reaction plate was used to inoculate 10 mL of LB media containing ampicillin (50 
µg/mL). This culture was incubated and allowed to shake at 37 °C overnight. The 
resulting cells were mini-prepped using an IBI High Speed Plasmid Mini Kit to 
extract the DNA. The isolated plasmids were analyzed for successful cloning 
through reaction with a restriction enzyme that cuts within the SSO Est gene. The 
reaction was prepared by mixing 20 µL of cloned plasmid with 0.5 µL BSA, 5 µL 
CutSmart buffer, 1 µL SpeI restriction enzyme, and 24 µL sterile deionized water. 
Successful digestion using the SpeI restriction site was confirmed using an 
agarose gel (1%) as described previously. Primers were obtained from IDT DNA 
Technologies Inc. and are as follows: 5’-GGT GGT GGT GCT CGA GAT GCC 
CCT AGA TCC TAG A-3’ (forward) and 5’-AAG GAG ATA TAC ATA TGT TAA 
ATT TTA TCA TAA AAT ACT CGT-3’.  
Expression and Purification of SSO: A pET 22(b)+ plasmid harboring a 
variable SSO Est TAG mutant (0.5 µL) was co-transformed with a pEVOL-pCNF 
plasmid (0.5 µL) into BL21 DE3 E. coli cells by heat shock using an Eppendorf 
eporator electroporator. The cells were then plated and cultured (300 µL) on LB 
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) at 37 °C in 
an incubator overnight. One colony was then utilized to inoculate LB media (4 
mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This 
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culture was then incubated and allowed to shake at 37 °C overnight. The 
following day, this culture was then used to inoculate an expression culture 
containing LB media (10 mL), ampicillin (50 µg/mL) and chloramphenicol (34 
µg/mL) at a starting OD600 of 0.1. The cultures were incubated and allowed to 
shake at 37 °C until an OD600 between 0.7 and 0.9 was reached. Protein 
expression was then induced by the addition of pPrF or pAzF (100 µL, 100 mM), 
20% arabinose (10 µL), and isopropyl β-D-1-thiogalactopyranoside (IPTG, 10 µL, 
0.8 mM). The cultures were then incubated with and allowed to shake at 37 °C 
for approximately 16 hours. The cells were then pelleted by centrifugation (5,000 
rpm, 10 minutes) and then stored at -80 °C until purification.  
 Purified SSO Est was obtained by resuspending the cell pellet with 500 µL 
Bugbuster (Novagen) containing lysozyme and 200 µL of lysis buffer. The 
mixture was then incubated and allowed to shake at 37 °C for 20 minutes. The 
mixture was then transferred to an Eppendorf tube and centrifuged at 13,200 rpm 
for 10 minutes to pellet cellular debris. The supernatant was decanted into a 
separate Eppendorf tube and incubated at 80 °C for 1 hour followed by 
centrifugation at 13,200 rpm for 10 minutes. Purified SSO Est was obtained in 
the supernatant and decanted into an equilibrated HisPur Ni-NTA spin (Qiagen) 
column containing Nickel resin (200 µL) and SSO Est was purified according to 
the manufacturer’s protocol. SDS-PAGE (BioRad 10% precise gels) was used to 
analyze purified SSO Est. SDS-PAGE gels were run at 120V for approximately 2 
hours, stained with Coomassie Brilliant Blue solution, and destained using a 
solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic 
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acid. Gels were analyzed using a Bio-Rad Molecular Imager (Gel Doc XR+) gel 
imager (Coomassie protocol) after 24 hours. Protein was used without further 
purification. 
Preparation of Epoxy Sepharose 6B Resin: Epoxy-activated 6B Sepharose 
(GE Healthcare, 1 g) was added to a double filter syringe and washed with 
deionized water (200 mL). The resin was dried via vacuum for 1 hour. Alkyn-ol (1 
mL) and alcohol coupling buffer (5 mL, pH 13) were added to a vial. Dried resin 
was added to the vial and the vial was shaken at 30 °C at 200 rpm for 16 hours. 
The resin was transferred to a double filter syringe and washed 4 times with 5 mL 
of alcohol coupling buffer. The resin was dried for 1 hour via vacuum. The 
sepharose was transferred to a vial and capped with ethanolamine (2M, 844 µL) 
and 7 mL of deionized water. The resin was shaken at 37 °C at 200 rpm 
overnight then washed in a filter syringe with acetate buffer (0.1 M, pH 4) and 
tris-HCl buffer (0.1 M, pH 8) using 3 alternating washes of 10 mL.  
General Click Immobilization Conditions: The following reagents were added 
to a sterile 1.5 mL eppendorf tube in the order listed: CuSO4 (50 mM in H2O, 2 
µL), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (5 mM in DMSO, TBTA, 20 
µL), 20 µL SSO Est/pAzF, 30 mg derivatized Sepharose 6B resin (GE 
Healthcare), tris(2-carboxyethyl)phosphine (50 mM in H2O, TCEP, 2 µL). The 
reactions were then diluted in phosphate buffered saline solution at pH 7.4 (PBS, 
6 µL). A control reaction was prepared using 20 µL SSO Est WT in place of SSO 
Est/pAzF. A second control reaction was prepared using 20 µL SSO Est/pAzF, 
30 mg derivatized Sepharose 6B resin (GE Healthcare), and 30 µL of PBS Buffer 
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in place of the catalyst system. The reaction was incubated for 14 hours at 4 °C. 
The reactions were then transferred to an empty spin column and washed with 
1x PBS Buffer (10 x 200 µL) and centrifuged at 3,600 rpm for 1 minute. Resins 
were then diluted in PBS Buffer (200 µL) and analyzed for protein activity via 
assay.  
General Glaser-Hay Immobilization Conditions: CuI (500 mM in H2O, 5 µL) 
and tetramethylethylenediamine (500 mM, TMEDA, 5 µL) were added to a sterile 
1.5 mL eppendorf tube and allowed to equilibrate for 10 minutes. Next, 30 mg 
derivatized Sepharose 6B resin (GE Healthcare) was added and allowed to 
equilibrate for an additional 10 minutes followed by the addition of 20 µL SSO 
Est/pPrF. The reactions were then diluted in phosphate buffered saline solution 
at pH 7.4 (PBS, 10 µL). A control reaction was prepared using 20 µL SSO Est 
WT in place of SSO Est/pPrF. A second control reaction was prepared using 20 
µL SSO Est/pAzF, 30 mg derivatized Sepharose 6B resin (GE Healthcare), and 
10 µL of PBS Buffer in place of the catalyst system. The reaction was shaken at 
200 rpm for 6 hours at 37 °C. The reactions were then transferred to an empty 
spin column and washed with 1x PBS Buffer (10 x 200 µL) and centrifuged at 
3,600 rpm for 1 minute. Resins were then diluted in PBS Buffer (200 µL) and 
analyzed for protein activity via assay. 
Arylesterase Assay: Prior to assay, purified SSO Est protein samples, were 
concentrated using Corning Spin-X UF purification columns and diluted with 1x 
PBS buffer to ensure uniform concentration between samples. Protein 
concentrations were determined by UV-Vis absorbance at 280 nm. The reaction 
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mixture was prepared in triplicate on ice by adding 2 µL of SSO Est TAG variant 
protein to a mixture of 76 uL of 100 mM acetate buffer, 4 µL of 4-nitophenyl-
hexanoate (0.114 g/mL), and 18 µL of 1x PBS (pH 7.4). A positive control mixture 
was prepared in triplicate as described using 2 µL of SSO Est WT protein. A 
negative control mixture was prepared in triplicate, containing an additional 2 µL 
of 1x PBS and no protein. To analyze immobilization reactions, assay reactions 
were prepared in triplicate as described previously with the exception of 15 µL of 
diluted resin samples being used in place of a protein sample. Resins were 
thoroughly resuspended by pipetting prior to transfer to ensure that equal 
amounts of resin were analyzed in each trial. Control and reaction mixtures were 
incubated at 80 °C for 30 minutes. The reaction was quenched using 100 µL of 
distilled water saturated with Na2CO3. An absorbance reading was immediately 
taken at 405 nm to measure product formation. A second absorbance reading 
was taken at 405 nm after allowing the reactions to incubate at room temperature 
for 1 hour.  
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Chapter 6: Toward the Development of 
Novel UAAs Containing Silyl and 
Aldehyde Functional Groups 
I. Introduction 
 Proteins are capable of a vast array of functions using the 20 natural 
amino acids; however, they possess a relatively small range of functional groups, 
limiting the number of possible chemical reactions that can occur using the 
canonical amino acids.1 The genetic incorporation of amino acids containing 
novel functional groups not found in the 20 canonical amino acids opens the door 
for a wider variety of applications. The ability to encode novel functional groups 
into the genetic code has allowed for modifications to be made to the structure 
and function of proteins, which is applicable to several fields of study.1-4 The 
addition of new amino acids to the genetic code has led to the development of 
proteins with novel biological and pharmacological properties.1 Furthermore, the 
ability to incorporate UAAs has enabled researchers to improve their 
understanding of processes within living systems in a nonintrusive manner.1,2  
The incorporation of UAAs into proteins has allowed for a remarkable 
number of applications.3 UAAs containing electron-withdrawing and electron-
donating groups can alter the acid-base properties and redox potential of natural 
amino acids, such as tyrosine, which can be useful in electron paramagnetic 
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resonance (EPR) studies of radical chemistry.5,6 In addition, crosslinking UAAs 
can be used to map protein interactions.7,8 Fluorescent UAAs can be used for 
both the in vitro and in vivo labeling of proteins in a site-specific manner that 
does not interfere with protein function.9 In addition, UAAs have been used as 
both infrared and NMR probes.10,11 UAAs capable of interacting with certain 
analytes have also been shown to play an important role as sensors by changing 
properties of proteins, such as fluorescence, upon interaction with a specific 
analyte.12 As previously described, chemically reactive UAAs can undergo 
bioorthogonal chemical reactions to chemically link proteins to a synthetic moiety 
in a site-specific manner.13,14 UAAs have also been used to encode post-
translationally modified UAAs, allowing researchers to understand and 
characterize these PTMs.15 UAAs have been used for the development of 
therapeutics owing to the ability to precisely control protein structure and 
function. These techniques have been applied to cytokines, growth factors, and 
antibodies to create bioconjugates, such as PEGylated proteins and antibody-
drug conjugates, in which researchers are able to control the stoichiometry and 
site of the reaction.4,16,17 UAAs can also be utilized to design proteins containing 
enhanced or novel functions, which has been demonstrated through the use of 
bipyridyl containing UAAs to design metal binding sites on proteins.18 The ability 
to incorporate UAAs containing novel functional groups has greatly aided our 
ability to understand and enhance protein structure and function in addition to 
allowing for significant advances in therapeutics and diagnostics. The continued 
development of new applications using UAAs underscores the need for 
161 
 
 
continued exploration and development of UAAs containing novel functional 
groups and their subsequent incorporation into proteins.  
 Trimethylsilyl (TMS) groups consist of three methyl groups bound to a 
central silicon atom (Figure 6.1). These groups are relatively inert and have a 
large molecular volume.19,20 TMS groups 
have several applications making them 
useful to chemists. They have been 
applied within organic synthesis, serving 
as protecting groups during chemical 
reactions when attached to reactant 
molecules.19 They can later be removed using fluorinated compounds or HCl.19 
In addition, TMS groups can be added to phenols, carboxylic acids, and alcohols 
allowing them to be more easily analyzed via mass spectrometry or gas 
chromatography.20 Due to their large size TMS-containing UAAs may also serve 
an important role in examining structure-function relationships in proteins. For 
example, a key residue in the active site of a protein can be replaced with a 
TMS-containing UAA to determine the impact of the residue on catalytic function. 
In a similar manner, a TMS-containing UAA could be used to replace key 
residues involved in protein folding to determine the role of specific residues in 
protein folding patterns. TMS installation may block protein activity initially, but 
function can be restored at a specific timepoint through removal of the TMS 
group, which can occur relatively easily. To our knowledge, no TMS-containing 
UAAs have been successfully synthesized and incorporated into proteins.  
Figure 6.1: The general structure of a 
TMS group. 
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Figure 6.2: Protein activation by UV light-induced 
removal of a photocaging group.24 
 A different approach to temporal control of protein function can be 
achieved with a different UAA. Proteins can be manipulated exogenously using 
stimuli such as light. Given the ability to control the wavelength and intensity of 
light and its ability to be used in both a temporal and spatial manner, precise 
control over protein function is possible when using light as a stimulus.21 Protein 
function can be regulated with light through the use of photochemical caging 
groups.21 These caging groups inactivate the protein; however, their removal via 
light irradiation can restore the function of the protein (Figure 6.2).21 O-
nitrobenzyl groups are the 
most commonly utilized 
photocaging groups.21,22 
They can be added to 
hydroxy, carboxy, thio, and 
amino groups.21-23 Irradiation 
using UV light causes 
cleavage of these groups. Previous research has demonstrated the ability to 
control protein activity in vivo using caged UAAs.21 In one example, a caged 
tyrosine UAA, ONBY, was successfully incorporated into β-galactosidase. It was 
shown that the replacement of a key tyrosine residue with ONBY reduced protein 
activity to 5% of wild type levels; however, upon irradiation with 365-nm light, 
protein activity was restored to nearly 67% of wild type levels.22 Several 
applications have developed from this research including studies involving 
phosphorylation, gene regulation, and perturbation of ion channels.21 More 
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recently, a UAA containing an alkyne modified dimethoxy-ortho-nitrobenzyl 
caging group has been incorporated into E. coli.21 In addition to being 
photocleavable, the UAA is able to undergo conjugation reactions to form a 
bioconjugate, which can then be released upon irradiation.21 This can be applied 
to the delivery of cytotoxic drugs using antibody targeting agents.21 In this case, a 
bioconjugate can be formed between the delivery agent and the small molecule. 
Once the bioconjugate has been delivered to the cell, it can be photocleaved and 
the drug can be released.21   
Herein, the initial steps toward the synthesis of novel UAAs containing 
TMS and caged aldehyde functional groups are described. First, several different 
synthetic routes were explored to obtain TMS-containing UAAs. Upon 
determination of the optimum synthetic route, we then made attempts to 
incorporate this UAA into GFP utilizing aminoacyl-tRNA synthetases (aaRSs) 
currently available in our laboratory. Several aaRSs with known promiscuity 
which are able to 
encode multiple 
UAAs were tested 
first to eliminate 
the need to evolve 
a new aaRS.25 
This represents 
the first such 
attempt to incorporate TMS-containing UAAs into proteins. In addition, the initial 
Figure 6.3: Incorporation of the caged aldehyde UAA into GFP. Upon 
incorporation, the caging group can be removed with UV light to 
activate the protein.26 
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steps toward the development of a caged aldehyde UAA are described. Attempts 
to incorporate the non-caged aldehyde UAA into GFP led to the discovery of two 
synthetases which may have potential to be used for the incorporation of the 
caged aldehyde UAA (Figure 6.3). Upon successful synthesis and incorporation 
of these novel UAAs, their applications will then be explored.  
II. Results and Discussion 
A. Synthesis of the Silyl UAA 
 Several different starting materials and synthetic routes were explored for 
the development of a novel UAA containing a TMS group. The first attempt 
involved the use of trimethyl-p-tolylsilane (1) as the starting material. This starting 
material already contains the desired silyl group; therefore, the synthetic route 
used to obtain the desired product was aimed at synthesizing the amino acid 
back bone followed by deprotection (Scheme 6.1). The first step involves allylic 
bromination using NBS to obtain 2. The reaction involved heating at 110 °C for 
approximately 1.5 hours. 2 was obtained in high purity, but a low yield of 
approximately 30%. The next step involved the alkylation of diethyl 
acetamidomalonate in the presence of a base to give 3, which was obtained in 
relatively high purity, but a low yield of approximately 25%. Diethyl 
acetamidomalonate is commonly used for synthesis of the general amino acid 
backbone as it can be deprotected in the presence of acid or base. Initial 
attempts to give 5 involved hydrolysis and decarboxylation of 3 using HCl to yield 
the amino acid backbone; however, the addition of HCl also led to the removal of 
the desired TMS group from the product. As a result, it was necessary to utilize 
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NaOH for the deprotection of 3. Using this method, a mixture of 4 and 5 was 
formed, primarily consisting of 4, which contains an acetamide group as opposed 
to the desired amine found in amino acids. Because 4 and 5 were similar in 
structure, differing only by the presence of an acyl group in 4, they were unable 
to be effectively separated by column chromatography. As a result of this 
difficulty, an acylase enzyme was utilized to remove the acyl group from 4 to 
produce 5. The reaction was performed in potassium phosphate buffer at a pH of 
8.0 by shaking the reaction at 215 rpm at 37 °C overnight. Based off the obtained 
NMR spectra following this reaction, the acylase enzyme did not effectively 
remove the acyl group as a mixture of 4 and 5 was still present. Because of the 
inability to obtain 5, we sought to obtain a TMS-containing UAA through a different 
methodology. 
Scheme 6.1: The synthetic route used to obtain 5. 
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 The starting material for the next reaction was Boc-4-iodo-L-phenylalanine 
(6), which is a derivative of the amino acid phenylalanine. Unlike the previous 
synthesis, this starting material does not have the TMS group attached; 
therefore, this synthesis involved the addition of the TMS protecting group, 
followed by removal of the Boc and methyl protecting groups to form the amino 
acid backbone (Scheme 6.2). Prior to addition of the TMS group, the carboxylic 
acid of the starting material must first be protected. Methylation was carried out 
using iodomethane in the presence sodium bicarbonate at 60 °C. The successful 
addition of the methyl group was confirmed using NMR and 7 was obtained in a 
moderate yield of 27.8%. The next step involved addition of the silyl group, which 
was accomplished through the reaction of TMS acetylene with 7. The 
Sonogashira reaction was catalyzed by CuI and Bis(triphenylphosphine) 
palladium(II) dichloride and was carried out at room temperature. The product, 8, 
was obtained in a moderate yield of 59% and the presence of the desired TMS 
protecting group was confirmed using NMR. To obtain the deprotected product 
(10), methyl deprotection was carried out using LiOH to obtain 9 followed 
immediately by Boc deprotection using TFA. The NMR spectra revealed that the 
silyl group was removed from the product resulting from the sensitivity of TMS 
groups to acids, which were involved in the Boc deprotection step. Due to the 
lack of a feasible method to remove the Boc group without the use of acid, an 
alternative method for synthesis of the TMS-containing UAA was warranted using 
a starting material containing different protecting groups.  
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Scheme 6.2: The first synthetic route used to obtain 10. 
 It was hypothesized that the utilization of different protecting groups, which 
do not require the addition of acid to be removed may facilitate the production of 
the TMS-containing UAA. Fmoc-4-iodo-L-phenylalanine (11) was chosen as the 
starting material for this reaction as the Fmoc group can be removed using a 
base. Like the previous reaction, this starting material is a derivative of 
phenylalanine. Because this starting material does not contain the desired silyl 
group, the synthetic route for this reaction necessitates the addition of the silyl 
group followed by deprotection of the Fmoc and methyl protecting groups to 
obtain the amino acid. The first step of the reaction involves protection of the 
carboxylic acid through methylation. The first attempt at methylation involving 
sodium bicarbonate and iodomethane was unsuccessful as this reaction utilizes 
a base, which caused removal of the Fmoc protecting group. As a result, 
methylation involving thionyl chloride and methanol was utilized. Thionyl chloride 
converts carboxylic acids into an acid chloride. The acid chloride then reacts with 
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methanol to form the desired methyl ester protecting group. This reaction yielded 
a white solid after 24 hours, and 12 was obtained in 99% yield. The next step 
involved the addition of the TMS group using the addition of TMS acetylene to 
12. The Sonogashira reaction was catalyzed by CuI and Bis(triphenylphosphine) 
palladium(II) dichloride and carried out at room temperature for 24 hours. After 
purification via column chromatography, 13 was obtained with a 93% yield. 
Methyl and Fmoc deprotection of 13 can be carried out using 1 M LiOH and 
dioxanes to yield 10.  
Scheme 6.3: The second synthetic route used to obtain 10. 
B. Synthesis of the Caged Aldehyde UAA 
Synthesis of the caged aldehyde UAA was initiated using a similar 
strategy initially attempted with the silyl UAA. The reaction scheme first 
generated the aldehyde functionality followed by the coupling with the amino acid 
backbone. This was then followed by addition of a photocleavable caging group 
to the aldehyde and subsequent deprotection (Scheme 6.4). The starting material 
for this reaction was 4-cyanobenzylbromide (14). The first step of the reaction 
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involved reduction of 4-cyanobenzylbromide using DIBAL to obtain 15, which 
was obtained in a moderate yield of 64% and high purity. The next step of this 
reaction used 15 to alkylate diethyl acetamidomalonate in the presence of a base 
to afford 16, which was obtained in relatively high purity, and very high yield of 
approximately 85%. A portion of 16 was deprotected using 6M HCl to give 17 
with an 80% yield. The remaining portion of 17 was then utilized for the caging 
step. This step involved the addition of 1-(2-nitrophenyl)-1,2-ethanediol catalyzed 
by pyridium-p-toluene sulfonate to give 18 with a yield of 37%. The low yield 
most likely resulted from the fact that the reaction had not gone to completion. 
This product was then deprotected using HCl; however, upon addition of HCl the 
caging group was removed as was evident by the reappearance of the aldehyde 
peak at 10 ppm on the NMR spectra indicating that 19 was not obtained. 
Scheme 6.4: The synthetic route used to obtain 19. 
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 A Portion of 17 was diluted to 100 mM using deionized water. Various 
aaRSs were assayed to determine if they could be used to successfully 
incorporate 17 and eventually 19 into protein. pEVOL-pCNF, pEVOL-pAcF, 
pEVOL-pCN 32, and pEVOL-pCN 32-65 aaRS plasmids were co-transformed 
with a pET-GFP-TAG plasmid to determine their ability to incorporate 17 into 
protein. Each of these plasmids encodes an orthogonal aaRS/tRNA pair which is 
used to incorporate UAAs into proteins. These aaRSs contain mutations in 
different locations, causing changes in their structure, which gives them different 
recognition abilities toward different UAAs. Because this is a new UAA, relatively 
promiscuous aaRSs were selected for these trials due to their ability to 
incorporate multiple UAAs with varying structures. In order to test the 
effectiveness of each synthetase for incorporation of 17, expressions were 
carried out in which protein expression was induced using 100 µL and 200 µL of 
a 100 mM solution of 17. An additional expression was carried out in which 17 
was not added. In theory, truncated protein should result due to the lack of UAA 
Figure 6.4: SDS-PAGE analysis of GFP 151 expression using pCN 32 and pCN 32-65 aaRSs 
in the absence and presence of 100 µL and 200 µL of 17 (left) and fluorescence images of 
GFP 151 in the absence and presence of 100 µL and 200 µL of 17 using pCN 32-65 (right).   
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present, meaning that the aaRS cannot recognize and incorporate an amino acid 
in response to the TAG mutation. Due to the promiscuity of some of the 
synthetases being tested, tyrosine may be incorporated resulting in low levels of 
protein expression. Proteins were analyzed via SDS-PAGE for differences in the 
protein expression levels in the presence and absence of 17. Additionally, 
proteins were examined for differences in fluorescence intensity. The pCN 32 
and pCN 32-65 synthetases showed the greatest differences in band intensity 
between expressions in the presence absence of 17 in SDS-PAGE gels. In 
addition, these samples had a significant difference in fluorescence intensity 
(Figure 6.4). It did not appear that addition of higher concentrations of 17 
improved the ability of the synthetase to incorporate 17; therefore, the traditional 
100 mM addition of UAA is sufficient.  
Both the pCNF-aaRS and pAcF-aaRS 
showed nearly identical expression 
levels in the presence and absence of 17 
as well as identical fluorescence 
intensities indicating that the UAA was 
not successfully incorporated (Figure 
6.5). The protein expression obtained 
using these synthetases most likely resulted from the incorporation of tyrosine as 
opposed to 17 at the location of the TAG mutation.  
In summary, three different synthetic routes have been employed toward 
the development of a silyl-containing UAA. In the first two cases, the use of acid 
Figure 6.5: SDS-PAGE analysis of GFP 
151 expressed in the absence and 
presence of 100 µl and 200 µl of 17 using 
the pEVOL pCNF aaRS.  
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during deprotection to yield the amino acid backbone led to removal of the TMS 
group. The third route appears to be the most promising option as it relies only 
on base for the removal of protecting groups. Future work will involve 
optimization of the deprotection of the methyl and Fmoc groups to obtain 10 and 
the subsequent incorporation of 10 into protein. An aldehyde-containing UAA 
was successfully synthesized and initial steps toward the incorporation of this 
UAA have pointed toward the use of the pCN 32 aaRS and the pCN 32-65 aaRS 
for the incorporation of 19 into protein. Attempts to add the caging group to 17 
resulted in successful caging; however, upon deprotection using HCl, the caging 
group was removed. In addition, the caged product was obtained in low yields. 
Further work is required to optimize a decaging mechanism that is less harsh and 
allows the caging group to remain attached.  
III. Materials and Methods 
General: Solvents and reagents were obtained from Sigma Aldrich, Alfa Aesar, 
or Fischer Scientific and used without further purification. Reactions were 
performed under ambient conditions with non-distilled solvents. NMR data was 
acquired using a Varian Gemini 400 MHz NMR. 
(4-(bromomethyl)phenyl)trimethylsilane (2): Trimethyl-p-tolylsilane (1) (500 
mg, 1 eq., 3.00 mmol) was added to a flame-dried vial along with n-
bromosuccinimide (534 mg, 1 eq., 3.00 mmol), azobisisobutyronitrile (50 mg, 0.1 
eq., 0.30 mmol), and chlorobenzene (10 mL).  The reaction was stirred in a 110 
°C oil bath for approximately 1.5 hours until a light orange color appeared. The 
reaction was monitored by TLC. Upon completion, the reaction was quenched by 
173 
 
 
placing the vial in an ice bath and adding 10 mL of ice water. The reaction was 
washed 3 times using hexanes (30 mL). The organic layer was then washed 3 
times using brine (20 mL). The organic layer was dried using anhydrous 
magnesium sulfate, filtered, and solvent was evaporated under reduced pressure 
to yield a solid (224 mg, 0.92 mmol, 30.3% yield). 1H NMR (CDCl3, 400 MHz): δ 
7.60 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 4.55 (s, 2H), 0.36 (s, 9H).  
 
Figure 6.6: 1H NMR of 2 in CDCl3. 
 
Diethyl 2-acetamido-2-(4-(trimethylsilyl)benzyl)malonate (3): A portion of 2 
was added to a flame dried vial (100 mg, 1 eq., 0.41 mmol) along with potassium 
carbonate (113 mg, 2 eq., 0.82 mmol), potassium iodide (68 mg, 1 eq., 0.41 
mmol), and diethyl acetamidomalonate (80 mg, 0.9 eq., 0.37 mmol). The mixture 
was dissolved acetonitrile (8.5 mL) and stirred at 80 °C overnight. The reaction 
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was monitored by TLC. The reaction was quenched by the addition of brine (5 
mL). The reaction was extracted 3 times with ethyl acetate (15 mL) then the 
organic layer was washed 3 times using brine (15 mL). The organic layer was 
then dried using anhydrous magnesium sulfate, filtered, and solvent was 
evaporated under reduced pressure to yield a solid. The product was then 
purified using column chromatography (silica gel, 4:1 Hexanes/ethyl acetate) to 
obtain a light brown solid (38.3 mg, 0.10 mmol, 24.6% yield). 1H NMR (CDCl3, 
400 MHz): δ 7.40-7.36 (m, 2H), 6.97 (d, J = 7.6 Hz, 2H), 4.28-4.21 (m, 4H), 3.62 
(s, 2H), 2.03 (s, 3H), 1.33-1.23 (m, 6H), 0.25-0.23 (m, 9H). 
 
Figure 6.7: 1H NMR of 3 in CDCl3. 
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2-acetamido-3-(4-trimethylsilyl)phenyl)propanoic acid (4): A small portion of 
3 (10 mg, 1 eq., 0.033 mmol) was added to a flame-dried vial and dissolved in 
acetone (2 mL) then mixed with 2M NaOH (2 mL). The reaction was stirred at 40 
°C overnight. Acetone and NaOH were evaporated under reduced pressure to 
yield a solid (7 mg). An impure mixture of 4 and 5 was obtained. NMR data is not 
reported for this compound as pure product was not successfully obtained. 
 
Figure 6.8: 1H NMR of the mixture of 4 and 5 in d-MeOH. 
 
2-amino-3-(4-(trimethylsilyl)phenyl)propanoic acid (5): A portion of a mixture 
of 4 and 5 (15 mg) was added to a flame-dried vial containing 100 mM (5 mL) 
potassium phosphate buffer (pH 8.0). A catalytic amount of acylase enzyme was 
added and the reaction was shaken at 215 rpm at 37 °C overnight. Potassium 
phosphate buffer was evaporated under reduced pressure to yield a brown solid. 
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The product was then dissolved in methanol (5 mL) and filtered to remove traces 
of acylase enzyme. Methanol was evaporated under reduced pressure to yield a 
light brown solid (14 mg). An impure mixture of 4 and 5 remained. NMR data is 
not reported for this compound as pure product was not successfully obtained. 
 
Figure 6.9: 1H NMR of the mixture of 4 and 5 in d-MeOH. 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate (7): Boc-
4-iodo-L-phenylalanine (6) (500 mg, 1 eq., 1.28 mmol) was added to a flame-
dried round-bottom flask and dissolved in DMF (20 mL). Sodium bicarbonate 
(323 mg, 3 eq., 3.85 mmol) and iodomethane (97 µL, 1.2 eq., 1.56 mmol) were 
added. The reaction was stirred at 60 °C in an oil bath overnight. The reaction 
was quenched using 10 mL brine. The product was extracted 3 times using ethyl 
acetate (60 mL). The organic layer was washed 3 times using brine (40 mL), 
dried using anhydrous magnesium sulfate, filtered, and solvent was evaporated 
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under reduced pressure to yield an oil (144 mg, 0.36 mmol, 27.8% yield). 1H 
NMR (CDCl3, 400 MHz): δ 7.57 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.0 Hz, 2H), 4.67 
(q, J = 8.0 Hz, 1H), 3.67 (s, 3H), 2.92 (s, 2H), 1.37 (s, 9H).   
 
Figure 6.10: 1H NMR of 7 in CDCl3. 
 
methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((trimethylsilyl)ethynyl)phenyl) 
propanoate (8): A round-bottom flask and vial were flame-dried and flushed with 
argon for 10 minutes. A portion of 7 (144 mg, 0.36 mmol, 1 eq.) was added to the 
vial and dissolved in TEA (20 mL). The solution was flushed with argon for 10 
minutes. A catalytic amount of CuI (20 mg) and Bis(triphenylphosphine) 
palladium(II) dichloride (30 mg) were added to the round-bottom flask under 
argon. The solution of 7 dissolved in TEA was transferred to the round-bottom 
flask under argon. Trimethylsilylacetylene (100 µL, 2 eq., 0.71 mmol) was added 
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dropwise to the reaction. The reaction was stirred at room temperature overnight. 
The reaction was quenched with 10 mL brine and extracted 3 times in ether (30 
mL). The organic layer was washed 3 times with brine (20 mL), dried using 
anhydrous magnesium sulfate, filtered, and solvent was evaporated under 
reduced pressure to yield a solid (138 mg, 0.37 mmol, 58.7% yield). 1H NMR 
(CDCl3, 400 MHz): δ 7.38 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.60 (q, J 
= 7.6 Hz, 1H), 3.69 (s, 3H), 3.10 (d, J = 8.0 Hz, 2H), 1.42 (s, 9H), 0.20 (s, 9H). 
 
Figure 6.11: 1H NMR of 8 in CDCl3. 
 
methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-iodophenyl) 
propanoate (12): Fmoc-4-iodo-L-phenylalanine (11) (500 mg, 1 eq., 0.97 mmol) 
was added to a flame-dried vial and dissolved in 5 mL methanol. Thionyl chloride 
(141.5 µL, 2 eq., 1.95 mmol) was added dropwise. The reaction was stirred at 
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room temperature overnight forming a white solid. The solid was dissolved in 
ethyl acetate (15 mL). This solution was washed 2 times with brine (20 mL) and 
once with saturated sodium bicarbonate (10 mL). The organic layer was dried 
using anhydrous sodium sulfate, filtered, and solvent was evaporated under 
reduced pressure to give a white solid (510 mg, 0.97 mmol, 99.4% yield). 1H 
NMR (CDCl3, 400 MHz): δ 7.79 (d, J = 7.6 Hz, 2H), 7.62-7.58 (d, J = 8.0 Hz, 4H), 
7.43 (t, J = 6.8 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 6.84 (d, J = 7.2 Hz, 2H), 4.74-
4.65 (m, 3H), 4.47 (d, J = 7.2 Hz, 1H), 3.73 (s, 3H), 3.09 (d, J = 4.8, 2H) 
 
Figure 6.12: 1H NMR of 12 in CDCl3. 
 
methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((trimethylsilyl) 
ethynyl)phenyl)propanoate (13): A round-bottom flask and vial were flame-
dried and flushed with argon for 10 minutes. A portion of 12 (144 mg, 0.36 mmol, 
1 eq.) was added to the vial and dissolved in TEA (20 mL) and DCM (20 mL). 
The solution was flushed with argon for 10 minutes. A catalytic amount of CuI (20 
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mg) and Bis(triphenylphosphine) palladium(II) dichloride (30 mg) were added to 
the round-bottom flask under argon. The solution of 12 dissolved in TEA/DCM 
was transferred to the round-bottom flask under argon. Trimethylsilylacetylene 
(100 µL, 2 eq., 0.71 mmol) was added dropwise to the reaction. The reaction was 
stirred at room temperature overnight. The reaction was quenched with brine (10 
mL) and extracted 3 times in ether (30 mL). The organic layer was washed 3 
times with brine (20 mL), dried using anhydrous magnesium sulfate, filtered, and 
solvent was evaporated under reduced pressure to yield a solid. The product was 
further purified using column chromatography (silica gel, 4:1 Hexanes/ethyl 
acetate) to give a brown oil (0.448 mg, 0.981 mmol, 93.1 % yield). NMR data is 
not reported as pure product was not successfully obtained.  
 
Figure 6.13: 1H NMR of 13 in CDCl3.  
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2-amino-3-(4-((trimethylsilyl)ethynyl)phenyl)propanoic acid (14): A portion of 
13 (271 mg, 1 eq., 0.51 mmol) was mixed with LiOH (2 mL) and dioxanes (2 mL). 
The reaction was stirred at 40 °C for 2 hours. Solvent was evaporated under 
reduced pressure to yield a white solid (200 mg, 0.40 mmol, 78.0% yield). NMR 
data and spectra are not reported as pure product was not successfully obtained.  
4-(bromomethyl)benzaldehyde (15): 4-cyanobenzylbromide (14) (1.021 g, 1 
eq., 5.08 mmol) was added to a flame-dried round-bottom flask. The flask was 
then flushed with argon for 25 minutes. A second round-bottom flask was flame-
dried and toluene (25 mL) was added. The toluene was flushed with argon for 25 
minutes. The toluene was then transferred to the first round-bottom flask under 
argon. The reaction was flushed for an additional 5 minutes. Diisobutylaluminum 
(7.2 mL, 0.008 eq., 0.040 mmol) was added dropwise. The reaction was stirred at 
room temperature under argon for 2 hours followed by the addition of 10% HCl 
(40 mL) and chloroform (13.2 mL). The reaction was stirred for an additional hour 
at room temperature under argon. The reaction was extracted 3 times using brine 
(75 mL), dried using anhydrous magnesium sulfate, filtered, and solvent was 
evaporated under reduced pressure to yield a solid (650 mg, 3.27 mmol, 64.3% 
yield). 1H NMR (CDCl3, 400 MHz): δ 10.01 (s, 1H), 7.87 (d, J = 6.4 Hz, 2H), 7.56 
(d, J = 8.4 Hz, 2H), 4.51 (s, 2H). 
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Figure 6.14: 1H NMR of 15 in CDCl3. 
 
Diethyl 2-acetamido-2-(4-formylbenzyl)malonate (16): A portion of 15 (650 
mg, 1 eq., 3.27 mmol) was added to a flame-dried round-bottom flask and 
dissolved in acetonitrile (25 mL). Potassium carbonate (904 mg, 2 eq., 6.54 
mmol), potassium iodide (543 mg, 1 eq., 3.27 mmol), and diethyl 
acetamidomalonate (639 mg, 0.9 eq., 2.94 mmol) were added to the reaction. 
The reaction was stirred at 80 °C overnight. The reaction was quenched with 
deionized water (20 mL) then the product was extracted three times using ethyl 
acetate (75 mL). The organic layer was washed 3 times using brine (60 mL), 
dried using anhydrous magnesium sulfate, filtered, and solvent was evaporated 
under reduced pressure. The product was then purified using column 
chromatography (silica gel, 1:1 Hexanes/ethyl acetate) and solvent was 
evaporated under reduced pressure to yield a white solid (937 mg, 2.79 mmol, 
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85.6% yield). 1H NMR (CDCl3, 400 MHz): δ 9.98 (s, 1H), 7.78 (d, J = 8.4 Hz, 2H), 
7.22 (d, J = 8.4 Hz, 2H), 4.29-4.25 (m, 4H), 3.74 (s, 2H), 2.04 (s, 3H), 1.30-1.25 
(m, 6H). 
 
Figure 6.15: 1H NMR of 16 in CDCl3. 
 
2-amino-3-(4-formylphenyl)propanoic acid (17): A portion of 16 was added to 
a flame-dried round-bottom flask and mixed with 6M HCl (15 mL). The reaction 
was stirred at 90 °C overnight. HCl was evaporated under reduced pressure to 
yield a brown solid (0.431 mg, 2.23 mmol, 79.8% yield). The resulting solid was 
diluted to a concentration of 100 mM using deionized water. 1H NMR (d-MeOH, 
400 MHz): δ 9.99 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.0, 2H), 4.82 (s, 
1H), 3.41-3.29 (m, 2H).   
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Figure 6.16: 1H NMR of 17 in d-MeOH. 
 
2-amino-3-(4-(4-(2-nitrophenyl)-1,3-dioxolan-2-yl)benzyl)malonate (18): Two 
vials were flame-dried and flushed with argon for 10 minutes. 1-(2-nitrophenyl)-
1,2-ethanediol (19 mg, 1 eq., 0.085 mmol), pyridium- p-toluene sulfonate (0.021 
mg, 1 eq., 0.085 mmol), and anhydrous magnesium sulfate (20 mg) were added 
to one of the vials. A portion of 17 (50 mg, 2 eq., 0.17 mmol) was dissolved in 
anhydrous THF (2 mL) then transferred to the first vial under argon. The reaction 
was protected from light and stirred at 40 °C in an oil bath for 24 hours. THF was 
evaporated under reduced pressure. The product was then purified using column 
chromatography (silica gel, 1:1 Hexanes/ethyl acetate) and solvent was 
evaporated under reduced pressure to yield a solid (12 mg, 0.024 mmol, 37.2 % 
yield). 1H NMR (CDCl3, 400 MHz): δ 8.13 (d, J = 8.0 Hz, 1H), 7.89 (t, J = 8.0, 1H), 
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7.68-7.64 (m, J = 6.0, 2H), 7.49 (d, J = 6.8 Hz, 2H), 7.10 (d, J = 6.8 Hz, 2H), 6.54 
(s, 1H), 4.32-4.25 (m, 5H), 4.04-4.00 (m, 2H), 3.71 (s, 2H), 2.04 (s, 3H), 1.33-
1.29 (m, 6H).     
 
Figure 6.17: 1H NMR of 18 in CDCl3. 
 
Expression and Purification of GFP containing 17: A pET-GFP-TAG plasmid 
(0.50 µL) was co-transformed with a pCN 32-65 plasmid (0.50 µL) into 
Escherichia Coli BL21 (DE3) competent cells by heat shock using an Eppendorf 
eporator electroporator. The cells were then plated (250 µL) on LB agar 
containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and incubated 
at 37 °C overnight. One colony was then used to inoculate LB media (4 mL) 
containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This culture 
was then incubated and allowed to shake at 37 °C overnight. The following day, 
this culture was used to inoculate an expression culture containing LB media (10 
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mL), ampicillin (50 µg/mL), and chloramphenicol (34 µg/mL) at a starting OD600 of 
0.1. The cultures were incubated and allowed to shake at 37 °C until an OD600 of 
0.7 was reached. Protein expression was then induced by the addition of 20% 
arabinose (10 µL), and isopropyl β-D-1-thiogalactopyranoside (IPTG, 10 µL, 0.8 
mM), and 17 (100 µL, 100 mM). A negative control expression was set up by 
inducing the expression in the absence of 17 and with the addition 20% 
arabinose and IPTG as previously described. The cultures were then incubated 
and allowed to shake at 30 °C for 16 hours. The cells were then pelleted by 
centrifugation (5,000 rpm, 10 minutes) and stored at -80 °C until purification.  
 Purified GFP was obtained by resuspending the cell pellet in 500 µL of 
Bug Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture 
was incubated with shaking at 37 °C for 20 minutes. The mixture was then 
transferred to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to 
pellet out cellular debris. The supernatant was decanted into an equilibrated 
HisPur Ni-NTA spin (Qiagen) column containing Nickel resin (200 µL) and GFP 
was purified according to the manufacturer’s protocol. Purified GFP was 
analyzed by SDS-PAGE (BioRad 10% precast gels, 120V, 2 hours). Gels were 
stained with Coomassie Brilliant Blue solution, and destained using a destain 
solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic 
acid. Gels were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel 
imager (Coomassie protocol) after 24 hours. Protein was then concentrated and 
buffer exchanged into PBS buffer at a pH of 7.4 using Corning Spin-X UF 
purification columns. Protein was used without further purification. 
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Chapter 7: Application of the Solid-
Supported Glaser-Hay reaction to 
Natural Product Synthesis 
I. Introduction 
Polyyne core structures are prevalent in various natural products and 
consist of a series of conjugated acetylenic units.1−3 Over 1,000 of these 
naturally occurring molecules have been isolated from organisms such as 
plants, fungi, and coral.2 These structures exhibit numerous biological activities 
including antibacterial, antifungal, anti-HIV, and anticancer properties.3−7 
Therefore, synthetic routes to the preparation of these structures are necessary 
to further study their benefits and develop novel therapeutic analogs. 
 One approach to access these conjugated alkyne cores involves the 
Glaser−Hay reaction. This reaction involves the coupling of two terminal alkynes 
and was developed in the 
1800s.8 The reaction was later 
optimized to lower the 
temperature and increase the 
rate of the reaction; however, 
the lack of chemoselectivity 
precluded its use, as a 
Figure 7.1: Glaser−Hay coupling of terminal alkynes. (A) 
Traditional Glaser−Hay reactions result in three diynes. 
(B) Solid-supported Glaser−Hay reaction yields only the 
heterodimeric product after resin cleavage. 
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mixture of three coupling products could be obtained when using two unique 
terminal alkyne reagents (Figure 7.1).9,10 This has been synthetically addressed 
via the transition to the Cadiot−Chodkiewicz reaction between a halo-alkyne and 
a terminal alkyne to differentiate the reaction partners.11,12 While this approach 
does proffer a degree of chemoselectivity, homocoupling is still observed and 
additional synthetic effort must be employed to prepare the halo-alkynes.13−15 
Based on the asymmetrical nature of many of these natural product derivatives, 
a more efficient mechanism to address chemoselectivity issues is required. 
Recently, we reported the solid-supported Glaser−Hay reaction as a mechanism 
to address several key pitfalls associated with the Glaser−Hay reaction.16−18 
The solid-supported Glaser−Hay coupling requires the immobilization of 
one terminal alkyne on a polystyrene resin. Subsequent reaction with another 
soluble alkyne affords the asymmetrical diyne in high yield and purity. 
Homodimerization of the immobilized alkyne is precluded by the pseudo-high 
dilution conditions of the solid support, and homodimerization of the soluble 
alkyne (used in excess) can simply be washed away from the solid support. 
Moreover, we developed a methodology to perform these solid-supported 
couplings with TMS-acetylene to sequentially add alkyne units, yielding highly 
conjugated asymmetrical polyynes.16 Based on the success of this methodology, 
we became interested in employing the solid-supported Glaser−Hay reaction 
toward the synthesis of biologically relevant natural products. Herein, we report 
the application of the reaction to the preparation of four natural products and their 
subsequent screening for antibacterial activity. 
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II. Results and Discussion 
Many corals have been found to be rich in natural products that contain 
antibacterial, antifungal, and cytotoxic properties. Specifically, numerous 
acetylenic polyynes have been isolated from the genus Montipora, a velvet 
coral.19 The most directly accessible natural product that lends itself to this 
technology is 2,4-dodecadinyl alcohol (3), an asymmetrical diyne shown to 
exhibit cytotoxicity against human tumor lines.2 Numerous research groups have 
described the synthesis of this natural product.20−24 For example, Stefani et al. 
report this synthesis via a Cadiot-Chodkiewicz coupling with a reported yield of 
76%.24 However, this reported synthesis requires hazardous reagents and 
requires a preliminary synthetic step to synthesize a halogenated alkyne. 
Another synthesis reported by Fiandanese et al. requires numerous and 
sometimes harsh reagents, six synthetic steps, and has a 42% yield.23 Both 
syntheses also required tedious purification steps postreaction. We 
hypothesized that the solid-supported Glaser−Hay reaction would be optimal to 
obtain this product in fewer steps using milder conditions while affording higher 
yields. 
Immobilization of propargyl alcohol on a trityl chloride polystyrene resin (1) 
at ∼0.7 mmol/g, as previously described,17 facilitated the subsequent Glaser−Hay 
reaction with 1-nonyne (2) in the presence of a CuI/TMEDA catalyst system 
(Scheme 7.1). Following successive DCM/MeOH washes of the resin, 3 was 
cleaved from the resin using 2% TFA in DCM in 1 h. After a silica plug, 3 was 
obtained in a 75% yield in high purity after essentially a single synthetic step. 
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Analysis via 1H NMR, 13C NMR, and GC/MS confirmed its identity and was in 
accordance with previously reported literature values.23 Overall, utilizing the solid-
supported Glaser−Hay methodology to synthesize this product eliminated harsh 
reagents, halogenated precursor compounds, and synthetic steps required in 
previously reported syntheses and produced the product in a better or 
comparable yield. 
A derivative of 3, Montiporic Acid A (5) is another common polyyne 
isolated from this velvet coral species.2 Montiporic Acid A has been isolated from 
the eggs of this coral and was shown to possess significant cytotoxicity against 
P-338 murine leukemia cells. It has also been proven to be an efficient 
antibacterial agent against E. coli.23 Conveniently, 5 can be accessed directly 
from 3 via an SN2 reaction with 2-bromoacetate (4) followed by an ester 
hydrolysis (Scheme 7.1) as previously reported. Synthesis of 5 was achieved in 
good yield (49%) and analyzed via 1H NMR, 13C NMR, and GC/MS to confirm its 
Scheme 7.1: The synthetic route used to obtain 5 from trityl chloride polystyrene resin (1) and 
1-nonyne (2). 
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purity and identity. Thus, our methodology allowed us to prepare 5 in three 
synthetic steps and in comparable yield to the previously reported synthesis that 
required six steps. 
This methodology can also readily be employed toward triyne natural 
products. Toward this end, we initially targeted the preparation of octatriyn-1-ol 
(8), originally isolated from a fungus, Kuehneromyces mutabilis, in 1973.25 This 
compound and similar derivatives were shown to possess antibacterial 
activities. Previous syntheses have utilized a Fritsch−Buttenberg−Wiechell 
rearrangement to prepare the triyne core.26 Overall, this synthesis requires eight 
synthetic steps to generate 8. This reported methodology also requires 
numerous reagents, including some that are hazardous, and careful reaction 
temperature control leading to an overall yield of only 3%.26 
Building on our previously reported methodology for extending the 
acetylenic scaffold,16 we developed a synthetic route toward octatriyn-1-ol 
(Scheme 7.2), decreasing the synthetic steps and number of reagents used from 
previous reports as well as increasing yield. Beginning with the previously 
described propargyl alcohol polystyrene resin (1), TMS-acetylene (6) was 
coupled using the Glaser−Hay conditions. The TMS group was then removed 
using a TBAF/DCM solution, regenerating the terminal alkyne. Propyne (7) was 
then coupled to the resin using the Glaser− Hay reaction and the product was 
cleaved with a 2% TFA solution, affording the desired asymmetrical triyne natural 
product, 8. Following a silica plug purification, 8 was obtained in a 68% yield and 
analyzed by NMR and MS, which corresponded to previously reported values. 
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This is a dramatic increase over the current literature synthesis, which was 
performed with only a 3% overall yield and with an additional four steps.26 
 
 
 
Finally, another triyne natural product is readily accessible using a similar 
methodology to the preparation of octariyn-1-ol. Phenylhepta-2,4,6-trinyl acetate 
(10) was originally isolated from several species of Bidens in the Aster family of 
plants and has shown antibacterial properties.2 A previously reported synthesis 
was utilized starting from 1,4-butynediol, and following the addition of a TBDPS 
protecting group, it is reacted with a lithiated phenylacetylene and undergoes a 
Fritch−Butenberg−Wiechell rearrangement to produce the triyne core.26 This 
synthetic strategy requires eight total steps and the use of harsh chemical 
Scheme 7.2: The synthetic route used to obtain 8. 
Scheme 7.3: The Synthetic Route used to obtain 10. 
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conditions, affording 10 in a 14% yield. Utilizing our previously described solid-
supported strategy the triyne core is readily accessible in minimal steps and can 
be further elaborated to generate the acetate (Scheme 7.3). 
The previously described Glaser−Hay coupling with TMS followed by 
TBAF-induced TMS deprotection was employed to prepare the immobilized 
polyyne core, followed by the capping of the polyyne with phenylacetylene (9). 
The solid support was then cleaved to afford the triynol product. The alcohol was 
acetylated with acetic anhydride in the presence of DMAP to afford the desired 
product. Upon acetylation, the reaction was extracted and washed with DCM/H2O 
and dried with MgSO4. The triyne 10 was then purified on a silica column, 
affording the desired natural product in a 46% yield, a marked improvement. The 
product was then analyzed via NMR and MS and matched to previously reported 
spectra. Utilizing the solid supported Glaser−Hay methodology we were able to 
eliminate synthetic steps, as well as harsh and excessive reagents, and 
drastically improve the yield of this natural product. 
With the natural products in hand, we wanted to quickly assess their 
antibacterial properties. Some have already been classified as antibacterial, while 
others exhibited other biological relevance, but all harbor a similar alkynyl core. 
Each of the products was dissolved in DMSO to generate stock solutions at 50 
mg/mL. The compounds were then introduced in triplicate at various 
concentrations to E. coli cultures at different cellular densities to assess if the 
compounds either prevented bacterial growth (assay at low density) or simply 
induced cell death (assay at high density). The cellular density of the bacteria 
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was then observed over a 48-h period. When added to dense cultures (OD600 ≈ 
1), no decrease in cell density was observed with any of the natural products, 
even at 5 mM concentrations (Figure 7.2).  
 
Figure 7.2. E. coli screens with natural products prepared via the solid-supported Glaser−Hay 
methodology. Compounds were added at varying concentrations up to 5 mM to cultures at 
OD600 ≈ 1 (high-density assay) or OD600 ≈ 0.1 (low-density assay) in a 96 well plate. 
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Chloramphenicol, a well-documented antibiotic, was used as a positive 
control, and a significant decrease in bacterial density was observed at much 
lower concentrations of 0.05 mM. However, when the natural products were 
introduced to newly 
inoculated E. coli 
cultures, 5 and 8 
prevented bacterial 
growth at 2 μM 
concentrations, and 
10 at 3 mM 
concentrations. No 
growth inhibition 
was observed for 3 
at even higher 
concentrations (Figure 7.3). This suggests that these natural products do indeed 
possess antibacterial properties and can be easily prepared with the solid-
supported Glaser−Hay methodology. Future work includes the use of more 
sophisticated bacterial assays to determine their mechanism of action and their 
investigation for other biological activity. Moreover, due to the modular synthesis, 
various analogs can be rapidly generated to conduct an extensive SAR study to 
further optimize their antibacterial properties. The application of the solid support 
also facilitates a wide range of combinatorial strategies to be employed toward 
the facile generation of large and varied polyyne libraries. 
Figure 7.3. E. coli screens with natural products prepared via the 
solid-supported Glaser−Hay methodology. Cultures were inoculated 
at an OD600 of 0.1 and grown in the presence of the compounds at 
approximately 2 μM in a 96 well plate. The bacterial growth was 
monitored at 6, 8, and 12 h. A DMSO control exhibited significant 
culture growth, while a positive control of chloramphenicol at 0.05 mM 
exhibited no growth. All cultures were grown in triplicate to establish 
experimental error. 
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Overall, we have demonstrated that the solid-supported Glaser−Hay 
reaction is a useful methodology in the synthesis of natural products. The 
methodology has been employed to access four key natural products in fewer 
synthetic steps, higher yields, and with less purification. These natural products 
have been assessed for their antibacterial properties and found to be comparable 
in efficacy to traditional antibacterials such as chloramphenicol. 
III. Materials and Methods 
General. Solvents and reagents were obtained from commercial sources and 
used without further purification, unless noted. Tritylchloride resin, 100-200 mesh, 
1% DVB crosslinking, was purchased from Advanced Chemtech. Reactions were 
conducted under ambient atmosphere with non-distilled solvents. NMR data was 
acquired on a Varian Gemini 400 MHz NMR. An Agilent J&W GC capillary 
column (30 m length, 0.32 mm diameter, 0.25 nm film) was employed with a 
splitless injection (250 ˚C inlet, 8.8 psi) with an initial 70 ˚C hold (2 minutes) and 
ramped for 15 minutes to 230 ˚C. BL21(DE3) E. coli were obtained from Novagen 
and cell growth was monitored using a microplate reader with a regulated 
temperature.  
Immobilization of Alcohol onto Trityl Chloride Resin in Low Loading 
Conditions: Trityl chloride resin (200 mg, 0.36 mmol, 1 eq.) was added to a 
flame-dried vial charged with dichloromethane (5 mL). The resin was swelled at 
room temperature with gentle stirring for 15 minutes. Alcohol (25.0 μL, ∼1.2 eq.) 
was added to reaction, followed by triethylamine (10.0 μL, 0.072 mmol, 0.2 eq.). 
The mixture was stirred at room temperature for 16 hours. The resin was 
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transferred to a syringe filter and washed with DCM and MeOH (5 alternating 
rinses with 5 mL each). The resin was swelled in CH2Cl2 and dried under vacuum 
for 45 minutes before further use. 
Polyyne Extension Protocol: Trimethylsilylacetylene (160 μL, 1.05 mmol, 15 
eq.) was added to a flame-dried vial containing the alcohol derivatized trityl resin 
(100 mg, 0.070 mmol, 1 eq.) and tetrahydrofuran (2.0 mL). The CuI (20 mg, 1.06 
mmol) and tetramethylethylenediamine (20 μL, 0.132 mmol) were added to a 
separate flame-dried vial and then dissolved in tetrahydrofuran (2.0 mL). The 
catalyst mixture was then added to the resin in one portion and stirred at 60 °C 
for 16 hours. The resin was transferred to a syringe filter and washed with DCM 
and MeOH (5 alternating rinses with 5 mL each). The TMS group was then 
cleaved by incubation in 1 M tetra-n-butylammonium fluoride trihydrate in DCM 
(TBAF, 1 mL, 1 hour). Then the reaction was again transferred to a syringe filter 
and washed with DCM and MeOH (5 alternating rinses with 5 mL each) and dried 
under vacuum for 45 minutes. Product was weighed and transferred to flame-
dried vial for future use. 
Dodeca-2,4-diyn-1-ol (3):23 1-Nonyne (115 μL, 0.70 mmol, 10 eq.) was added to 
a flame-dried vial containing the propargyl alcohol derivatized trityl resin (100 mg, 
0.070 mmol, 1 eq.), and tetrahydrofuran (2 mL). CuI (10 mg, 0.053 mmol, ∼0.7 
eq.) and tetramethylethylenediamine (30 μL) were added to a separate flame-
dried vial and then dissolved in tetrahydrofuran (2 mL). The catalyst mixture was 
then added to the resin in one portion and stirred at 60 °C for 16 hours. The resin 
was transferred to a syringe filter and washed with DCM and MeOH (5 alternating 
203 
 
 
rinses with 5 mL each). The product was then cleaved from the resin by 
treatment with 1 mL of 2% TFA (DCM, 1 h) and filtered into a vial. A short silica 
plug was utilized to remove unreacted starting material (1:1 EtOAc/Hex), and 
pure product was obtained (0.010 g, 0.052 mmol, 75% yield). 1H NMR (CDCl3, 
400 MHz): δ 4.27 (s, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.55 (quint, J = 7.2 Hz, 2H), 
1.39−1.31 (m, 2H), 1.30−1.19 (m, 6H), 0.90 (t, J = 6.9 Hz, 3H). 13C NMR (CDCl3, 
400 MHz): δ = 51.7, 31.8, 29.5, 28.7, 28.1, 22.4, 19.2, 14.0. GC: tR = 10.43 min; 
MS: m/z calculated for C12H18O [M+]: 178.136; found: 178.092. 
 
Figure 7.4: 1H NMR of 3 in CDCl3.  
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Figure 7.5: 13C NMR of 3 in CDCl3. 
 
Figure 7.6: GC trace of 3. 
Montiporic Acid A (5):23 Ethyl bromoacetate (10 μL, 0.10 mmol, 2 eq.) was 
added at 10 °C to a vial containing 3 (0.010 g, 0.052 mmol, 1 eq.) dissolved in 
 
  
HO 
3 
CDCL 3  
205 
 
 
toluene (1 mL), 50% KOH (200 μL), and tetrabutyl ammonium sulfate (10 mg, 
0.030 mmol, ∼0.5 eq.). The reaction was then vigorously stirred at 10 °C for 3 
hours. Upon completion, the reaction was quenched with dilute HCl (5 mL), 
extracted with EtOAc, and washed with water (3 × 5 mL). The product was then 
dried over anhydrous MgSO4, and solvent was removed in vacuo. Purification 
was performed via column chromatography (hexanes/EtOAc 10:1 to 1:3) to yield 
the desired product (8 mg, 0.039 mmol, 49% yield). 1H NMR (CDCl3: δ 4.38 (s, 
2H), 4.21 (s, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.49 (quint, J = 7.2 Hz, 2H), 1.34−1.31 
(m, 2H), 1.29−1.19 (m, 6H), 0.84 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 400 MHz): 
δ 74.5, 71.1, 64.8, 64.6, 58.0, 51.5, 4.8; GC: tR = 11.02 min; MS: m/z calculated 
for C14H20O3 [M+]: 236.141; found: 236.172. 
Figure 7.7: 1H NMR of 5 in CDCl3. 
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Figure 7.8: 13C NMR of 5 in CDCl3. 
 
Figure 7.9: GC trace of 5.  
Octatriyn-1-ol (8):26 The described polyyne extension protocol was used to 
obtain the immobilized terminal alkyne diyne. 1-Propyne (53 μL, 0.70 mmol, 10 
eq.) was added to a flame-dried vial containing the immobilized resin (100 mg, 
0.070 mmol, 1 eq.) and tetrahydrofuran (2 mL). The copper catalyst (10 mg, 
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0.053 mmol, ∼0.7 eq.) and tetramethylethylenediamine (30 μL) were added to a 
separate flame-dried vial then dissolved in tetrahydrofuran (2 mL). The catalyst 
mixture was then added to the resin reaction in one portion and stirred at 60 °C 
for 16 hours. The resin was transferred to a syringe filter and washed with DCM 
and MeOH (5 alternating rinses with 3 mL each). The product was then cleaved 
from the resin by treatment with 1 mL 2% TFA (DCM, 1 hour) and filtered into a 
vial. A short silica plug was performed to remove unreacted starting material (5:1 
EtOAc/Hex), affording product 8 (4 mg, 0.040 mmol, 68% yield). 1H NMR (CDCl3, 
400 MHz) δ 4.70 (s, 1H), 4.34 (s, 2H), 1.96 (s, 3H); 13C NMR (CDCl3, 400 MHz): 
δ 74.2, 71.1, 65.0, 64.8, 58.4, 51.7, 4.5; GC: tR = 10.99 min; MS: m/z calculated 
for C8H6O [M+]: 118.042; found: 118.051. 
Figure 7.10: 1H NMR of 8 in CDCl3. 
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Figure 7.11: 13C NMR of 8 in CDCl3. 
Figure 7.12: GC trace of 8.  
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Phenylhepta-2,4,6-triynyl Acetate (10):26 The described polyyne extension 
protocol was used to obtain the immobilized terminal alkyne diyne. 
Phenylacetlyene (0.70 mmol, 10 eq.) was added to a flame-dried vial containing 
the starting material (100 mg, 0.070 mmol, 1 eq.) and tetrahydrofuran (2 mL). 
The CuI (10 mg, 0.053 mmol) and tetramethylethylenediamine (30 μL) were 
added to a separate flame-dried vial and then dissolved in tetrahydrofuran (2 
mL). The catalyst mixture was then added to the resin reaction in one portion and 
stirred at 60 °C for 16 hours. The resin was transferred to a syringe filter and 
washed with DCM and MeOH (5 alternating rinses with 5 mL each). The product 
was then cleaved from the resin by treatment with 1 mL of 2% TFA (DCM, 1 
hour) and filtered into a vial. Solvent was removed in vacuo to afford the free 
alcohol (10 mg, 0.056 mmol, 80% yield). Acetic anhydride (1 mL) and a catalytic 
amount of DMAP were added and dissolved in 1 mL of DCM. The reaction was 
allowed to stir at room temperature for 3 hours, followed by an extraction using 
DCM/H2O (3 × 5 mL) and drying with MgSO4. The product was then purified on a 
silica gel column using 5:1 Hex/EtOAc yielding 10 (9 mg, 0.041 mmol, 46% 
yield), which was then analyzed via 1H NMR (CDCl3, 400 MHz): δ 7.70−7.61 (m, 
2H), 7.56−7.32 (m, 3H), 4.85 (s, 2H), 2.16 (s, 3H); 13C NMR (CDCl3, 400 MHz): δ 
171.0, 134.5, 131.5, 129.9, 121.2, 78.5, 76.3, 74.3, 70.8, 66.2, 63.8, 53.1, 20.9; 
GC: tR = 9.89 min; MS: m/z calculated for C15H10O2 [M+]: 222.068; found: 
222.079. 
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Figure 7.13: 1H NMR of 10 in CDCl3. 
Figure 7.14: 13C NMR of 10 in CDCl3. 
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Figure 7.15: GC trace of 10. 
Preparation of Stock Solutions. Following synthesis, each natural product 
analog was transferred to a pre-weighed, flame dried vial. The mass of each 
product was noted and dimethyl sulfoxide (DMSO) was added (between 40 to 
180 µL) to create 50 mg/mL stock solutions of each product. Each solution was 
then transferred to eppendorf tubes and stored at -26 °C.  
Preparation of Working Plate.  A serial dilution of the stock solution for each 
product was performed in order to produce working solutions with concentrations 
of 5, 0.5, 0.05, and 0.005 mg/mL. For each product, the stock solution was 
transferred (15 µL) into the well of a 96 well microplate (Greiner Bio- One). 
DMSO (135 µL) was subsequently added to the well to create a 5 mg/mL solution 
of the product. The 5mg/mL solution (15 µL) was then pipetted into a neighboring 
well and DMSO (135 µL) was added to create a 0.5 mg/mL solution. This 
process was repeated to form the 0.05 mg/ml and 0.005 mg/mL solutions, 
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respectively. Similarly, a serial dilution of chloramphenicol (34 mg/mL) was plated 
as well as DMSO controls. The completed plate was stored at -26°C.  
Low Cell Density Absorbance Assay: Luria−Bertani (LB) media (10 mL) was 
inoculated with the Escherichia coli Novagen BL21(DE3) strain of cells and then 
incubated for 16 hours at 37 °C. Optical density measurements on a 
spectrophotometer at 600 nm (OD 600) were used to assess the density of the 
starter culture. The culture was diluted to an OD600 of 0.1 (low density) by addition 
of fresh LB media. In a new 96 well microplate (Greiner Bio-One), the solutions of 
varying concentration for each product from the working plate were plated 
including chloramphenicol and DMSO (20 μL). Subsequently, the low-density cell 
solution was added to each well in which solution had been previously added. An 
initial absorbance was read using a Synergy HT Microplate Reader set to shake 
the plate for 10 seconds prior to reading the OD600. An absorbance reading was 
taken again at 2, 4, 6, 8, 12, and 24 hours. Between OD600 readings the 
microplate was allowed to shake at 37 °C. 
High Cell Density Absorbance Assay.  Luria-Bertani (LB) media (10 mL) was 
inoculated with Escherichia coli Novagen BL21(DE3) strain of cells and then 
incubated for 16 hours at 37 °C. Optical density measurements taken on a 
spectrophotometer at 600nm (OD600) were used to assess the density of the 
starter culture. The culture was diluted to an OD600 of 1 (high-density) by addition 
of fresh LB media. In a new 96 well microplate (Greiner Bio- One), the solutions 
of varying concentration for each product from the working plate were plated 
including chloramphenicol and DMSO (20 µL). Subsequently, the high-density 
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cell solution was added to each well in which solution had been previously 
added.  An initial absorbance was read using a Synergy HT Microplate Reader 
set to shake the plate for 10 seconds prior to reading the OD600. An absorbance 
reading was taken again at 2, 4, 6, 8, 12, 24 hours. Between OD600 readings the 
microplate was allowed to shake at 37 °C.   
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